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ABSTRACT 
 
Epithelial cells that lose attachment to the extracellular matrix (ECM) 
undergo a specialized form of apoptosis called anoikis. Anoikis has an important 
role in preventing oncogenesis, particularly metastasis, by eliminating cells that 
lack proper ECM cues. The basis of anoikis resistance remains to be determined 
and to date has not been linked to alterations in expression or activity of 
previously identified anoikis effector genes. Here, I utilized two different 
screening strategies to identify novel anoikis effector genes and miRNAs in order 
to gain a deeper understanding of anoikis and the potential mechanisms of 
anoikis resistance in cancer.  
 
Using large-scale RNA interference (RNAi) screening, I found that 
KDM3A, a histone H3 lysine 9 (H3K9) mono- and di-demethylase plays a pivotal 
role in anoikis induction. In attached breast epithelial cells, KDM3A expression is 
maintained at low levels by integrin signaling. Following detachment, integrin 
signaling is decreased resulting in increased KDM3A expression. RNAi-mediated 
knockdown of KDM3A substantially reduces apoptosis following detachment and, 
conversely, ectopic expression of KDM3A induces cell death in attached cells. I 
found that KDM3A promotes anoikis through transcriptional activation of BNIP3 
and BNIP3L, which encode pro-apoptotic proteins. Using mouse models of 
breast cancer metastasis I show that knockdown of Kdm3a enhances metastatic 
potential. Finally, I find defective KDM3A expression in human breast cancer cell 
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lines and tumors. Collectively, my results reveal a novel transcriptional regulatory 
program that mediates anoikis. 
 
Next, I sought to discover miRNAs involved in anoikis by investigated 
changes in miRNA expression during anoikis using small RNA sequencing 
technology. Through this approach I discovered that miR-203 is an anoikis 
effector miRNA that is also highly down-regulated in invasive breast cancer cells. 
In breast epithelial cells, miR-203 is induced upon the loss of ECM attachment 
and inhibition of miR-203 activity leads to a resistance to anoikis. I utilized a dual 
functional- and expression- based RNA sequencing approach and found that 
miR-203 directly targets a network of pro-survival genes to induce cell death 
upon detachment. Finally, I found that the loss of miR-203 in invasive breast 
cancer leads to the elevation of several anoikis-related pro-survival target genes 
to contribute to anoikis resistance. Taken together, my studies reveal novel 
pathways through which cell death is induced upon detachment from the ECM 
and provide insight into potential mechanisms of anoikis resistance in cancer.  
 
  
  
 
viii 
 
 
TABLE OF CONTENTS 
 
 
TITLE PAGE ......................................................................................................... i 
SIGNATURE PAGE ............................................................................................. ii 
DEDICATION ...................................................................................................... iii 
ACKNOWLEDGEMENTS ................................................................................... iv 
ABSTRACT ......................................................................................................... vi 
TABLE OF CONTENTS .................................................................................... viii 
CHAPTER I: INTRODUCTION ............................................................................. 1 
CHAPTER II: MATERIALS AND METHODS ..................................................... 27 
CHAPTER III: The histone H3K9 demethylase KDM3A promotes anoikis by 
transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L .......... 45 
Preface ....................................................................................................................... 45 
Abstract ...................................................................................................................... 47 
Introduction ............................................................................................................... 48 
Results ....................................................................................................................... 50 
Figures ....................................................................................................................... 60 
Conclusions ............................................................................................................... 93 
CHAPTER IV: miR-203 regulates anoikis through targeting a network of 
pro-survival genes ............................................................................................ 96 
Preface ....................................................................................................................... 96 
Abstract ...................................................................................................................... 98 
Introduction ............................................................................................................... 99 
Results ..................................................................................................................... 102 
Figures ..................................................................................................................... 112 
Conclusions ............................................................................................................. 138 
CHAPTER V: DISCUSSION AND CONCLUDING REMARKS ....................... 142 
APPENDIX I ..................................................................................................... 142 
Bibliography ............................................................ Error! Bookmark not defined. 
 
 
  
  
 
ix 
LIST OF TABLES 
 
2.1 qRT-PCR primer sequences for Chapter III…………………………………....38 
2.2 ChIP-qRT-PCR primer sequences for Chapter III……………………………..39 
2.3 List of qRT-PCR primers for miR-203 candidate target genes……………….40 
2.4 List of miRNA-qRT-PCR primer sequences……………………………………42 
3.1 Identification of anoikis effectors………………………………………………...59  
4.1 Each sample for small RNA sequencing had a miRNA content of greater than        
75%....................................................................................................................110  
4.2 Changes in miRNA expression after detachment……………………………111  
4.3 The list of miR-203 direct target genes that are degraded by miR-203 after 
detachment from the ECM in MCF10A cells………………………………………126 
4.4 List of shRNA sequences against ten miR-203 target genes……………….129    
  
 
x 
LIST OF FIGURES 
 
3.1 Schematic of the design of the large-scale RNAi screen to identify anoikis 
effectors…………………………………………………………………………………58 
3.2 Knockdown of anoikis effector candidate genes causes a resistance to 
anoikis…………………………………………………………………………………..60  
3.3 Knockdown of anoikis effector candidate genes with a  second shRNA also 
causes a resistance to anoikis……………………………………………………….61 
3.4 Analysis of BIM and candidate shRNA knockdown efficiencies……………..62 
3.5 Ectopic expression of WT KDM3A but not a catalytic dead mutant causes cell 
death in MCF10A cells………………………………………………………………..63 
3.6 KDM3A is induced upon detachment from the ECM………………………….64 
3.7 The induction of KDM3A upon detachment from the ECM is due to the loss of 
integrin signaling……………………………………………………………………….65 
3.8 Inhibition of FAK in attached MCF10A cells causes induction of KDM3A…..66 
3.9 Ectopic expression of EGFR or an activated form of MEK blocks the induction 
of KDM3A upon detachment from the ECM………………………………………...67 
3.10 Inhibition of EGFR in attached MCF10A cells causes induction of 
KDM3A………………………………………………………………………………….68 
3.11 Inhibition of ERK in attached MCF10A cells causes induction of KDM3A...69 
3.12 Knockdown of KDM3A abrogates the induction of BNIP3 and BNIP3L upon 
detachment of MCF10A cells from the ECM………………………………………..70 
3.13 BNIP3 and BNIP3L are induced upon detachment from the ECM………....71  
3.14 KDM3A is enriched on the promoters of BNIP3 and BNIP3L upon 
detachment from the ECM……………………………………………………………72 
3.15 The levels of H3K9me1 and H3K9me2 on the BNIP3 and BNIP3L promoters 
are diminished following detachment, which is counteracted by knockdown of 
KDM3A………………………………………………………………………………….73 
3.16 Overexpression of KDM3A, but not KDM3A(H1120G/D1122N), in attached 
MCF10A cells results in decreased levels of H3K9me1 and H3K9me2 on the 
  
 
xi 
BNIP3 and BNIP3L promoters and increased expression of BNIP3 and 
BNIP3L………………………………………………………………………………….74 
3.17 Analysis of BNIP3 and BNIP3L shRNA knockdown efficiencies……………75 
3.18 Knockdown of BNIP3 and BNIP3L causes resistance to anoikis upon 
detachment from the ECM……………………………………………………………76 
3.19 Ectopic expression of BNIP3 and BNIP3L causes cell death in attached 
MCF10A cells…………………………………………………………………………..77   
3.20 KDM3A induces anoikis by transcriptionally activating BNIP3 and 
BNIP3L………………………………………………………………………………….78 
3.21 Breast cancer cell lines are resistant to anoikis………………………………79 
3.22 KDM3A is not induced in anoikis resistant breast cancer cell lines upon 
detachment from the ECM……………………………………………………………80 
3.23 Ectopic expression of WT KDM3A, but not catalytically inactive KDM3A, 
causes cell death in a panel of breast cancer cell lines…………………………...81 
3.24 Oncomine analysis of KDM3A expression in breast cancer………………...82 
3.25 Human breast cancers have a low expression of KDM3A compared to 
normal breast tissue…………………………………………………………………...83 
3.26 A panel of breast cancer cells have a low level of basal KDM3A expression 
in attached cells………………………………………………………………………..84 
3.27 Knockdown of Kdm3a in CLS1 cells causes resistance to anoikis in vivo...85 
3.28 Kdm3a expression progressively decreases across a mouse breast cancer 
carcinoma progression series………………………………………………………..86 
3.29 Knockdown of Kdm3a in 67NR cells causes tumor growth in the lungs…..87  
3.30 Analysis of Kdm3a shRNA knockdown efficiency in mouse 4T07 cells……88 
3.31 Knockdown of Kdm3a in 4T07 cells leads to increased metastatic burden in 
the lungs………………………………………………………………………………..89 
3.32 Confirmation of the results of Figure 3-31 with a second unrelated Kdm3a 
shRNA…………………………………………………………………………………..90 
  
 
xii 
4.1 Several miRNAs show a significant change in expression upon detachment in 
MCF10A cells…………………………………………………………………………112 
4.2 Three miRNAs are significantly upregulated upon detachment in MCF10A 
cells…………………………………………………………………………………….113 
4.3 Confirmation of miR-203 upregulation upon detachment in MCF10A cells.114 
4.4 The induction of miR-203 is due to increased processing of the mature 
miRNA…………………………………………………………………………………115 
4.5 Ectopic expression of miR-203 in MCF10A cells…………………………….116 
4.6 Ectopic expression of miR-203 results in cell death in MCF10A cells……..117 
4.7 Ectopic expression of miR-203 results in apoptosis in MCF10A cells……..118 
4.8 Inhibition of miR-203 causes resistance to anoikis in MCF10A cells………119 
4.9 Confirmation of miR-203 inhibitor activity in 293T cells……………………..120 
4.10 The induction of miR-203 after detachment from the ECM is due to the loss 
of integrin signaling…………………………………………………………………..121 
4.11 Schematic of the design of the dual RNA sequencing approach to identify 
direct targets of miR-203…………………………………………………………….122 
4.12 Forty-two candidate miR-203 target genes were identified by the dual RNA 
sequencing approach………………………………………………………………..123 
4.13 Validation of thirty direct miR-203 target genes…………………………….124 
4.14 Twenty-five miR-203 target genes are significantly downregulated upon 
MCF10A cell detachment from the ECM………………………………………….125 
4.15 The knockdown of ten miR-203 target genes results in cell death in 
MCF10A cells………………………………………………………………………..127 
4.16 Analysis miR-203 target shRNA knockdown efficiencies…………………128 
4.17 miR-203 is highly downregulated in invasive breast cancer cell lines…..130 
4.18 miR-203 is not induced upon detachment in a triple negative breast cancer 
cell line……………………………………………………………………………….131 
4.19 Ectopic expression of miR-203 causes cell death in a triple negative breast 
cancer cell line………………………………………………………………………132 
  
 
xiii 
4.20 Four miR-203 target genes are elevated in triple negative breast cancer 
samples from the TCGA dataset……………………………………………………133 
4.21 Knockdown of the four miR-203 target genes that are elevated in triple 
negative breast cancer results in cell death in a triple negative breast cancer cell 
line……………………………………………………………………………………..134 
4.22 Model of miR-203 during detachment………………………………………..138 
  
  
 
xiv 
LIST OF PUBLICATIONS 
 
 
The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally 
activating pro-apoptotic genes BNIP3 and BNIP3L. 
Pedanou, V.E., Gobeil, S., Tabaries, S., Simone, T.M., Zhu, L.J., Siegel, P.M., 
and Green, M.R. (2016). Elife 5. 
  
  
 
1 
CHAPTER I: INTRODUCTION 
 
Cancer Background and History 
 
The disease of cancer is, at its core, a genetic disease rising from 
acquired mutations and alterations in the genome over time that cause an 
uncontrolled growth of cells. Over the last few decades significant advances in 
cancer research have allowed us to have a better understanding of how cancer 
develops and the genetic events that are required to result in tumorigenesis. 
Although most of the knowledge we now have about cancer has been discovered 
in the last few decades, cancer itself is not a new disease. The first known 
description of cancer comes from ancient Egypt where they described breast 
tumors that were removed by cauterization and it was also stated back then that 
“there is no treatment” for these tumors. (History of Cancer, ACS, pg 1) 
 
Genetic alterations that contribute to cancer development can occur by a 
multitude of mechanisms. One method is by DNA mutation, which happens at a 
constant rate in human cells but occasionally a mutation occurs in a gene that 
contributes to tumorigenesis. Another method of genetic alteration is by 
epigenetic changes, which are modifications made to DNA that do not alter the 
DNA sequence but do affect gene expression. Finally, chromosome alterations 
such as deletions, translocations, or duplications can dramatically alter gene 
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expression and lead to tumor development (Hsu and Moorhead, 1956; Stich and 
Emson, 1959). These types of genomic instability give rise to the heterogeneous 
traits of cancers.  
 
 In the past decade, with the complete sequencing of the human genome 
and the significant advances in massive sequencing technology we have been 
able to identify traits of cancer including gene expression profiles, mutations 
across cancer genomes, chromosomal abnormalities and microRNA (miRNA) 
expression profiles (Consortium, 2001). These methods have identified multiple 
genetic and epigenetic changes within the cancer cells themselves and within the 
tumor microenvironment that lead to the development of cancer and subsequent 
metastasis of some cancers.  
 
In addition to the genetic components of cancer development, recent work 
has shown that the tumor microenvironment is also an important aspect of 
cancer biology (Hofmann et al., 2003; Kaur et al., 2016; Lizotte et al., 2016). The 
tumor microenvironment of a solid tumor includes multiple different types of cells 
and the extra cellular matrix (ECM), all of which evolve as the tumor progresses. 
Cancer stem cells, cancer cells, cancer associated fibroblasts, endothelial cells, 
pericytes, and immune inflammatory cells all make up the tumor 
microenvironment and each cell type contributes to the development of the tumor 
(the immune inflammatory cells can be either tumor-promoting or tumor-killing 
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cells).  All of these components play a significant role in tumorigenesis and add a 
layer of complexity to the study of cancer biology (Hanahan and Weinberg, 
2011). 
 
One widely accepted hypothesis of how genetic alterations lead to 
tumorigenesis is the “two hit” hypothesis which states that a cell must acquire two 
cancer driving mutations in order for that cell to begin uncontrolled proliferation 
and subsequent tumor growth (Tomlinson et al., 2001). Alfred Knudson 
suggested the Two Hit Hypothesis in 1971 after studying children with heritable 
and sporadic retinoblastoma. Knudson found that heritable retinoblastoma 
always presented in both eyes and occurred earlier than sporadic 
retinoblastoma. From these results Knudson hypothesized that multiple genetic 
alterations are required for the development of tumors and that the children with 
heritable retinoblastoma were already born with one “hit” and had a higher 
chance of acquiring a second “hit” than normal children (Knudson, 1971). This 
hypothesis was later confirmed by the finding that the Retinoblastoma (Rb) tumor 
suppressor gene is inactivated in children with heritable retinoblastoma and is 
commonly inactivated in a variety of other cancers (Horowitz et al., 1990). 
 
 It has been proposed that genomic instability leads to eight biological 
capabilities of cancer cells termed, “hallmarks” of cancer, that are acquired 
during the development of human tumors. Resisting cell death is counted as one 
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of these hallmarks of cancer (Hanahan and Weinberg, 2000, 2011). Cell death or 
apoptosis was first identified as a barrier to cancer development in hormone-
dependent tumors. When the hormone is present, the cancer cells thrive and 
proliferate uncontrolled but when the hormones were withdrawn from these 
tumors it resulted in massive apoptosis in the tumor cells (Kerr et al., 1972). 
Additionally, the overexpression of the activated MYC oncogene in primary 
human cells resulted in apoptosis, suggesting that apoptosis is a mechanism of 
ridding the body of cells with mutations that activate oncogenes (Evan et al., 
1992).  
 
Death from cancer is not caused by the primary tumor in most cases but is 
eventually caused by metastasis, a greek word meaning “displacement”, to 
distant organs, which then result in organ failure. In 1889 Stephen Paget 
proposed that the “seed and soil” theory of metastasis where certain cells from 
the primary tumor, the “seeds”, are able to form secondary tumors in specific 
organ microenvironments, the “soil” (Fidler, 2003). The general principle behind 
the “seed and soil” hypothesis remains true today and the multiple steps that lead 
the “seed” to the “soil” has been defined and is termed the “metastatic cascade” 
(Colombano and Reese, 1980).  
 
The metastatic cascade involves multiple steps that primary tumor cells 
must go through to establish a tumor in a secondary site. In the first step of the 
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metastatic cascade, cells detach from the primary tumor and invade and 
intravasate into the circulatory system where the tumor cells are able to travel 
through the bloodstream. Next, metastatic cells must extravasate and invade into 
secondary tumor sites, usually specific organs that depend on the primary 
cancer. Finally, the metastatic cells must interact with the microenvironment of 
the secondary organ site and initiate tumor growth (Chambers et al., 2002). As 
with the primary tumor, the tumor microenviroment plays a significant role in 
metastatic tumor development, when the primary tumor cells reach a secondary 
site a supportive microenvironment is developed to facilitate tumor growth 
(Hanahan and Weinberg, 2011). While the metastatic cascade has been 
delineated and there has been a great deal of research on metastatic cancers in 
recent times, there remains a vast amount of unknowns and further studies on 
the genetic alterations and changes in the tumor microenvironment that 
contribute to metastasis are needed.  
 
Anoikis 
 
Epithelial cells that lose attachment to the extracellular matrix (ECM), or 
attach to an inappropriate ECM, undergo a specialized form of apoptosis called 
anoikis meaning “the state of being without a home” (Frisch and Francis, 1994a; 
Frisch and Francis, 1994b). Anoikis was first identified in Madin-Darby canine 
kidney epithelial (MDCK) cells through the observation that disruption of the cell-
matrix interactions by forcing the cells to grow in suspension, resulted in 
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apoptosis. The result was confirmed by the addition of integrin blocking 
antibodies to the media of attached cells, which also led to apoptosis due to the 
loss of integrin signaling.  This initial study on anoikis also found that both the 
overexpression of BCL-2 and the transformation of cells with activated RAS or 
SRC conferred resistance to anoikis, suggesting early on that anoikis resistance 
might be an important aspect of cancer biology and might contribute to the 
cancer hallmark of avoiding apoptosis (Frisch and Francis, 1994b).  
 
Several signaling pathways have been shown to regulate anoikis. In 
particular, anoikis is suppressed by integrin signaling, which functions through 
focal adhesion kinase (FAK), a non-receptor tyrosine kinase and an activator of 
the RAF/MEK/ERK pathway (King et al., 1997). Upon interactions of integrins 
with ECM proteins, FAK is auto-phosphorylated and activated. The auto-
phosphorylation of FAK leads to activation and recruitment of SRC, which then 
further phosphorylates FAK leading to the fully active form of FAK. Activated FAK 
leads to downstream pro-survival signals through the PI3K pathway and the 
RAF/MEK/ERK pathway (Calalb et al., 1995; Lietha et al., 2007). Following 
detachment and loss of integrin signaling, FAK is inactivated and the 
downstream pro-survival signals are lost (Frisch et al., 1996).  Ectopic expression 
of a constitutively active form of FAK causes resistance to anoikis in two different 
epithelial cells lines, MDCK and HaCat cells (Frisch et al., 1996), similarly, FAK 
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blocking antibodies or a dominant-negative FAK mutant leads to increased 
sensitivity to anoikis (Bouchard et al., 2007).  
 
Upstream of FAK are integrins, which directly contact ECM proteins to 
initiate downstream pro-survival signaling. Integrins consist of two subunits, the α 
and β subunits, and each integrin is defined depending on the specific subunits. 
There are 4 integrins that are known to play a role in cell survival signaling, α5β1, 
αvβ3, α1β1 and α6β1, all of which result in different downstream signaling 
consequences (Brassard et al., 1999; Matter et al., 1998; O'Brien et al., 1996; 
Zhang et al., 1995). The interactions between integrins and the ECM act through 
a pro-survival signaling pathway within cells to promote survival, growth and 
proliferation. When the integrin-ECM interactions are lost or disrupted or when a 
cell interacts with an ECM that is not ideal for the cell-specific integrins, the pro-
survival signals are lost leading to cell death.  
 
Anoikis is also suppressed by integrin-mediated, ligand independent 
activation of the epidermal growth factor receptor (EGFR) signaling pathway, 
which, like FAK, also stimulates pro-survival RAF/MEK/ERK activity.  Integrin-
ECM interactions lead to the production of reactive oxygen species (ROS), which 
activate SRC. SRC activation leads to the ligand independent phosphorylation 
and activation of EGFR leading to the activation of the pro-survival MAPK and 
Akt pathways (Moro et al., 1998). Upon detachment of cells from the ECM, 
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EGFR expression is lost which leads to accumulation of the pro-apoptotic protein 
BIM and subsequent anoikis, however ectopic expression of EGFR causes 
resistance to anoikis in detached cells (Reginato et al., 2003).  
 
The FAK and EGFR cell signaling pathways have been found to regulate 
the levels of BIM (also called BCL2L11) and BMF, two pro-apoptotic members of 
the BCL2 family of apoptosis regulators that are known to contribute to anoikis 
(Reginato et al., 2003; Schmelzle et al., 2007). Specifically, activated EGFR and 
ERK suppress BIM activity through phosphorylation and ubiquitin-mediated 
degradation of BIM when cells are attached to the ECM (Collins et al., 2005). 
However, depletion of BIM or BMF diminishes but does not completely prevent 
anoikis (Reginato et al., 2003; Schmelzle et al., 2007), suggesting the existence 
of other pro-apoptotic factors and regulatory pathways that can promote anoikis. 
The basis of anoikis resistance remains to be determined and to date has not 
been linked to alterations in expression or activity of BIM or BMF. 
 
While the major signaling pathways involved in anoikis have been identified, 
to date there have been many groups that have identified downstream novel 
anoikis effector genes. The previously discussed BIM and BMF were identified by 
specifically looking at the expression of a subset of BCL2 pro-apoptotic proteins 
and microarray analysis, respectively (Reginato et al., 2003; Schmelzle et al., 
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2007), other studies have utilized multiple approaches to identify other anoikis 
effector genes.  
 
Previous unbiased screening approaches have identified several other novel 
anoikis effector genes. A genome wide retroviral cDNA library was the first 
screening approach used to discover anoikis effectors in rat intestinal epithelial 
(RIE-1) cells. The screen identified a neurotrophic tyrosine kinase receptor, TrkB, 
that activates downstream PI3K signaling to suppress anoikis and enhance 
metastasis (Douma et al., 2004). A more recent genome wide shRNA loss of 
function screen in RWPE-1 prostate cells found that alpha/beta hydrolase 
domain containing 4 (ABHD4) promotes anoikis through cleavage of PARP and 
Caspase-3 (Simpson et al., 2012).  
 
Additional studies have taken more directed approaches to identifying anoikis 
effector genes such as studying genes already known to play a role in apoptosis. 
One such study identified IGF-1 as an anoikis suppressor in mouse embryonic 
fibroblast cells (MEF) that acts through activation of Ras (Valentinis et al., 1999). 
Another directed study found that angiopoietin-like 4 (ANGPTL4) promotes cell 
survival upon detachment by elevating levels of reactive oxygen species (ROS), 
which then activate the pro-survial ERK and PI3K pathways (Zhu et al., 2011).  
 
  
 
10 
Anoikis is studied in cell culture by detaching cells from adherent 
conditions and plating the cells on poly-hydroxyethylmethacrylate (polyHEMA) 
coated or ultra low attachment plates to force the cells to grow in suspension. 
The polyHEMA coating prevents cell attachment by preventing the deposition of 
ECM because of its non-ionic nature, thereby forcing cells to grow in suspension 
(Frisch and Francis, 1994b). While there are now standard experiments to model 
anoikis in vitro, in vivo anoikis experiments are less straightforward. Cells require 
specific ECM attachments from their native environment, therefore when cells 
enter a foreign environment anoikis should occur.  Sensitivity to anoikis in vivo 
was observed in one study that found that tumor cells show enhanced metastasis 
when the primary tumor is orthotopically grown as compared to ectopic tumors, 
which proved the importance of tumor cell and ECM interactions (Glinskii et al., 
2003).  
 
Anoikis Resistance and Metastasis 
 
Throughout the metastatic cascade, cells need the ability to survive 
without attachment to neighboring cells and the original ECM and thus need to 
acquire resistance to anoikis (Frisch and Ruoslahti, 1997). Metastatic cells need 
to bypass anoikis both when the tumor cell detaches from the primary tumor, and 
therefore from the ECM, and enters the bloodstream and then when the tumor 
cell arrives at a secondary site where there is a different ECM composition and 
therefore different signaling from the primary tumor microenvironment.  
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Anoikis plays an important role in preventing oncogenesis, particularly 
metastasis, by eliminating cells that lack proper ECM cues (Simpson et al., 2008; 
Zhu et al., 2001). Previous studies have shown that when malignant cells lose 
contact with both neighboring tumor cells and their ECM, the cells will normally 
undergo apoptosis (Glinskii et al., 2003). However, metastatic cells must bypass 
this cell death in order to detach from the primary tumor and enter the circulatory 
system and finally extravasate into a secondary site and form a tumor in that 
secondary site. Since the secondary tumor site most often contains a different 
ECM than the primary site, the metastatic cells also need to bypass anoikis after 
the last step of metastasis (Berezovskaya et al., 2005; Howard et al., 2008).  
 
In addition to the role anoikis plays in preventing metastasis, there is also 
evidence to suggest that anoikis functions to prevent the invasion of tumor cells 
into the luminal space, which is a characteristic of epithelial tumors (Debnath et 
al., 2002). In general, epithelial-derived cancers, such as breast cancer, develop 
resistance to anoikis which results in the filling of the luminal space or ductal 
carcinoma in situ (DCIS), an early stage in breast cancer tumorigenesis 
(Schwartz, 1997). 
 
While multiple anoikis pathways and effectors have been discovered and 
studied since anoikis was first identified, there are likely many other factors 
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involved in anoikis. Anoikis is proving to be a complex biological process that has 
a link to tumorigenesis and metastasis that has yet to be fully defined. The 
mechanism of resistance to anoikis in cancer remains largely unknown. It is likely 
that critical anoikis effectors are genetically altered in cancer so it is important to 
relate anoikis research back to human cancer in order to understand the 
mechanism by which cancer cells, specifically metastatic cells, bypass anoikis. 
This knowledge would lead to a greater understanding of metastasis and 
potentially new avenues for therapeutics.  
 
Epigenetics and Cancer 
Epigenetics, DNA modifications that do not change the DNA sequence, affect 
gene expression through chromatin associated proteins and post-translational 
modifications of histones. Specific mechanisms of epigenetic regulation include 
DNA methylation, post-translational modifications of histones (methylation, 
acetylation, sumoylation, ubiquitination), and nucleosome remodeling. The 
mysregulation of epigenetic mechanisms has been shown to contribute to human 
disease and many defects in epigenetic mechanisms have been linked to cancer 
development (Bracken et al., 2003; Lin and Nelson, 2003; Sato et al., 2003).   
Identification of epigenetic alterations in cancer has led to the development of 
various therapies that target epigenetic mechanisms that promote cancer. Two 
drugs that target DNA methyl transferases (5-azacytidine and decitabine) were 
some of the first epigenetic-based drugs to be approved to treat human disease 
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(SAIKI et al., 1978; van Groeningen et al., 1986). Rapid advances in the field of 
epigenetics and cancer have led to the development of several potent inhibitors 
of histone methyltransferases (Kubicek et al., 2007), histone demethylases (Feng 
et al., 2016), and chromodomain proteins (Ren et al., 2015). Because the 
epigenetic landscape and mechanisms are complex we likely do not have a full 
understanding of the involvement of all epigenetic regulating proteins in cancer 
development and further studies and developments are needed to create a 
clearer picture.  
 
Histone Methylation 
 
One major aspect of epigenetic control of gene expression and source of 
aberrant gene expression in cancer is changes in chromatin modifications. In 
general, histone modifications change the structure and function of chromatin, 
subsequently leading to changes in gene expression. Transcription can either be 
activated or repressed by histone modifications based on the modifications that 
are present on a specific gene (Liu et al., 2005; Pokholok et al., 2005). Lysine 
acetylation on histones is associated with transcriptional activation whereas 
lysine methylation can be associated with either transcriptional activation or 
transcriptional repression depending on which lysine residue is methylated. The 
differing effects on transcription by methylated lysines occur from the formation of 
differing binding sites for chromo-domain proteins that have different effector 
functions (Vakoc et al., 2005). Histone modifications can be altered in cancer 
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through the differing expression of histone modifying enzymes. This can lead to 
aberrant changes in gene expression that can promote tumor growth and 
metastasis (Van Rechem et al., 2015; Xiang et al., 2007; Yamane et al., 2007).   
 
Methylation is a post-translational modification of lysine and arginine 
residues on histones that affects gene expression. It has been demonstrated that 
histone lysine methylation can occur in the mono-, di-, or tri-methyl state and 
arginine methylation can occur in the mono- or di-methylated state. Histone 
methylation affects gene expression through the recruitment of “reader” proteins, 
which then recruit protein complexes that can either repress or enhance 
transcription (reviewed in (Musselman et al., 2012)). Histone methylation was 
found to be a reversible modification with the discovery of the first histone 
demethylase, KDM1A/LSD1 (Shi et al., 2004). Since the discovery of LSD1, a 
family of proteins that contain homologous JmjC domains have been identified 
and each member of the family has been shown to demethylate specific histone 
lysine residues, some specifically demethylate mono- di- or tri-methylated 
lysines, while one member of the JmjC family has been shown to demethylate 
histone arginine residues (Chang et al., 2007).  
 
KDM3A is a member of the JmjC domain-containing protein family of 
histone demethylases. Proteins in this family have a catalytic JmjC domain that 
demethylates lysine and arginine residues on histones in an oxidative reaction 
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that requires Fe(II) and alpha-ketoglutarate as cofactors (Tsukada et al., 2006). 
KDM3A (also called JMJD1A or JHDM2A) is a histone demethylase that has 
been shown to specifically demethylate mono- and di-methyl histone H3 lysine 9 
(H3K9me1 and H3K9me2) but not tri-methyl Histone H3 lysine 9 (H3K9me3) 
(Yamane et al., 2006). Both H3K9me1 and H3K9me2 have been identified as 
transcriptionally repressive marks, although H3K9me2 has also been discovered 
to be present on several actively transcribed genes (Lienert et al., 2011; 
Snowden et al., 2002). As suggested by its function, KDM3A has been implicated 
as an activator of transcription and acts as a coactivator for androgen receptor 
(AR) (Yamane et al., 2006) and hypoxia-inducible factor (HIF) (Beyer et al., 
2008). In addition to the JmjC domain, KDM3A also contains a Zinc Finger 
domain that likely contributes to DNA binding and transcriptional activation of 
specific target genes (Yamane et al., 2006).  
 
While the exact mechanism by which KDM3A controls gene expression is 
known, the role KDM3A plays in cancer is not well understood and has so far 
been controversial. There have been differing studies suggesting that KDM3A is 
both anti-oncogenic (Du et al., 2011) and pro-oncogenic (Krieg et al., 2010), 
suggesting that the role of KDM3A is likely dependent on other factors and could 
differ among tissue types. Further research is needed to determine the factors 
that influence the tissue or cancer type specific role that KDM3A plays in cancer 
progression.  
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microRNA 
 
microRNAs (miRNAs) are short RNA molecules (~22 nucleotides) that 
regulate gene expression through translational repression and mRNA decay 
(Djuranovic et al., 2012), recent evidence even suggests that mRNA degradation 
by miRNAs is the predominant reason for reduced protein levels in mammals 
(Guo et al., 2010). The first miRNA (lin-4) was discovered in C. elegans in 1993 
and in the more than two decades since the discovery of miRNAs, over a 
thousand miRNAs have been identified in the human genome (Griffiths-Jones et 
al., 2008; Lee et al., 1993 
). The discovery that miR-15 and miR-16 are frequently downregulated in 
chronic lymphocytic leukemia (CLL) marked the first implication of miRNA 
involvement in cancer (Calin et al., 2002). In the time since the CLL study, there 
have been thousands of other published studies that aim to define the 
relationship between miRNAs and cancer.  
 
The genes encoding miRNAs are transcribed by RNA polymerase II into 
long transcripts, which are then processed by the RNAse III protein, DROSHA, 
into a ~60 nucleotide precursor miRNA hairpin (pre-miRNA) (Zeng et al., 2005). 
Exportin5 then transports the pre-miRNA into the nucleus where it is further 
processed by another RNAse III protein, DICER (Zhang et al., 2002), which 
generates a mature ~22 nucleotide mature miRNA. The mature miRNA is then 
loaded into an Argonaute (Ago) protein in the RNA-induced silencing complex 
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(RISC), which is then directed to specific target mRNAs. While mature miRNAs 
can interact with Ago1-4, Ago2 is the Argonaute responsible for targeted mRNA 
degradation by miRNAs (Meister et al., 2004). 
 
miRNAs control the expression of target genes through specificity in the 
seed sequence region (7 nucleotides) of the miRNA that binds to the 
complementary sequence in the 3’ untranslated region (3’UTR) of transcripts to 
inhibit translation of the mRNA and inhibit transcription by causing the 
deadenylation and decay of the target mRNA (Guo et al., 2010).  Classicaly, it 
was thought that the major mechanism of miRNA repression was through 
inhibition of translation, however recent data suggests that the main mechanism 
of mammalian miRNA repression is by mRNA degradation (Guo et al., 2010). 
Several databases (including Targetscan and miRDB) exist to predict the target 
mRNAs of miRNAs based on matching the seed sequence of the miRNA to a 
complementary sequence in the 3’UTR of known genes (Agarwal et al., 2015).  
 
The expression of miRNAs themselves is regulated by two different 
methods— transcriptional changes that can affect the levels of pri-miRNA 
transcripts or post-transcriptional changes in processing of the pre-miRNA or the 
mature miRNA. One method by which the transcription of pri-miRNAs is 
controlled is through transcription factors. For example, E2F7 (a member of the 
E2F family of transcription factors) directly binds to the promoters of miR-25, 
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miR-92a, and miR-7 to repress the transcription of the corresponding pri-miRNAs 
(Mitxelena et al., 2016). Another mechanism of transcriptional control of miRNAs 
is by DNA methylation. Previous studies have identified miR-31 (Augoff et al., 
2012), the miR-200 cluster (Wee et al., 2012) , and miR-33b (Yin et al., 2016) as 
just a few of the miRNAs that are aberrantly expressed in cancer due to DNA 
hypermethylation.  
 
The processing of all miRNAs requires the same large protein complex 
machinery (i.e. DROSHA and DICER), however recent studies have started to 
uncover regulatory factors that influence the processing of specific miRNAs or 
specific groups of miRNAS.  On a global level, mutations in both DROSHA and 
DICER have been discovered to effect miRNA processing in cancer (Heravi-
Moussavi et al., 2012; Rakheja et al., 2014). Recent discoveries provide 
examples of how specific miRNA expression can be regulated by DICER 
regulatory factors that influence the processing of that specific miRNA. One 
example of miRNA-specific altered processing occurs when RNA editing of the 
pri-miR-151 completely blocks DICER cleavage of pre-miR-151 (Kawahara et al., 
2007). The processing of specific miRNAs can also be regulated uridylation, 
mediated by Lin28 and TUT4, of the pre-miR, which also blocks DICER cleavage 
of the pre-miR (Heo et al., 2009). The study of factors affecting miRNA 
processing is a relatively new field of research and knowledge on miRNA 
processing will likely grow over the coming years.  
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 Previous studies have established that miRNAs are widely dysregulated in 
cancers (Zhang et al., 2006), however few miRNAs have been implicated in 
promoting or suppressing anoikis. Because miRNAs have not been widely 
studied in the context of anoikis, the role of miRNAs in anoikis remains to be 
determined. Previous studies have suggested that the miR-200 family both 
enhances anoikis sensitivity (Howe et al., 2012) and promotes anoikis resistance 
and metastasis (Yu et al., 2013). Given the critical role that miRNAs play in gene 
expression, it is likely that miRNAs play a yet to be determined role in anoikis, 
revealing that further studies should be done to fully delineate the role of miRNAs 
during anoikis.  
 
While many miRNAs can be grouped into families or clusters, there is a 
subset that do not cluster with any other miRNAs, miR-203 falls into this 
category. miR-203 was identified in multiple genome wide miRNA profiling 
studies but a group that studied the role of miR-203 in primary keratinocyte 
differentiation was the first to identify a function of miR-203 when they showed 
that miR-203 suppressed the “stemness” of skin stem cells (Lena et al., 2008). 
Since the first miR-203-specific study in 2008, research has mostly been focused 
on the role miR-203 plays in cancer.  
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Several groups have implicated miR-203 as a tumor suppressor and anti-
invasion miRNA specifically. Since 2008 there have been similar studies 
performed in multiple different tissues that suggest miR-203 is universally an 
anti-proliferative miRNA (Ding et al., 2013; Furuta et al., 2010; Noguchi et al., 
2012; Saini et al., 2011; Viticchie et al., 2011), while the exact mechanism of 
proliferation and invasion suppression likely differs between cancer types. 
Further investigation showed that miR-203 is epigenetically silenced by promoter 
methylation in some cancers including ovarian carcinoma (Iorio et al., 2007) and 
rhabdomyosarcoma (Diao et al., 2014). Expression analysis of several miRNAs 
in breast cancer cells lines revealed that miR-203 is highly downregulated in 
invasive breast cancer cell lines compared to both normal breast epithelial 
(MCF10A cells) and less invasive breast cancer cell lines (Luo et al., 2013) and 
is significantly downregulated in human triple negative breast cancer samples 
(Yu et al., 2012). Furthermore, ectopic expression of miR-203 in cancer cell lines 
inhibits proliferation, migration, and invasion (Noguchi et al., 2012). To date, miR-
203 has not been implicated in anoikis and the exact role miR-203 plays in 
inhibiting breast cancer invasion and metastasis has yet to be determined.  
 
As stated above, the main mechanism by which miRNAs control cellular 
processes is by targeting one or more specific mRNAs resulting in decreased 
protein output of those targets. There are several hundred predicted miR-203 
target genes based on the seed sequence of miR-203 and the sequences of the 
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3’UTR of target mRNAs. However, only a few of these predicted targets have 
been confirmed as bona fide miR-203 targets including p63 (Yi et al., 2008), 
ABL1 (Bueno et al., 2008), BMI1 (Chen et al., 2015), BIRC5, LASP1 (Wang et 
al., 2012), Survivin (Bian et al., 2012), E2F3 (Noguchi et al., 2012), SNAI2 
(Zhang et al., 2011) and RUNX2 (Taipaleenmaki et al., 2015). Interestingly, most 
of the bona fide target genes have been identified across different tissues and 
the targets do not seem to overlap between tissue types, with the exception of 
p63 which has been confirmed in multiple cell types (Lena et al., 2008; Yi et al., 
2008; Yuan et al., 2011) This suggests that tissue type could play an important 
role in determining the specific miR-203 target genes.  
 
RNAi screens 
 
RNA interference (RNAi) is a cellular process that involves degradation of 
mRNAs through sequence specific binding of small interfering RNAs (siRNAs) 
that was first discovered in Caenorhabditis elegans (C. elegans) (Fire et al., 
1998). For more than a decade, scientists have utilized RNAi as a research tool 
to deplete specific mRNA transcripts by inserting sequence specific RNAi 
reagents into cell culture or whole organisms in order to delineate the function of 
specific genes. In addition to targeted gene depletion, libraries consisting of small 
hairpin RNAs (shRNAs) designed to target the whole genome have been used to 
perform genome wide screens with phenotypic readouts. shRNA libraries are 
designed using microRNA (miRNA) and small interfering RNA (siRNA) 
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technology, where a hairpin similar to the structure of pre-miRNA transcripts are 
ligated into lentiviral or retroviral plasmids. Once the plasmid is inside the cell, the 
hairpin is loaded into the endogenous small RNA processing machinery, which 
results in small RNAs that inhibit the transcription of its target gene in a siRNA-
like mechanism. The genome wide shRNA libraries contain multiple different 
shRNAs to target each gene in the genome and are normally used in a pool 
format. This has proven to be a successful unbiased approach that has allowed 
scientists to identify novel genes that are involved in biological processes from 
immunology (Ng et al., 2007) to cancer biology (Gazin et al., 2007). 
 
shRNA screens (both whole genome and directed smaller scale screens) 
have proven to be useful research tools in cancer research. The most common 
form of RNAi screening used to study cancer biology are cell culture based loss 
of function screens with a phenotypic readout (e.g. (Wajapeyee et al., 2008) and 
(Kessler et al., 2012)). More recently, in vivo shRNA screens have been 
successful in identifying novel oncogenes and tumor suppressors in mouse 
models of cancer because of the long-term stable suppression of mRNA 
transcripts by shRNAs (Gargiulo et al., 2014). The research in the Green lab in 
recent years has been focused on utilizing shRNA genome wide screens to 
identify novel factors in multiple aspects of transcription and cancer biology. 
Specifically, our lab has used RNAi screens to identify new genes involved in 
oncogene induced senescence (Wajapeyee et al., 2008), genome integrity (Fang 
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et al., 2015), chemotherapy resistance (Ma et al., 2014), lung cancer progression 
(Lin et al., 2014), aberrant oncogenic methylation (Fang et al., 2014), and glioma 
progression (Sheng et al., 2010). We use a genome wide small hairpin RNA 
(shRNA) library that contains ~62,400 shRNAs directed against ~28,000 genes 
(Silva et al., 2003; Silva et al., 2005).  
 
 
Small RNA Profiling 
 
 After the discovery of miRNA and subsequent identification of multiple 
miRNAs that are dysregulated in cancer, the field was seeking to study the 
expression of multiple miRNAs in cancers but in the early 2000’s northern 
blotting was the only technique available to determine the expression of a 
miRNA. Northern blots had many limitations for detecting multiple miRNAs in a 
study, including the high amount of RNA needed for one northern blot and the 
need to use radioactive labels to detect the miRNA. Thus, a miRNA microarray 
was developed to profile the expression of all known miRNAs in human and 
mouse tissues (Liu et al., 2004).  Not long after the development of the miRNA 
microarray multiple groups started using high throughput sequencing as a direct 
method of profiling small RNA expression, this method has allowed for both 
determining the expression of known miRNAs in the genome and identifying 
novel miRNAs (Lu et al., 2006; Ruby et al., 2006). 
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 Small RNA profiling has become a standard, unbiased method for 
identifying miRNAs that are involved in cellular processes and diseases. The 
advantages of using the small RNA sequencing method of profiling miRNAs 
include the high sequence accuracy, which has the potential of identifying novel 
miRNAs. While there have been a plethora of miRNA profiling studies done in 
human cancers there has yet to be any study of miRNA changes during the 
process of anoikis—there has even been very few directed miRNA studies in 
anoikis research.  
 
Focus of this dissertation 
 
While there are several known anoikis effector genes reviewed above, in 
the first part of my thesis research, I chose to use a genome wide RNAi screen to 
identify novel anoikis effector genes. With this approach, I sought to identify 
novel anoikis pathways by performing the unbiased genome wide shRNA screen 
in breast epithelial cells to identify novel anoikis effector genes. The screen 
identified multiple novel factors as anoikis effector genes, including KDM3A, 
ZCCHC24, ZNF345, METAP1D, and PIH1D3. I chose to focus my investigation 
on the histone demethylase, KDM3A, because of the intriguing possibility that 
epigenetics and transcription play a major role in the control of anoikis. In this 
study, I identify KDM3A as an anoikis effector that is induced upon detachment of 
cells from the ECM. I further delineated the mechanism by which KDM3A 
functions to promote anoikis in human breast epithelial cells and showed that the 
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activation of KDM3A upon detachment from the ECM causes transcriptional 
activation of two pro-apoptotic BH3-only proteins, BNIP3 and BNIP3L resulting in 
anoikis. Also, knockdown of KDM3A causes a non-metastatic breast cancer cell 
line to become metastatic, implicating the loss of KDM3A in anoikis resistance 
and enhanced metastasis.  
 
In the second part of my thesis research, I sought to identify changes in 
miRNA expression during anoikis to discover miRNAs that could be implicated in 
anoikis resistance during cancer development. To date there have been a wide 
array of whole genome miRNA studies completed in cancers (Iorio et al., 2007; 
Mi et al., 2007; Wölfl et al., 2011) including breast cancers (Fassan et al., 2009; 
Luo et al., 2013) and even profiling miRNAs at different stages of breast cancer 
(Dadiani et al., 2016). However, there have not yet been any anoikis-related 
genome wide miRNA studies completed, only directed miRNA investigations into 
how a few single miRNAs play a role in anoikis have been done (as discussed 
above), leaving the possibility that there are other miRNAs involved in anoikis 
that have yet to be identified. I completed genome wide miRNA profiling during 
the early stages of anoikis by using small RNA sequencing. Through these 
miRNA profiling experiments, I found a group of miRNAs that are upregulated 
during anoikis and a separate group that are downregulated during anoikis. From 
these two group of miRNAs, I chose to focus on the most highly upregulated 
miRNA, miR-203, because miR-203 had already been implicated as a tumor-
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supressive miRNA (as discussed above). I found that miR-203 is significantly 
upregulated during anoikis and promotes cell death. I also identified several pro-
survival miR-203 target genes that are downregulated by miR-203 upon 
detachment of the cells from the ECM and therefore lead to cell death.  My 
results show that miR-203 is a novel anoikis effector miRNA and in addition to 
previous studies, my results suggest that miR-203 is a tumor suppressor miRNA 
in triple negative and invasive breast cancers.  
 
In conclusion, I have identified two novel factors that are critical anoikis 
effectors, KDM3A and miR-203. My research furthers the general understanding 
of the process of anoikis and provides insight into potential mechanisms of 
anoikis resistance in metastatic tumor cells.  
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CHAPTER II: MATERIALS AND METHODS 
 
Cell lines and culture 
 
T47D, MDA-MB-231, BT549, Hs578t, and CLS1 cells were obtained from ATCC 
(Manassas, VA) and grown as recommended by the supplier. MCF7 cells 
(National Cancer Institute, Bethesda, MD) were maintained in DMEM (GE 
Healthcare Life Sciences, Marlborough, MA) supplemented with 1X nonessential 
amino acids (NEAA; Thermo Scientific, Waltham, MA) and 10% fetal bovine 
serum (FBS; Atlanta Biologics, Norcross, GA). MCF10A cells (ATCC) were 
maintained in DMEM/F12 (GE Healthcare Life Sciences) supplemented with 5% 
donor horse serum (Thermo Scientific), 20 ng/ml epidermal growth factor 
(Peprotech, Rocky Hill, NJ), 10 µg/ml insulin (Life Technologies, Grand Island, 
NY), 1 ng/ml cholera toxin (Sigma-Aldrich, St. Louis, MO), 100 µg/ml 
hydrocortisone (Sigma-Aldrich), 50 U/ml penicillin (Thermo Scientific), and 50 
µg/ml streptomycin (Invitrogen, Grand Island, NY). SUM149 cells were obtained 
from Dr. Donald Hnatowich (University of Massachusetts Medical School, 
Worcester, MA) and grown in RPMI (Invitrogen) supplemented with 10% FBS, 
0.01% insulin, 50 U/ml penicillin, and 50 µg/ml streptomycin. 67NR and 4T07 
cells were obtained from Dr. Fred Miller (Wayne State University School of 
Medicine, Detroit, MI) and were grown in high glucose DMEM (GE Healthcare 
Life Sciences) supplemented with 10% FBS, 50 U/ml penicillin, and 50 µg/ml 
streptomycin.  
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Ectopic expression 
 
KDM3A and KDM3A(H1120G/D1122N) were PCR amplified from pCMV-
JMJD1A and pCMV-JMJD1A(H1120G/D1122N), respectively, obtained from Dr. 
Peter Staller (Biotech Research and Innovation Centre, University of 
Copenhagen, Denmark), using primers (forward, 5’-
CTCGAGCCGTTAAGGTTTGCCAAAAC-3’ and reverse, 5’-
ATCGTTAACAGGGAGATT AAGGTTTGCCA-3’) engineered with XhoI and HpaI 
restriction sites and then cloned into pMSCVpuro (ClonTech Laboratories, Inc., 
Mountain View, CA). BNIP3L was PCR amplified from Bnip3L pcDNA3.1 
(plasmid #17467, Addgene, Cambridge, MA) using primers (forward, 5’-
AATCTCGAGCATGTCGTCCCACCTAGT-3’ and reverse 5’-
ATCGAATTCTTAATAGGT GCTGGCAGAGG-3’) engineered with XhoI and 
EcoRI restriction sites and cloned into pMSCVhygro (ClonTech Laboratories, 
Inc.). BNIP3 was PCR amplified from MGC Human BNIP3 cDNA (Dharmacon, 
Marlborough, MA) using primers (forward, 5’-AATCTCGAGCAT 
GTCGCAGAACGGAGCG-3’ and reverse 5’- 
ATCGAATTCACTAAATTAGGAACGCAGC AT-3’) engineered with XhoI and 
EcoRI restriction sites and cloned into pMSCVpuro.  
 
MCF10A cells stably expressing pMSCVpuro-JMJD1A, pMSCVpuro-JMJD1A-
H1120G/D1122N, pMSCVpuro-BNIP3, pMSCVhygro-BNIP3L, pMSCVpuro-
empty, pMSCVhygro-empty, pBABE-MEK2DD (obtained from Dr. Sylvain 
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Meloche, Universite de Montreal), pBABE-EGFR (Addgene), or pBABE-empty 
(Addgene) were generated by retroviral transduction as described previously 
(Santra et al., 2009). Twelve days after puromycin or hygromycin selection, cells 
were stained with 0.5% crystal violet.  
 
RNA interference  
 
The human shRNAmir pSM2 library (Open Biosystems/Thermo Scientific, 
Pittsburgh, PA) was obtained through the University of Massachusetts Medical 
School RNAi Core Facility (Worcester, MA). Retroviral pools were generated and 
used to transduce MCF10A cells as described previously (Gazin et al., 2007). 
Following puromycin selection, transduced cells were divided into two 
populations: one was plated on poly-HEMA-coated tissue culture plates (plates 
were coated with poly-HEMA (20 mg/ml) (Sigma-Aldrich), dried at room 
temperature overnight, and washed with phosphate buffered saline (PBS) before 
use) and grown for 10 days, and the other was grown for 10 days under normal 
tissue culture conditions. Cells that survived 10 days in suspension (a time point 
at which >95% of cells transduced with the control NS shRNA were killed) were 
seeded under normal tissue culture conditions to expand the population. shRNAs 
present in the surviving suspension population and the attached population were 
identified by deep sequencing at the University of Massachusetts Medical School 
Deep Sequencing Core Facility (Worcester, MA). The frequency of individual 
shRNAs in each sample was determined as described previously (Xie et al., 
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2012). The raw sequencing data have been uploaded to NCBI Gene Expression 
Omnibus with accession number GSE80144, and are accessible to reviewers 
through the following link: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=inevskwqzxaprmb&acc=G
SE80144. 
 
For stable shRNA knockdowns, 1x105 cells were seeded in a six-well plate to 
50% confluency and subsequently transduced with 200 µl lentiviral particles 
expressing shRNAs (obtained from Open Biosystems/Thermo Scientific through 
the UMMS RNAi Core Facility, listed in Supplementary file 1) in a total volume of 
1 ml of appropriate media supplemented with 6 µg/ml polybrene (Sigma-Aldrich). 
Media was replaced after overnight incubation to remove the polybrene, and viral 
particles and cells were subjected to puromycin selection (2 µg/ml) for 3 days. 
 
qRT-PCR 
 
Total RNA was isolated and reverse transcription was performed as described 
(Gazin et al., 2007), followed by qRT-PCR using Power SYBR Green PCR 
Master Mix (Applied Biosystems, Grand Island, NY). RPL41 or GAPDH were 
used as internal reference genes for normalization. See Table 2.1 and 2.3 for 
primer sequences. Each sample was analyzed three independent times and the 
results from one representative experiment, with technical triplicates or 
quadruplicates, are shown. 
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Anoikis assays 
 
Cells were placed in suspension in normal growth media in the presence of 0.5% 
methyl cellulose (Sigma Aldrich) (to avoid clumping of cells) on poly-HEMA-
coated tissue culture plates. All anoikis assays were done at a cell density of 
3x105 cells/ml. Control cells were cultured under normal cell culture conditions. 
Cell death was measured by staining the cells with FITC-conjugated Annexin-V 
(ApoAlert, ClonTech) according to the manufacturer’s instructions followed by 
analysis by flow cytometry (Flow Cytometry Core Facility, University of 
Massachusetts Medical School) at the indicated times. To restore integrin 
signaling in suspension, media was supplemented with 5% growth-factor-
reduced Matrigel (BD Biosciences, San Diego, CA). Each sample was analyzed 
in biological triplicate 
 
Immunoblot analysis 
 
Cell extracts were prepared by lysis in Laemmli buffer in the presence of 
protease inhibitor cocktail (Roche, Indianapolis, IN). The following commercial 
antibodies were used: beta-ACTIN (Sigma-Aldrich); BNIP3, BNIP3L, KDM3A, 
H3K9me2 (all from Abcam, Cambridge, MA); cleaved Caspase 3, BIM, phospho-
ERK1/2, total ERK1/2, phospho-EGFR, total EGFR, phospho-FAK (all from Cell 
Signaling Technology, Danvers, MA); total FAK (Millipore, Billerica, MA); GFP 
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(One World Lab, San Diego, CA); and α-tubulin (TUBA; Sigma-Aldrich). 
 
Chemical Inhibitor Treatment 
 
Cells were treated with dimethyl sulfoxide (DMSO), 1, 5 or 10 µM U0126 (Cell 
Signaling Technology), gefitinib (Santa Cruz Biotechnology, Inc., Dallas, TX), or 
FAK inhibitor 14 (CAS 4506-66-5, Santa Cruz Biotechnology, Inc.) for 48 hours 
prior to preparation of cell extracts or total RNA isolation, as described above.  
 
ChIP assays 
 
ChIP assays were performed as previously described (Gazin et al., 2007) using 
antibodies against KDM3A and H3K9me2 (both from Abcam) and H3K9me1 
(Epigentek). ChIP products were analyzed by qPCR (see Table 2.2 for promoter-
specific primer sequences). Samples were quantified as percentage of input, and 
then normalized to an irrelevant region in the genome (~3.2 kb upstream from the 
transcription start site of GCLC). Fold enrichment was calculated by setting the 
IgG control IP sample to a value of 1. Each ChIP experiment was performed 
three independent times and the results from one representative experiment, with 
technical duplicates, are shown.  
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Analysis of KDM3A expression in human breast cancer samples 
 
This study was approved by the institutional review boards at the University of 
Massachusetts Medical School (UMMS) and the Mayo Clinic. Total RNA from 24 
breast cancer patient samples were obtained from Fergus Couch (Mayo Clinic, 
Rochester, MN) and total RNA from five normal breast samples were obtained 
from the University of Massachusetts Medical School Tissue and Tumor Bank 
Facility. KDM3A expression was measured by qRT-PCR in technical triplicates of 
each patient sample. Statistical analysis (unequal variance t-test) was performed 
using R, a system for statistical computation and graphics (Ihaka and Gentleman, 
1996). The Oncomine Cancer Profiling Database (Compendia Bioscience, Ann 
Arbor, MI) was queried using the cancer type Breast Cancer and a threshold p-
value of 0.05 to access Finak (Finak et al., 2008), Sorlie (Sorlie et al., 2001), 
Zhao (Zhao et al., 2004) and TCGA (TCGA, 2011) datasets. Histograms 
depicting KDM3A gene expression in each sample, and the p value for the 
comparison of KDM3A expression between the groups, were obtained directly 
through the Oncomine software. 
 
Animal experiments 
 
All animal protocols were approved by the Institution Animal Care and Use 
Committee (IACUC). Animal sample sizes were selected based on precedent 
established from previous publications.  
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In vivo anoikis assays 
 
CLS1 cells were stably transduced with either a NS or Kdm3a shRNA and 
selected with 2 µg/ml puromycin for 5 days. Stably transduced CLS1 cells 
(2x105) were injected into the tail vein of 4-6 week old female BALB/c mice 
(Taconic Biosciences) (n=4 mice per shRNA). Two weeks post injection the lungs 
were harvested, dissociated into single cell suspension, and plated onto tissue 
culture plates. Transduced CLS1 cells were selected for by treating the 
dissociated lung cells with 2 µg/ml puromycin. Surviving colonies were stained 
with crystal violet and quantified by counting. All experiments were performed in 
accordance with the Institutional Animal Care and Use Committee (IACUC) 
guidelines. 
 
Pulmonary tumor assay 
 
67NR cells were transduced with a NS or Kdm3a shRNA and selected with 2 
µg/ml puromycin for 5 days. Stably transduced 67NR cells (2x105) were injected 
into the tail vein of 6-8 week old female BALB/c mice (n=3 mice per shRNA). Five 
weeks post injection, mice were given an intraperitoneal injection of D-Luciferin 
(100 mg/kg) (Gold Biotechnology, St. Louis, MO) and imaged on the Xenogen 
IVIS-100 (Caliper Life Sciences). Images were taken with Living Image software. 
All experiments were performed in accordance with the Institutional Animal Care 
and Use Committee (IACUC) guidelines. 
  
 
35 
 
 
 
Spontaneous metastasis assays 
 
Female BALB/c mice (4-6 weeks) were purchased from Charles River 
Laboratories (Shrewsbury, MA). The mice were housed in facilities managed by 
the McGill University Animal Resources Centre (Montreal, Canada), and all 
animal experiments were conducted under a McGill University–approved Animal 
Use Protocol in accordance with guidelines established by the Canadian Council 
on Animal Care.  
 
Spontaneous metastasis studies were carried out as previously described 
(Tabaries et al., 2011). Briefly, 4T07 cells expressing a NS or Kdm3a shRNA 
were harvested from subconfluent plates, washed once with PBS, and 
resuspended (5x103 cells) in 50 µl of a 50:50 solution of Matrigel (BD 
Biosciences) and PBS. This cell suspension was injected into the right abdominal 
mammary fat pad of BALB/c mice (n=10 mice per shRNA) and measurements 
were taken beginning on day 7 post-injection. Animals that did not develop a 
primary tumor were excluded from the study. Tumor volumes were calculated 
using the following formula: πLW2/6, where L is the length and W is the width of the 
tumor. Tumors were surgically removed, using a cautery unit, once they reached 
a volume around 500 mm3, approximately 3 weeks post injection. Lungs were 
collected 8 weeks post-injection. Tumor burden in the lungs was quantified from 
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four H&E stained step sections (200 µm/step). The number of lesions per section 
were counted using Imagescope software (Aperio, Vista, CA). 
 
Small RNA Profiling 
 
Total RNA was isolated with the mirVana kit (Thermo Fisher Scientific), then 18–
24-nt-long RNA was gel purified.  Size-selected RNA was derived from at least 
50 μg total RNA for attached and detached (24 hours) MCF10A cells. Small RNA 
Library preparation was as described previously (Ghildiyal et al., 2008). Deep 
sequencing was performed at the Umass Medical School Deep Sequencing Core 
Facility. Reads were mapped to known human miRNAs using miRAnalyzer 
(Hackenberg et al., 2011). 
 
Northern Blot Analysis 
 
Total RNA was isolated with the mirVana kit (Thermo Fisher Scientific). At least 
20 μg total RNA was loaded on a 15% denaturing urea-polyacrylamide gel. Semi-
dry transfer was used to transfer the gel to a Hybond N+ nylon membrane (GE 
Healthcare Life Sciences). RNA was crosslinked to the membrane by irradiation 
with 254 nm UV light and the membrane was pre-hybridized with Church buffer 
at 37oC. 5’end P32-labeled Starfire probes (Integrated DNA Technologies) for 
miR-203 (TAGTGGTCCTAAACATTTCA) and U6 
(CACGAATTTGCGTGTCATCCTTGCGCAGGGGCC) were added to the pre-
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hybridization reaction and incubated overnight to detect miRNA. U6 RNA was 
used as a loading control.  
 
miRNA-qRT-PCR 
 
Total RNA was isolated with the mirVana kit (Thermo Fisher Scientific).  At least 
1 μg of RNA was used for cDNA reactions using the miScript II RT Kit (Qiagen) 
according to the manufacturer’s protocol followed by qRT-PCR using the miScript 
SYBR Green kit (Qiagen) with the Universal Primer included in the kit and a 
forward primer specific to the miRNA of interest. U6 RNA was used as an internal 
control (see Table 2.4 for primer sequences).  Each sample was analyzed three 
independent times and the results from one representative experiment, with 
technical triplicates or quadruplicates, are shown. 
 
miRNA Ectopic Expression and Inhibition 
 
For ectopic expression, the pre-miR-203 hairpin sequence was obtained from 
miRBase (mirbase.org). Pre-miR-203 was PCR amplified from MCF10A genomic 
DNA using primers (Forward 5’-AATCTCGAGCTCCTCTCTCCGCAGCTC-3’ 
and Reverse 5’- ATCGAATTCGCACCCCTGACTGTGACTCTG-3’) engineered 
with restriction sites, EcoRI and XhoI, then cloned into pMSCVpuro (ClonTech 
Laboratories, Inc.). Cells stably expressing pMSCVpuro-pre-miR-203 or 
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pMSCVpuro-emtpy were generated by retroviral transduction as described 
previously (Santra et al., 2009). 
 
For miRNA inhibition, a miArrest miRNA Inhibitor specific to miR-203 was 
obtained from Genecopoeia (Rockville, MD). The inhibitor was packaged into 
lentiviral particles and used to infect cells. The scrambled control inhibitor was 
also obtained from Genecopoeia.  
 
AGO2 Immunoprecipitation 
 
Cells were lysed for 30 minutes on ice in cell lysis buffer then centrifuged for 30 
minutes at 14,000 rpm at 4°C. The supernatant was used as cell lysate for the IP. 
Mouse anti-AGO2 (Abcam) was coupled to Protein G Dynabeads (Thermo Fisher 
Scientific) then added to lysates. Antibody-lysate mixtures were rotated for 4 
hours at 4°C to bind RISC in each sample. The beads were washed in IP wash 
buffer supplemented with a protease inhibitor cocktail then eluted in TriPure 
Reagent (Roche Life Sciences). mRNA was purified from immunoprecipitated 
protein complexes using the mirVana miRNA isolation kit (Thermo Fisher 
Scientific). 
 
RNA sequencing and Data Analysis 
 
Total RNA was extracted from MCF10A cells expressing a pMSCV-empty vector 
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control or a pMSCV-pre-miR-203 using the mirVana miRNA Isolation Kit (Thermo 
Fisher Scientific) and mRNA purification, cDNA synthesis, and amplification were 
carried out according to the TrueSeq RNA sample preparation guide (Illumina). 
Libraries were sequenced as 100-bp paired end using Illumina HiSeq 2000. All 
reads were mapped to the human genome using TopHat, followed by running 
Cufflinks to assemble and quantify the transcriptome (Trapnell et al., 2012). 
Empty Vector control and pMSCV-pre-miR-203 total RNA samples were run in 
duplicate. Ago2 IP RNA isolates were run in identical fashion. Relative 
abundances were measured in fragments per kilobase of exon per million 
fragments mapped (FPKM). 
 
Statistics 
 
All quantitative data were collected from experiments performed in at least 
triplicate, and expressed as mean ± standard deviation, with the exception of 
Figures 3.31 and 3.32, which are expressed as mean ± SEM. Differences 
between groups were assayed using two-tailed Student’s t test, except where 
noted above. Significant differences were considered when P<0.05. 
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Gene Forward primer sequence (5’->3’) Reverse primer sequence (5’->3’) 
BAD 
aagactccagctctgcagag 
 
Atgatggctgctgctggttg 
BAK 
tcgacttcatgctgcatcac 
 
acaaactggcccaacagaac 
BAX 
actggacagtaacatggagctg 
 
aaacatgtcagctgccactc 
 
BID 
tgttctgacaacagcttccg 
 
atcagtctgcagctcatcgtag 
 
BIK 
tggctttcatctacgaccagac 
 
gtggtgaaaccgtccatgaaac 
 
BIM tgcagacattttgcttgttcaa 
Gaaccgctggctgcataataat 
 
BMF gaggtacagattgcccgaaa 
Ttcaaagcaaggttgtgcag 
 
BNIP3 
Acgagcgtcatgaagaaagg 
 
aatccgatggccagcaaatg 
BNIP3L 
tgcgaggaaaatgagcagtc 
 
tgccattgctgctgttcatg 
 
BOK 
Acatctccctgcagtctgag 
 
tgcctgcagagaagatgtgg 
 
Gapdh tgcaccaccaactgcttagc 
Ggcatggactgtggtcatgag 
 
HRK 
caccagcgcaccatgtgg 
 
cagccaaggccagtaggtg 
 
JMJD1A 
gagttcaaggctgggctattgt 
 
ttcagccactttgatgcagcta 
Jmjd1a 
attcgagctgtttcccacac 
 
tccaagactccccatcaaac 
METAP1D 
aacaacgtgctctgtcatgg 
 
accacattcgtccacattgc 
 
MULE 
tcaccgcactgtgttaaacc 
 
tgcgcttgacatcaaagtcg 
 
NOXA 
agagctggaagtcgagtgtg 
 
gaagtttctgccggaagttcag 
 
PIH1D3 tattcagacagcaggtgggaac 
agccactagttcactgcaac 
 
PUMA 
acctcaacgcacagtacgag 
 
acctaattgggctccatctcg 
 
RPL41 cattaaatagccgtagacggaactt 
gcgcagaggtttccaaaaaa 
 
ZCCHC24 
Tgccacatcaacgtgtatcca 
 
ggccgtcgggcttctc 
ZNF345 
aaacagggatctcaggaaggac 
 
ggatactgaaagtgggcatgtc 
 
 
  
Table 2.1. qRT-PCR primer sequences for Chapter III.  
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Gene Forward primer sequence (5’ -> 
3’) 
Reverse primer sequence (5’ -> 
3’) 
BNIP3 CACTAGCAGGATGGAAAGACG ACTCTCTGGGCACTGGCTAC 
BNIP3L AGATACCCTGGGTAGCAGTAAC ACCCGGTAAAGAACTAGCAGAG 
JMJD1A CGCTTGTAAAATGGGAGGCATG TTGTGTGCTCTGGACCTGAAG 
NCR (GCLC) ATGGTTGCCACTGGGGATCT TGCCAAAGCCTAGGGGAAGA 
 
  
Table 2.2. ChIP-qRT-PCR primer sequences for Chapter III.  
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Gene Forward primer sequence (5’->3’) Reverse primer sequence (5’->3’) 
AKAP7 acgctgaactagtaaggctcag tgcttcggttttcacagagc 
ANKH ttcatggacgcaatggcatg atctgagattgaggcacatccc 
C4orf33 tgggaaggcaaagcttatctcc tgtccttgctgcagttcatg 
CSRNP2 ttaaatgccaggtggatcgc attcaatgcgtcctgccatg 
GMEB1 tttgcagttacagcctgtgc tccgacccagcttcataaatcc 
HBEGF tttgaaagcccaaggtgctg aaagctacaggcatggaagc 
IFIT3 aagggcgaaggtgtgttttg tacatcgcaattgccagtcc 
IMPACT accccaaatggacactttgc taaatccgcacgttcttgcc 
KIAA1430 tagcacccgggaaaaactactc ttttgcttcccggcttttcc 
KLC4 tgtacaggagtttgggtctgtg tgccggcttttgctcatttc 
LIN7C tgaaagccgcacaaggaaag ttgcctgcgttttgctgatc 
LNX2 aaccgagcacacaaccattc aatgccaagctgttcaccag 
MAP4K3 aattgcatcagcgaggacac ttaggctttggtggcaaagg 
MSRB3 ttggccttcattccacgatg aaaatgtgcccaaggtgagc 
NEDD9 atcttggccatcaacaagcc tgcgttggtgttgatggttg 
NFIL3 aggccacgcaaaaactttcc ttggggcactatgcttttcg 
NIPAL3 acgccaacaacattgtcgtg cccttgaatggacaagacaagc 
PAPSS2 aaatatccgccggattgctg attttgcgggcattctcacg 
PARP11 ttgcaggaaaaaggctcagc tgctggtaccatgaaacagc 
PDE4D tctgagcaacccaacaaagc tttccacggaagcattgtgc 
PDE6D tggctttgtgatccctaactcc ttaagacgcttgctggcatc 
PPAP2B aaatgacgctgtgctctgtg agcagcccacttgcttatagag 
PRKAB1 tctttgtggatggtcagtggac acacatcggagcacttttgg 
PRPS2 aggctgttgtcgtcacaaac ttgcttcggccaagatcatg 
PSMD5 tacggccattgcaaaccaac agctttgtcatgctccacag 
RAPGEF1 tgttgtactgcgaggcattc tgacgcgcttcttgaatgtg 
RASSF6 atcacagcaacaccctgaag agctgcttcactcatggttc 
RPRD2 tctcagcagagacccatttcac atgggcgttttggtgcaaag 
SEC24D aatggctgccatcgattgtg acactggattaaggctccactg 
SEMA5A aaggcctgttacagcaaagg agacaggcgtgaatgcattg 
SMG8 ttgctggaccaacttaggagtc aaagttgttgtcggctgtgc 
SOX13 tgccatgctgtttgagaagc tgctgctgctttgcaatctg 
TP63 tgcaggactcggacctgagt tgttcaggagccccaggtt 
TRPV4 ttttccgattcctgctcgtc ttgcacaccttcatgttggc 
TTC39A aaaggcggcatcaaagttcg ttgtgaggactgaacaaggc 
USP8 gctgtcgaagaagctgaaagac ttttgttgtagccgctgtgc 
VAV3 tccaaaagtgctgggcattg accagccatttgcactcatc 
WDR69 tgcaactgcttcagctgatg accttccagtttggcaatgc 
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ZNF281 ttgccaaagcctccttttgg aggtgtcaactgctgatgtg 
ZNF440 ttgtgtgtggagaagttggc tgccttgtgtccaatgtcac 
ZXDB acacttggaaaagccgttgc aaccatgtgcgtcttcatgc 
pre-miR-
203 gctgggtccagtggttctta gccgggtctagtggtcctaa 
  
Table 2.3. List of qRT-PCR primers for miR-203 candidate target genes 
(Chapter IV).  
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RNA 
Forward primer sequence (5’-
>3’) 
Reverse primer sequence (5’-
>3’) 
miR-197    cgggtagagagggcagtgggagg     Universal Primer (Qiagen) 
miR-203 gtgaaatgtttaggaccactag Universal Primer (Qiagen) 
miR-324 cgcatcccctagggcattggtgt   Universal Primer (Qiagen) 
U6 ctcgcttcggcagcaca aacgcttcacgaatttgcgt 
 
 
 
 
 
 
 
 
  
Table 2.4. List of miRNA-qRT-PCR primer sequences (Chapter IV).  
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CHAPTER III: The histone H3K9 demethylase KDM3A promotes anoikis by 
transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L 
 
Preface 
 
 This research chapter derives from the work I started in my first year in 
Michael Green’s lab, which was completed in the summer of 2016 when it was 
published in the journal eLife entitled “The histone H3K9 demethylase KDM3A 
promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and 
BNIP3L”. I am the first author of this publication with additional authors Stephane 
Gobeil, Sebastien Tabaries, Tessa Simone, Lihua (Julie) Zhu, Peter Siegel and 
Michael Green.  
 
The project was initiated by Stephane Gobeil, a post doctoral associate in 
the Green lab who was my direct mentor for my first year in the lab. Stephane 
developed and performed the genome wide screen for anoikis effector genes and 
validated the candidates. Lihua (Julie) Zhu performed the bioinformatic analysis 
to identify the shRNAs in the deep sequencing of the genome wide screen. 
Stephane also helped perform the in vivo anoikis experiments. Michael Green 
and myself conceived all of the other experiments in this chapter. I performed 
and analyzed all of the subsequent experiments except for the in vivo 
spontaneous metastasis assays which were performed by Sebastien Tabaries in 
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the lab of Peter Siegel at McGill University, Sebastien and Peter also collected 
and analyzed the data from these experiments. Tessa Simone assisted with 
performing and analyzing the annexin-V FACS experiments and Lynn 
Chamberlain and Alysia Bryll provided experimental assistance. Michael Green 
and myself wrote the manuscript with editorial assistance from Sara Deibler. 
Douglas Green (St. Jude Hospital) provided valuable advice on the manuscript. 
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Abstract 
 
Epithelial cells that lose attachment to the extracellular matrix undergo a 
specialized form of apoptosis called anoikis. Here, using large-scale RNA 
interference (RNAi) screening, we find that KDM3A, a histone H3 lysine 9 (H3K9) 
mono- and di-demethylase, plays a pivotal role in anoikis induction. In attached 
breast epithelial cells, KDM3A expression is maintained at low levels by integrin 
signaling. Following detachment, integrin signaling is decreased resulting in 
increased KDM3A expression. RNAi-mediated knockdown of KDM3A 
substantially reduces apoptosis following detachment and, conversely, ectopic 
expression of KDM3A induces cell death in attached cells. We find that KDM3A 
promotes anoikis through transcriptional activation of BNIP3 and BNIP3L, which 
encode pro-apoptotic proteins. Using mouse models of breast cancer metastasis 
we show that knockdown of Kdm3a enhances metastatic potential. Finally, we 
find defective KDM3A expression in human breast cancer cell lines and tumors. 
Collectively, our results reveal a novel transcriptional regulatory program that 
mediates anoikis. 
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Introduction 
 
Epithelial cells that lose attachment to the extracellular matrix (ECM), or 
attach to an inappropriate ECM, undergo a specialized form of apoptosis called 
anoikis. Anoikis has an important role in preventing oncogenesis, particularly 
metastasis, by eliminating cells that lack proper ECM cues (Simpson et al., 2008; 
Zhu et al., 2001). Anoikis also functions to prevent the invasion of tumor cells into 
the luminal space, which is a hallmark of epithelial tumors (Debnath et al., 2002). 
In general, epithelial-derived cancers, such as breast cancer, develop resistance 
to anoikis (reviewed in (Schwartz, 1997). Several signaling pathways have been 
shown to regulate anoikis (reviewed in (Paoli et al., 2013). In particular, anoikis is 
suppressed by integrin signaling, which functions through focal adhesion kinase 
(FAK), an activator of the RAF/MEK/ERK pathway (King et al., 1997). FAK 
signaling is active in attached cells and is inactive following detachment (Frisch 
et al., 1996). Anoikis is also suppressed by integrin-mediated, ligand independent 
activation of the epidermal growth factor receptor (EGFR) signaling pathway 
(Moro et al., 1998), which, like FAK, also stimulates RAF/MEK/ERK activity.  
 
These cell signaling pathways have been found to regulate the levels of 
BIM (also called BCL2L11) and BMF, two pro-apoptotic members of the BCL2 
family of apoptosis regulators previously shown to contribute to anoikis (Reginato 
et al., 2003; Schmelzle et al., 2007). However, depletion of BIM or BMF 
diminishes but does not completely prevent anoikis (Reginato et al., 2003; 
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Schmelzle et al., 2007), suggesting the existence of other factors and regulatory 
pathways that can promote anoikis. Moreover, the basis of anoikis resistance 
remains to be determined and to date has not been linked to alterations in 
expression or activity of BIM or BMF. 
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Results 
 
Identification of KDM3A as an anoikis effector in breast cancer epithelial 
cells. 
 
To investigate the possibility that there are additional factors and 
regulatory pathways that promote anoikis, we performed a large-scale RNA 
interference (RNAi) screen for genes whose loss of expression confer anoikis 
resistance. The screen was performed in MCF10A cells, an immortalized but 
non-transformed human breast epithelial cell line that has been frequently used 
to study anoikis (see, for example, (Huang et al., 2010; Reginato et al., 2003; 
Schmelzle et al., 2007; Taube et al., 2006). A genome-wide human small hairpin 
RNA (shRNA) library comprising ~62,400 shRNAs directed against ~28,000 
genes (Silva et al., 2003; Silva et al., 2005) was divided into 10 pools, which 
were packaged into retroviral particles and used to stably transduce MCF10A 
cells. Following selection, the cells were divided into two populations, one of 
which was plated on poly-2-hydroxyethylmethacrylate (HEMA)-coated plates for 
10 days to inhibit cell attachment to matrix, and another that was cultured 
attached to matrix for 10 days as a control (Figure 3.1). Surviving cells were 
selected and shRNAs identified by deep sequencing. Bioinformatic analysis of 
the two populations identified 26 shRNAs whose abundance was significantly 
enriched >500-fold following detachment (Table 3.1); such shRNAs presumably 
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confer upon MCF10A cells a selective advantage by protecting them from 
undergoing anoikis.  
 
 To validate candidates isolated from the primary screen, we selected the 
top 20 most highly enriched shRNAs and analyzed them in an independent 
assay for their ability to confer resistance to anoikis. Briefly, MCF10A cells were 
transduced with a single shRNA, detached from matrix for 96 hours, and 
analysed for cell death by annexin V staining. As expected, knockdown of BIM, a 
positive control, decreased cell death following detachment compared to the 
control non-silencing (NS) shRNA (Figure 3.2). Of the 20 candidate shRNAs 
tested, five reduced the level of detachment-induced apoptosis compared to the 
NS shRNA, indicating they conferred anoikis resistance (Figure 3.2). Similar 
results were obtained using a second, unrelated shRNA directed against the 
same target gene (Figure 3.3). Quantitative RT-PCR (qRT-PCR) confirmed in all 
cases that expression of the target gene was decreased in the knockdown cell 
line (Figure 3.4).  
 
One of the top scoring validated candidates was KDM3A (Table 3.1), a 
histone demethylase that specifically demethylates mono-methylated (me1) and 
di-methylated (me2) histone H3 lysine 9 (H3K9) (Yamane et al., 2006). H3K9 
methylation is a transcriptional repressive mark, and the identification of KDM3A 
raised the intriguing possibility that induction of anoikis involves transcriptional 
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activation of specific genes through H3K9me1/2 demethylation. Therefore, our 
subsequent experiments focused on investigating the role of KDM3A in anoikis.  
 
We asked whether ectopic expression of KDM3A was sufficient to 
promote cell death in attached cells. MCF10A cells were transduced with a 
retrovirus expressing wild-type KDM3A, a catalytically inactive KDM3A mutant 
[KDM3A(H1120G/D1122N)] (Beyer et al., 2008) or, as a control, empty vector 
(Figure 3.5), and then treated with puromycin for 10 days at which time viability 
was assessed by crystal violet staining. The results of Figure 3.5 show that 
ectopic expression of wild-type KDM3A but not KDM3A(H1120G/D1122N) 
greatly reduced MCF10A cell viability. Collectively, these results demonstrate 
that KDM3A is necessary and sufficient for efficient induction of anoikis in breast 
epithelial cells. 
 
Detachment and loss of integrin and growth factor receptor signaling 
induces KDM3A expression. 
 
We next examined the relationship between KDM3A expression and 
induction of anoikis. The immunoblot of Figure 3.6 shows that KDM3A protein 
levels were undetectable in attached MCF10A cells, but robustly increased in a 
time-dependent manner following detachment. The qRT-PCR analysis of Figure 
3.6 shows that an increase in KDM3A expression following detachment was also 
detected at the mRNA level. 
  
 
53 
We next sought to understand the basis for the increase in KDM3A levels 
following detachment. As mentioned above, anoikis is suppressed by integrin 
signaling, which functions through FAK, a regulator of the RAF/MEK/ERK 
pathway (Frisch et al., 1996; King et al., 1997). Detachment causes a disruption 
in integrin–ECM contacts, resulting in a loss of FAK signaling in the detached 
cells (Frisch and Francis, 1994a; Frisch et al., 1996), which we observed have 
elevated KDM3A levels (see Figure 3.6). We therefore tested whether restoration 
of integrin signaling in detached cells would block the increase in KDM3A levels. 
The results of Figure 3.7 show that the addition of growth factor reduced Matrigel 
basement membrane-like matrix, which restores integrin signaling, to detached 
cells markedly blocked the elevated levels of the BIM isoform BIMEL, as 
expected, and KDM3A. Treatment of MCF10A cells with a FAK inhibitor 
increased the levels of KDM3A protein and mRNA (Figure 3.8). Thus, the 
increase in KDM3A levels upon detachment of MCF10A cells is due, at least in 
part, to the loss of integrin/FAK signaling.   
 
We next analyzed the relationship between the EGFR signaling pathway 
and KDM3A levels. In the first set of experiments, we ectopically expressed 
either EGFR or a constitutively active MEK mutant, MEK2(S222D/S226D) 
(MEK2DD) (Voisin et al., 2008), both of which have been previously shown to 
block anoikis in detached cells (Reginato et al., 2003). Consistent with these 
previous results, Figure 3.9 shows that in detached MCF10A cells, expression of 
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either EGFR or MEK2DD substantially decreased the level of BIMEL (Reginato et 
al., 2003). Expression of either EGFR or MEK2DD also decreased the levels of 
KDM3A in detached MCF10A cells. Conversely, KDM3A protein levels were 
increased in attached MCF10A cells treated with the EGFR inhibitor gefitinib 
(Barker et al., 2001; Ward et al., 1994) (Figure 3.10) or the MEK inhibitor U0126 
(Favata et al., 1998) (Figure 3.11). Both gefitinib and U0126 treatment also 
resulted in increased KDM3A mRNA levels (Figure 3.10 and 3.11).  
 
KDM3A induces anoikis by transcriptionally activating BNIP3 and BNIP3L. 
 
The results described above suggest a model in which following 
detachment, the resulting increase in KDM3A demethylates H3K9me1/2 to 
stimulate expression of one or more pro-apoptotic genes. To test this model and 
identify pro-apoptotic KDM3A target genes, we took a candidate-based approach 
and analyzed expression of a panel of genes encoding pro-apoptotic BCL2 
proteins (Boyd et al., 1994; Lomonosova and Chinnadurai, 2008; Matsushima et 
al., 1998) in attached MCF10A cells and detached cells expressing a NS or 
KDM3A shRNA. We sought to identify genes whose expression increased 
following detachment in control but not in KDM3A knockdown cells. We found 
that expression of the vast majority of genes encoding pro-apoptotic BCL2 
proteins were unaffected by detachment in MCF10A cells (Figure 3.12). 
Consistent with previous results (Reginato et al., 2003; Schmelzle et al., 2007), 
expression of BIM and BMF were increased upon detachment. However, 
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knockdown of KDM3A did not decrease expression of either BIM or BMF. By 
contrast, following detachment, expression of BNIP3 and BNIP3L increased, and 
were the only genes whose expression was diminished more than 2-fold by 
KDM3A knockdown (Figure 3.12). We therefore performed a series of 
experiments to determine whether BNIP3 and BNIP3L are critical KDM3A target 
genes that mediate anoikis. 
 
In the first set of experiments we analyzed BNIP3 and BNIP3L protein 
levels during anoikis induction. The immunoblot of Figure 3.13 shows that BNIP3 
and BNIP3L levels were very low in attached cells and substantially increased 
following detachment, with a time course similar to that of detachment-induced 
KDM3A expression (see Figure 3.6). The chromatin immunoprecipitation (ChIP) 
experiment of Figure 3.14 shows that KDM3A was bound to the BNIP3 and 
BNIP3L promoters in detached but not attached cells. Moreover, the levels of 
H3K9me2 and H3K9me1 (Figure 3.15) on the BNIP3 and BNIP3L promoters 
were greatly diminished following detachment, which was counteracted by 
knockdown of KDM3A. Conversely, overexpression of KDM3A but not 
KDM3A(H1120G/D1122N) in attached MCF10A cells resulted in decreased 
levels of H3K9me1 and H3K9me2 on the BNIP3 and BNIP3L promoters and 
increased expression of BNIP3 and BNIP3L (Figure 3.16). Finally, knockdown of 
BNIP3 or BNIP3L (Figure 3.17) resulted in decreased apoptosis following 
detachment (Figure 3.18). To further establish the pro-apoptotic role of BNIP3 
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and BNIP3L in MCF10A cells, we ectopically expressed BNIP3, BNIP3L or both 
in attached cells (Figure 3.19). Figure 3.19 shows that moderate cell death was 
observed upon ectopic expression of either BNIP3 or BNIP3L, but substantial cell 
death occurred in cells ectopically expressing both BNIP3 and BNIP3L. 
Collectively, these results establish BNIP3 and BNIP3L as critical KDM3A target 
genes that mediate anoikis (Figure 3.20).   
 
KDM3A prevents metastasis and its expression is defective in human 
breast cancer cell lines and tumors. 
 
We considered the possibility that decreased KDM3A expression may 
contribute to anoikis resistance in breast cancer cells and performed a series of 
experiments to test this idea. We first analyzed a panel of human breast cancer 
cell lines (BT549, MDA-MB-231, MCF7, SUM149 and T47D) comparing, as a 
control, anoikis-sensitive MCF10A cells. As expected, detachment-induced 
apoptosis was significantly diminished in breast cancer cell lines compared to 
MCF10A cells, indicative of anoikis resistance (Figure 3.21). Moreover, following 
detachment of the breast cancer cell lines, induction of KDM3A at both the 
protein and mRNA (Figure 3.22) levels was much lower than that observed in 
MCF10A cells. However, ectopic expression of KDM3A was sufficient to induce 
apoptosis in each of the five breast cancer cell lines (Figure 3.23). Collectively, 
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these results indicate that anoikis-resistance of human breast cancer cells is due, 
at least in part, to inefficient induction of KDM3A following detachment. 
 
We next analyzed KDM3A expression in human breast cancer patient 
samples. Interrogation of the Oncomine database (Rhodes et al., 2007) revealed 
decreased expression levels of KDM3A in several breast cancer datasets (Figure 
3.24). To confirm these in silico results, we analyzed KDM3A expression by qRT-
PCR in a series of human breast cancer patient samples. The results of Figure 
3.25 show that compared to normal breast epithelium KDM3A expression was 
significantly decreased in a high percentage of breast cancers. Likewise, basal 
KDM3A expression levels were also diminished in most human breast cancer cell 
lines analyzed (Figure 3.26).   
 
 Finally, we performed a series of experiments to determine whether 
KDM3A affects metastatic potential. We first asked whether depletion of KDM3A 
would promote anoikis resistance in vivo using a mouse pulmonary survival 
assay. Briefly, immortalized but non-transformed mouse mammary epithelial 
CLS1 cells were stably transduced with an NS or Kdm3a shRNA (Figure 3.27) 
and injected into the tail vein of syngeneic mice. After 2 weeks, the lungs were 
harvested, dissociated into single cell suspensions, and plated in media 
containing puromycin to select for cells expressing the shRNA. The surviving 
colonies were visualized by crystal violet staining and quantified. The results of 
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Figure 3.27 show that Kdm3a knockdown significantly increased the number of 
cells that survived in the mouse lung relative to the control NS shRNA. 
 
 In a second set of experiments, we used a well-characterized mouse 
breast cancer carcinoma progression series comprising isogenic cell lines with 
increasing metastatic potential: (1) non-invasive and non-metastatic 67NR cells, 
which form primary tumors, (2) invasive and non-metastatic 4T07 cells, which 
enter the circulation but fail to establish secondary tumors, and (3) highly 
metastatic 4T1 cells, which disseminate widely and colonize distant organ sites 
(Aslakson and Miller, 1992). qRT-PCR analysis revealed decreased Kdm3a 
expression in cell lines with greater metastatic potential (Figure 3.28). We 
expressed either a control NS shRNA or a Kdm3a shRNA in 67NR cells 
containing a luciferase reporter gene (Figure 3.29). Cells were injected into the 
tail veins of three syngeneic mice and pulmonary metastases were visualized by 
live animal imaging after 5 weeks. The results of Figure 3.29 show, as expected, 
that control 67NR cells failed to form pulmonary metastases in any of the three 
mice analyzed. By contrast, Kdm3a knockdown 67NR cells formed substantial 
pulmonary metastases in all three mice.  
 
 Finally, in a more stringent metastasis experiment, control and Kdm3a 
knockdown 4T07 cells (Figure 3.30), a non-metastatic mouse breast cancer cell 
line, were injected in the mammary fat pad of ten syngeneic mice. After 22 days 
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the primary tumors were surgically removed and 8 weeks post-injection the 
animals were sacrificed and pulmonary tumors quantified. The growth of primary 
tumors formed by NS or Kdm3a knockdown cells was similar (Figure 3.31). 
However, Kdm3a knockdown cells caused significantly increased metastatic 
burden in the lungs compared to control 4T07 cells (Figure 3.32). Consistent with 
our results, knockdown of Bnip3 has also been shown to cause increased 
metastasis in similar in vivo experiments (Manka et al., 2005). Collectively, these 
results show that KDM3A functions to prevent metastasis.  
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Transduce with human retrovirual shR N A pools
Puromycin select
Pool surviving cells
Purify genomic DNA
PCR amplify and sequence by high-throughput sequencing to identify    
shRNAs
MCF10A human breast epithlial cells
Replate cells on
poly-HEMA-coated plates
After 10 days, wash and add fresh media containing 
puromycin
Replate on non-poly-HEMA-coated plates for 5 days
Replate cells on
non-poly-HEMA-coated plates
Bioinformatics to identify shRNAs enriched following detachment
Validate with individual shRNAs
Figure 3.1. Schematic of the design of the large-scale RNAi screen to identify 
anoikis effectors. 
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Fold 
enrichment 
(detached vs. 
attached) 
shRNA sequence Gene symbol Gene name 
1620.792946 TAACACTTCACTGTAACTC ZCCHC24 zinc finger CCHC-type containing 24 
1324.931564 AAATGCTTCACAATCAAAG KDM3A lysine demethylase 3A 
1139.789798 TAATCTTCAAATAAGCTGA RALBP1 ralA binding protein 1 
947.6848454 TCACTTACAAGTTTCTTTC RFC1 Replication factor C subunit 1 
848.4223889 AATATAAGGATTGCTATCG LRIG3 
leucine-rich repeats and 
immunoglobulin like domains 3 
798.0503961 TTAAGTAGCTTAGAGAGGG PIH1D3 PIH1 domain containing 3 
720.0231915 TGTCATTCCAAGAGATCCT DKK1 
dickkopf WNT signaling pathway 
inhibitor 1 
710.1463302 ATTTGCCGGAGGATCAAGG SENP6 SUMO1/sentrin specific peptidase 6 
681.0095893 AATCTAATACATTAATCTG PLEKHG1 
pleckstrin homology and RhoGEF 
domain containing G1 
671.1327279 TTGGAGATGAGGCTCAGTG FGD5 
FYVE, RhoGEF and PH domain 
containing 5 
665.2066111 TAATCCAATAATTCATTTC LOC339524  
659.2804943 TTAAAATGGAGACACCATC METAP1D 
methionyl aminopeptidase type 1D 
(mitochondrial) 
645.3541198 ATTCCTTCAAGATTTCAAG VMP1 vacuole membrane protein 1 
633.6006548 TCTCTGATGCTGAGTAAGG ZNF345 zinc finger protein 345 
619.2792059 TTCTATCGAATAAGCAATC FAM227B 
family with sequence similarity 227 
member B 
610.5022036 TTACGTTTCTGAATTTCTG PDE7A(variant 2) phosphodiesterase 7A 
609.6640814 AACTTATAGACATTCAGAC GPC5 glypican 5 
605.9454431 TTCCCTCACATGTGGGATG AP4M1 
adaptor related protein complex 4 mu 1 
subunit 
598.4192748 ATTGAAATATTGAAACTTC SUSD1 sushi domain containing 1 
561.9934101 ATAGAGAAAGTCTTTATAC RBFOX3 
RNA binding protein, fox-1 homolog (C. 
elegans) 3 
559.5241948 TAGAATAAGAACTACTGTC DNAJB9 
DnaJ heat shock protein family (Hsp40) 
member B9 
543.6619555 TTAATCTTATCTTTGCCTG CYP39A1 
cytochrome P450 family 39 subfamily A 
member 1 
527.4243955 TGAAAGACTTAACAATTGG CECR5-AS1 CECR5 antisense RNA 1 
526.4367093 TAACTTCAAAGGTGTATCC ADH7 
alcohol dehydrogenase 7 (class IV), mu 
or sigma polypeptide 
518.5352203 ATAGATATATGCATTTAGG RNF125 
ring finger protein 125, E3 ubiquitin 
protein ligase 
513.1029465 TATTAGGAATCTTAACCAC HOXA11 homeobox A11 
Table 3.1 List of 26 shRNAs, and the target genes, whose abundance was significantly 
enriched >500-fold following detachment of MCF10A cells. 
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Figure 3.2. Knockdown of anoikis effector candidate genes causes a 
resistance to anoikis. (A) Cell death, monitored by annexin V staining, in 
MCF10A cells expressing a non-silencing (NS) shRNA and cultured attached to 
the matrix, or in detached cells (cultured in suspension for 96 h) expressing a 
NS shRNA or one of five candidate shRNAs. Error bars indicate SD. P value 
comparisons are made to the detached, NS shRNA control. **P<0.01. (B) FACS 
analysis. Representative FACS plots corresponding to the bar graph in A. 
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Figure 3.3. Knockdown of anoikis effector candidate genes with a second 
shRNA also causes a resistance to anoikis. (A) Cell death, monitored by 
annexin V staining, in MCF10A cells expressing a non-silencing (NS) shRNA and 
cultured attached to the matrix, or in detached cells (cultured in suspension for 96 
h) expressing a NS shRNA or one of five candidate shRNAs unrelated to those 
used in Figure 3-2. Error bars indicate SD. **P<0.01. (B) Representative FACS 
plots corresponding to (A). 
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Figure 3.4. Analysis of BIM and candidate shRNA knockdown 
efficiencies. qRT-PCR analysis monitoring knockdown efficiencies of BIM 
and two unrelated shRNAs directed against the five candidate genes in 
MCF10A cells. Error bars indicate SD. *P<0.05; **P<0.01. 
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Figure 3.5. Ectopic expression of WT KDM3A but not a catalytic dead 
mutant causes cell death in MCF10A cells. (A) Crystal violet staining of 
MCF10A cells expressing vector, KDM3A or the catalytically-inactive 
KDM3A(H1120G/D1122N) mutant. (B) Immunoblot analysis monitoring levels of 
KDM3A in MCF10A cells expressing vector, KDM3A or 
KDM3A(H1120G/D1122N). The results confirm increased expression of KDM3A 
in cells transfected with KDM3A-expressing plasmids. α-tubulin (TUBA) was 
monitored as a loading control. 
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Figure 3.6.  KDM3A is induced upon detachment from the ECM. (A) 
Immunoblot monitoring KDM3A levels in attached MCF10A cells, or 
detached cells cultured in suspension for 4, 8 or 24 h. β-actin (ACTB) was 
monitored as a loading control. (B) qRT-PCR analysis monitoring KDM3A 
mRNA levels in attached MCF10A cells, or detached cells cultured in 
suspension for 24 h. Error bars indicate SD. **P<0.01. 
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Figure 3.7. The induction of KDM3A upon detachment from the ECM is due 
to the loss of integrin signaling. Immunoblot monitoring levels of KDM3A and 
BIMEL in attached MCF10A cells or detached MCF10A cells cultured in 
suspension for 24 h and treated in the presence or absence of Matrigel. α-
tubulin (TUBA) was monitored as a loading control. 
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Figure 3.8. Inhibition of FAK in attached MCF10A cells causes 
induction of KDM3A. (A) Immunoblot monitoring levels of KDM3A, 
phosphorylated FAK (p-FAK) or total FAK (t-FAK) in MCF10A cells 
treated for 48 hours with 0, 1, 5 or 10 µM FAK inhibitor. (B) qRT-PCR 
analysis monitoring KDM3A expression in MCF10A cells treated for 48 
hours with 0, 1, 5 or 10 µM FAK inhibitor.  
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Figure 3.9. Ectopic expression of EGFR or an activated form of MEK 
blocks the induction of KDM3A upon detachment from the ECM. 
Immunoblot monitoring levels of KDM3A and BIMEL in MCF10A cells 
expressing either vector, EGFR or MEK2DD and cultured as attached (A) or 
detached (D) cells grown in suspension for 24 h. 
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Figure 3.10.  Inhibition of EGFR in attached MCF10A cells causes 
induction of KDM3A. (A) Immunoblot monitoring levels of KDM3A, 
phosphorylated EGFR (p-EGFR) or total EGFR (t-EGFR) in MCF10A cells 
treated for 48 hours with 0, 1, 5 or 10 µM Gefitinib. (B) qRT-PCR analysis 
monitoring KDM3A expression in MCF10A cells treated for 48 hours with 0, 
1, 5 or 10 µM Gefitinib. 
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Figure 3.11.  Inhibition of ERK in attached MCF10A cells causes 
induction of KDM3A. (A) Immunoblot monitoring levels of KDM3A, 
phosphorylated ERK (p-ERK) or total ERK (t-ERK) in MCF10A cells 
treated for 48 hours with 0, 1, 5 or 10 µM U0126. (B) qRT-PCR 
analysis monitoring KDM3A expression in MCF10A cells treated for 
48 hours with 0, 1, 5 or 10 µM U0126. 
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Figure 3.12. Knockdown of KDM3A abrogates the induction of BNIP3 
and BNIP3L upon detachment of MCF10A cells from the ECM. (A) qRT-
PCR analysis monitoring expression of pro-apoptotic BCL2 genes in 
detached MCF10A cells grown in suspension for 24 h and expressing a NS 
or KDM3A shRNA. The expression of each gene is shown relative to that 
obtained in attached cells expressing a NS shRNA, which was set to 1. P 
value comparisons for each gene are made to the NS shRNA control. Genes 
whose expression is decreased >2-fold upon KDM3A knockdown are 
indicated in red. (B) qRT-PCR analysis monitoring expression of BCL2 pro-
apoptotic genes in detached MCF10A cells expressing a NS or a second, 
unrelated KDM3A shRNA to that used in Figure 3A. The expression of each 
gene is shown relative to that obtained in attached cells, which was set to 1. 
Error bars indicate SD. *P<0.05; **P<0.01. 
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Figure 3.13. BNIP3 and BNIP3L are induced upon detachment 
from the ECM.  Immunoblot analysis monitoring levels of BNIP3 and 
BNIP3L in attached MCF10A cells, and detached cells following 
growth in suspension for 4, 8 or 24 h. 
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Figure 3.14. KDM3A is enriched on the promoters of BNIP3 and 
BNIP3L upon detachment from the ECM. ChIP monitoring binding 
of KDM3A on the promoters of BNIP3 and BNIP3L or a negative 
control region (NCR) in attached MCF10A cells or detached cells 
grown in suspension for 24 h. P value comparisons for each region 
are made to the attached control. Error bars indicate SD. *P<0.05; 
**P<0.01 
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Figure 3.15. The levels of H3K9me1 and H3K9me2 on the BNIP3 and BNIP3L 
promoters are diminished following detachment, which is counteracted by 
knockdown of KDM3A. (A) ChIP monitoring the levels of H3K9me1 on the 
promoters of BNIP3 and BNIP3L or a negative control region (NCR) in attached 
MCF10A cells or detached cells expressing a NS or KDM3A shRNA and grown in 
suspension for 24 h. (B)ChIP monitoring the levels of H3K9me2 on the promoters 
of BNIP3 and BNIP3L or a negative control region in attached MCF10A cells or 
detached cells expressing a NS or KDM3A shRNA and grown in suspension for 24 
h. P value comparisons for each region are made to the detached, NS shRNA 
control. Error bars indicate SD. *P<0.05; **P<0.01. 
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Figure 3.16. Overexpression of KDM3A, but not 
KDM3A(H1120G/D1122N), in attached MCF10A cells results in decreased 
levels of H3K9me1 and H3K9me2 on the BNIP3 and BNIP3L promoters 
and increased expression of BNIP3 and BNIP3L. (A) ChIP monitoring the 
levels of H3K9me1, H3K9me2 and KDM3A on the promoters of BNIP3 and 
BNIP3L or a negative control region (NCR) in attached MCF10A cells 
expressing empty vector, wild-type KDM3A or KDM3A(H1120G/D1122N). The 
increased occupancy of KDM3A(H1120G/D1122N) on the BNIP3 and BNIP3L 
promoters is not unexpected because the mutations are in the catalytic 
domain and should not affect DNA binding. (B) qRT-PCR analysis monitoring 
expression of BNIP3, BNIP3L or KDM3A in attached MCF10A cells expressing 
empty vector, wild-type KDM3A or KDM3A(H1120G/D1122N). Error bars 
indicate SD. *P<0.05; **P<0.01. 
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Figure 3.17. Analysis of BNIP3 and BNIP3L shRNA knockdown 
efficiencies. qRT-PCR analysis monitoring knockdown efficiency of two 
unrelated BNIP3 and BNIP3L shRNAs in MCF10A cells. Error bars 
indicate SD. **P<0.01. 
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Figure 3.18.  Knockdown of BNIP3 and BNIP3L causes resistance to anoikis upon 
detachment from the ECM. (A) Cell death, monitored by annexin V staining, in 
MCF10A cells expressing a NS, BNIP3 or BNIP3L shRNA. (B) Cell death, monitored by 
annexin V staining, in MCF10A cells expressing a non-silencing (NS) shRNA or BNIP or 
BNIP3L shRNA unrelated to that used in A. Error bars indicate SD. *P<0.05; **P<0.01. 
(C) Representative FACS plots corresponding to A and B 
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Figure 3.19. Ectopic expression of BNIP3 and BNIP3L causes cell death in 
attached MCF10A cells.  (A) Immunoblot analysis monitoring levels of BNIP3 or 
BNIP3L in MCF10A cells expressing vector, BNIP3 or BNIP3L. The results confirm 
increased expression of the proteins. α-tubulin (TUBA) was monitored as a loading 
control. (B) Crystal violet staining of MCF10A cells expressing vector, BNIP3, 
BNIP3L or both BNIP3 and BNIP3L 
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Figure 3.20. KDM3A induces anoikis by transcriptionally activating 
BNIP3 and BNIP3L. Model of KDM3A activity in response to detachment 
from the ECM in MCF10A cells. When MCF10A cells are detached from the 
ECM the loss of integrin signaling leads to the induction of KDM3A, which 
then demethylates H3K9me1 and H3K9me2 on the promoters of BNIP3 and 
BNIP3L leading to transcriptional activation and subsequent cell death.   
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Figure 3.21. Breast cancer cell lines are resistant to anoikis. (A) Cell death, 
monitored by annexin V staining, in MCF10A cells and a panel of human breast 
cancer cell lines cultured as attached cells or detached following growth in 
suspension for 96 h. Error bars indicate SD. P value comparisons for each breast 
cancer cell line are made to the detached MCF10A sample. *P<0.05; **P<0.01. 
(B) Representative FACS plots corresponding to A.  
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Figure 3.22. KDM3A is not induced in anoikis resistant breast 
cancer cell lines upon detachment from the ECM. (A) Immunoblot 
analysis monitoring KDM3A levels in MCF10A cells and a panel of 
human breast cancer cell lines cultured as attached (A) cells or detached 
(D) following growth in suspension for 24 h. All images for the KDM3A 
antibody were cropped from the same blot, and thus were processed and 
exposed in the same manner, as were images for the TUBA loading 
control. (B) qRT-PCR analysis monitoring KDM3A expression in MCF10A 
cells and a panel of human breast cancer cell lines cultured as attached 
cells or detached following growth in suspension for 24 h. Error bars 
indicate SD. P value comparisons for each breast cancer cell line are 
made to the detached MCF10A sample.  *P<0.05; **P<0.01. 
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Figure 3.23.  Ectopic expression of WT KDM3A, but not catalytically 
inactive KDM3A, causes cell death in a panel of breast cancer cell 
lines. Crystal violet staining of human breast cancer cells expressing vector, 
KDM3A or KDM3A(H1120G/D1122N). 
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Figure 3.24. Oncomine analysis of KDM3A expression in breast cancer. 
The Oncomine Cancer Profiling database was queried to access Finak (A), 
Sorlie (B), Zhao (C) and The Cancer Genome Atlas (TCGA) (D) breast 
cancer data sets. The results reveal that KDM3A is significantly under-
expressed in breast carcinoma relative to normal tissue. 
  
 
85 
       
 
 
 
  
N
or
m
al TN
E
R
- H
ER
2+
ER
+ 
H
ER
2+
ER
+ 
H
ER
2-
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
R
e
la
tiv
e
 K
D
M
3
A
 e
x
p
re
s
s
io
n
** ******
qRT-PCR
Figure 3.25. Human breast cancers have a low expression of KDM3A 
compared to normal breast tissue. qRT-PCR analysis monitoring KDM3A 
expression in normal breast epithelial cells and human breast tumors. TN, 
triple negative [estrogen receptor-negative (ER-), human epidermal growth 
factor receptor 2-negative (HER2-) and progesterone receptor-negative (PR-
)]. Error bars indicate SD. The differences in expression between subtypes 
were not statistically significant. *P<0.05; **P<0.01. 
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Figure 3.26.  A panel of breast cancer cells have a low level of basal 
KDM3A expression in attached cells. qRT-PCR analysis of KDM3A 
expression in MCF10A cells and a panel of human breast cancer cell 
lines cultured as attached cells. The results were normalized to that 
obtained in MCF10A cells, which was set to 1. The results show that 
basal KDM3A expression levels were diminished in four of five human 
breast cancer cell lines analyzed. Error bars indicate SD. *P<0.05; 
**P<0.01. 
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Figure 3.27. Knockdown of Kdm3a in CLS1 cells causes resistance to 
anoikis in vivo. (A) qRT-PCR analysis monitoring knockdown efficiency of 
Kdm3a in CLS1 cells. Error bars indicate SD. (B) Mouse pulmonary survival 
assay. (Left) Representative plates showing colony formation of CLS1 cells 
expressing a NS or Kdm3a shRNA that had been isolated from mouse lungs 
following tail vein injection. (Right) Quantification of colony formation (n=4 mice 
per shRNA). Error bars indicate SD. *P<0.05; **P<0.01. 
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Figure 3.28. Kdm3a expression progressively decreases across a 
mouse breast cancer carcinoma progression series. qRT-PCR 
analysis of Kdm3a expression in 67NR, 4T07, and  4T1 cells. Error bars 
indicate SD. **P<0.01. 
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Figure 3.29. Knockdown of Kdm3a in 67NR cells causes tumor growth 
in the lungs. (A) Analysis of Kdm3a shRNA knockdown efficiency in mouse 
67NR cells. qRT-PCR analysis monitoring knockdown efficiency of Kdm3a in 
67NR cells. Error bars indicate SD. **P<0.01. (B) Live animal imaging 
monitoring lung tumor metastasis in mice following injection of 67NR cells 
expressing a NS or Kdm3a shRNA (n=3 mice per group). 
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Figure 3.30. Analysis of Kdm3a shRNA knockdown efficiency in 
mouse 4T07 cells. qRT-PCR analysis monitoring knockdown 
efficiency of two unrelated Kdm3a shRNAs in 4T07 cells. Error bars 
indicate SEM. *P<0.05. 
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Figure 3.31. Knockdown of Kdm3a in 4T07 cells leads to increased 
metastatic burden in the lungs. (A) Primary tumor growth in mice 
injected with 4T07 cells expressing a NS (n=7) or Kdm3a (n=8) shRNA. 
Error bars indicate SEM. The differences in primary tumor growth 
between groups were not statistically significant. (B) Metastatic burden. 
Number of metastatic lesions per lung in mice injected with 4T07 cells 
expressing a NS (n=7) or Kdm3a (n=8) shRNA. Error bars indicate SEM. 
**P<0.01. 
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Figure 3.32. Confirmation of the results of Figure 3-31 with a second 
unrelated Kdm3a shRNA. (A) Primary tumor growth in mice injected with 4T07 
cells expressing a NS (n=7) or Kdm3a (n=9) shRNA unrelated to that used in 
Figure 3-31. Error bars indicate SEM. (B) Number of metastatic lesions per lung 
in mice injected with 4T07 cells expressing a NS (n=7) or Kdm3a (n=9) shRNA 
unrelated to that used in Figure 4I. Error bars indicate SEM. **P<0.01. The 
differences in primary tumor growth between groups were not statistically 
significant. 
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Conclusions 
 
 
Based on the results presented above, we propose a model of anoikis 
induction that is illustrated in Figure 3.20 and discussed below. Following 
detachment of non-transformed cells, integrin signaling is decreased leading to 
decreased FAK, EGFR and RAF/MEK/ERK signaling and subsequent 
transcriptional induction of KDM3A. The increased levels of KDM3A result in its 
recruitment to the pro-apoptotic genes BNIP3 and BNIP3L, where it promotes 
demethylation of inhibitory H3K9me1/2 marks and transcriptional activation of the 
two genes, resulting in anoikis induction. Consistent with this model, previous 
studies have shown that hypoxia results in transcriptional activation of KDM3A, 
BNIP3 and BNIP3L (Beyer et al., 2008; Sowter et al., 2001).  
 
We have found that in anoikis-resistant human breast cancer cell lines and 
tumors, KDM3A expression is defective, highlighting the importance of this 
pathway in promoting anoikis. And we found that the knockdown of Kdm3a 
caused a non-metastatic mouse mammary carcinoma cell line to metastatize to 
the lung. In agreement with this result it has been previously shown that the 
knockdown of BNIP3 causes enhanced metastasis to the lung in the same 
mouse cell line (Manka et al., 2005). Collectively, our results reveal a novel 
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transcriptional regulatory program that mediates anoikis in non-transformed cells 
and is disabled during cancer development.  
 
As described above, previous studies have shown that BIM and BMF are 
also effectors of anoikis (Reginato et al., 2003; Schmelzle et al., 2007). However, 
we have found that unlike BNIP3 and BNIP3L, BIM and BMF are not regulated 
by KDM3A. Thus, our results reveal that anoikis is promoted by multiple non-
redundant pathways, which may help prevent the development of anoikis 
resistance.  
 
The role of KDM3A in cancer has not been thoroughly studied and has so 
far been controversial. There has been evidence to suggest that KDM3A has 
both an anti-oncogenic effect on cancer, as we presented here, (Du et al., 2011) 
and a pro-oncogenic effect (Krieg et al., 2010). In fact, in the time since we 
submitted our manuscript another group has published a study that shows 
KDM3A plays a pro-oncogenic role in breast cancer and that the knockdown of 
KDM3A sensitized breast cancer stem cells to chemotherapeutic drugs 
(Ramadoss et al., 2016). Although this other study on KDM3A did not specifically 
study anoikis, it is contradictory to our results in breast cancer. However, the 
opposing study does not use the same cell lines or mouse model of breast 
cancer as we do, leaving open the possibility that the role of KDM3A is context 
dependent and can even differ within the same cancer type.  Further research is 
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needed to fully elucidate the context dependent mechanism by which KDM3A 
functions in breast cancer and in other types of cancer.  
 
One aspect that has so far not been studied is the transcriptional control of 
KDM3A. We find that KDM3A is transcriptionally activated upon the loss of 
integrin signaling and the subsequent loss of FAK, EGFR and RAF/MEK/ERK 
signaling.  However, we have not identified the specific transcription factors or 
complexes that control the expression of KDM3A, which could be factors in 
identifying how the role of KDM3A differs between cancers. It is also possible 
that KDM3A activates the transcription of genes other than BNIP3 and BNIP3L 
following detachment, as we did not perform genome wide ChIP-sequencing 
experiments to identify all possible KDM3A sites.  
 
In conclusion, our results provide identification of a novel pathway that 
promotes anoikis and furthers the knowledge of the function of KDM3A. We offer 
insight into a potential mechanism of anoikis resistance in breast cancer and 
show that this mechanism of anoikis resisance can lead to increased metastasis. 
Taken together, our results have had a significant impact on the field of anoikis 
research.  
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CHAPTER IV: miR-203 regulates anoikis through targeting a network of 
pro-survival genes 
 
 
Preface 
 
 
This research chapter derives from a project that I designed and initiated 
in 2012 and has continued until the preparation of this dissertation. Michael 
Green and I had discussed the potential role of miRNAs during anoikis and after 
realizing that miRNA expression profiling during anoikis had not yet been 
performed, I set out to do just that. Desiree Brady, a graduate student in Phillip 
Zamore’s lab assisted me with the initial small RNA sequencing, which I 
performed in the Zamore lab with the help of Desiree. Phillip Zamore and his lab 
provided me with expertise, reagents, and protocols to assist in the successful 
completion of the small RNA sequencing. The small RNA sequencing data was 
generated by the UMMS Deep Sequencing Core Facility and analyzed by Lihua 
(Julie) Zhu and Jianhong Ou. The TCGA data was analyzed by Jun Yu. 
 
 The total RNA sequencing and AGO2-Immunoprecipitation RNA 
sequencing was conceived of and designed by me and performed by Alexander 
Boardman, a UMMS medical student who did a research project in the Green 
lab. All of the RNA sequencing data was also generated by the UMMS Deep 
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Sequencing Core Facility and analyzed by Lihua (Julie) Zhu and Jianhong Ou. 
Amy Virbasius and the UMMS shRNA Core Facility provided targeted shRNAs.  
 
 Tessa Simone assisted with the Annexin-V FACS experiments. Michael 
Green and myself conceived of and designed all other experiments and I 
performed all of the other experiments. I analyzed all the data and composed all 
of the figures with editorial assistance from Sara Deibler. Lynn Chamberlain 
provided experimental assistance with most of the qRT-PCR experiments.  
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Abstract 
 
Anoikis, apoptosis after detachment of cells from the ECM, is a complex and 
diverse biological process that is not yet fully understood. While genome wide 
studies have been performed to identify gene expression changes that play a 
role in anoikis, similar genome wide microRNA (miRNA) studies have not yet 
been done. Here, I completed miRNA expression profiling during the early stages 
of anoikis in breast epithelial cells and have identified miR-203 as a critical pro-
anoikis miRNA. After detachment, miR-203 is significantly upregulated and 
ectopic expression of miR-203 in attached cells causes widespread cell death. 
Likewise, inhibition of miR-203 causes a resistance to anoikis. Coordinated RNA 
sequencing and AGO2-immunoprecipitation RNA sequencing revealed miR-203 
directly targets a network of pro-survival genes after detachment to promote 
anoikis. Finally, I show that the elevation of four anoikis-related pro-survival miR-
203 target genes are elevated in breast cancers that have low miR-203.  
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Introduction 
 
Anoikis, cell death after detachment of epithelial cells from the extra 
cellular matrix (ECM) happens due to the loss of integrin signaling. Resistance to 
anoikis is a critical step in metastasis (reviewed in (Simpson et al., 2008)) 
however, the mechanism by which metastatic cells become resistant to anoikis is 
not well understood. Here, we performed genome wide small RNA sequencing 
analysis in anoikis-sensitive breast epithelial cells to determine changes in 
miRNA expression upon detachment from the ECM. We identified miR-203 as an 
anoikis effector miRNA and show that miR-203 is highly induced upon 
detachment and that inhibition of miR-203 results in a resistance to anoikis. 
Furthermore, we find that ectopic expression of miR-203 is sufficient to induce 
apoptosis in attached cells. Finally, we identified direct miR-203 target mRNAs 
through a dual functional- and expression-based RNA-sequencing approach. We 
show that a subset of miR-203 target genes contributes to cell survival and upon 
detachment, miR-203 targets this subset of mRNAs subsequently leading to 
detachment-induced apoptosis.  
 
The detachment-induced loss of integrin signaling triggers downstream 
intercellular signaling events leading to cell death. Many signaling pathways are 
known to be involved in anoikis, including FAK and RAF/MEK/ERK signaling. 
When cells are attached to the ECM, integrin signaling activates FAK which 
recruits and activates SRC. The activation of SRC then leads to 
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autophosphorylation and further activation of FAK, which activates PI3K and 
RAF/MEK/ERK signaling.  In addition to FAK, SRC activation also leads to 
phosphorylation and activation of EGFR, in a ligand-independent manner, which 
also activates RAF/MEK/ERK signaling. All of these signaling events in attached 
cells contribute to proliferation, growth, and survival of cells and when this 
signaling is lost upon detachment from the ECM it results in anoikis.  
 
Many studies to date have identified genes involved in anoikis whose 
expression is altered upon detachment (Pedanou et al., 2016; Reginato et al., 
2003; Schmelzle et al., 2007) leading to the hypothesis that anoikis is the 
consequence of global changes in gene expression upon detachment. While 
there have been studies that explore global mRNA expression changes upon 
detachment (Schmelzle et al., 2007), another mode of gene expression control 
that has yet to be well studied upon detachment is changes in microRNA 
(miRNA) expression. miRNAs control mRNA and protein expression by binding 
to the 3’UTRs of specific target genes which inhibits translation and degrades the 
mRNA. To date, few miRNAs have been shown to play a role in anoikis however, 
the global change in miRNA expression upon detachment has not been studied.  
 
While miRNAs have not been well studied in anoikis, they have been 
widely studied in breast cancer. Profiling studies have revealed multiple miRNAs 
that are either up- or down-regulated at different stages of breast cancer 
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progression (Luo et al., 2013; Wang and Wang, 2012). This led us to hypothesize 
that there are global changes in miRNA expression that are critical for anoikis 
and the alteration of these miRNAs in cancer could lead to anoikis resistance. 
Since the only studies to date that link miRNAs to anoikis investigate single (or a 
few) miRNAs, it is likely that we do not yet have a clear picture of the role of 
miRNAs during the process of anoikis.  
 
Here, we investigate changes in miRNA levels upon detachment of breast 
epithelial cells by small RNA sequencing. We show miR-203 is significantly 
induced upon detachment of cells and this induction is critical for anoikis. 
Additionally, we utilized a dual RNA-sequencing approach to identify direct miR-
203 target genes. We further show that a subset of these target genes 
contributes to cell survival and miR-203 targeted repression of these genes after 
detachment from the ECM contributes to anoikis. Finally, we found that four 
direct miR-203 anoikis-related target genes are significantly elevated in triple 
negative breast cancer, a subset of breast cancer where miR-203 has been 
shown to be highly downregulated compared to other types of breast cancer. 
Together, these results implicate miR-203 as an anoikis effector miRNA and 
suggest a link between decreased miR-203 expression and anoikis resistance in 
triple negative breast cancer.  
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Results 
 
 
Small RNA profiling identifies miR-203 as an anoikis effector in breast 
epithelial cells 
 
To investigate the role of miRNAs in anoikis we sought to measure 
changes in miRNA expression upon detachment of cells using small RNA 
sequencing (small RNA-seq). The small RNA-seq was performed in MCF10A 
cells, an immortalized but non-transformed breast epithelial cell line that is 
sensitive to anoikis in cell culture (Debnath et al., 2002; Reginato et al., 2003). 
Briefly, small RNA (18-24 nucleotides) was isolated from total RNA from attached 
MCF10A cells and detached MCF10A cells, cultured in suspension for 24 hours 
(on polyHEMA coated plates). After mapping the deep sequencing reads to the 
human miRNA genome, the analysis showed the miRNA content of each small 
RNA-seq sample was over 75% (Table 4.1). The deep sequencing analysis 
identified 9 upregulated miRNAs and 8 downregulated miRNAs that were greater 
than 100 counts per million in the sequencing reads and had P-values of less 
than 0.01 following detachment from the ECM (Table 4.2 and Figure 4.1). We 
were interested in the miRNAs that were upregulated post-detachment because 
the induction suggested that those miRNAs could be critical anoikis effector 
miRNAs.  
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To validate the upregulated miRNAs we first identified which miRNAs 
were either implicated as tumor suppressive miRNAs or were implicated as pro-
apoptosis miRNAs. We then measured the level of individual miRNAs in 
MCF10A cells after detachment by directed miRNA-qRT-PCR analysis. We 
found that 3 of these miRNAs, miR-197 (Yang et al., 2015), miR-324 (XU et al., 
2014), and miR-203 (Wang et al., 2013) were significantly induced in MCF10A 
cells following detachment for 24 and 48 hours (Figure 4.2).   
 
Both the small RNA-seq data and the miRNA-qRT-PCR revealed miR-203 
to be the most highly upregulated miRNA upon detachment, which we further 
confirmed by northern blot (Figure 4.3). Additionally, miR-203 has been shown to 
inhibit cancer cell invasion and proliferation (Benaich et al., 2014) and inhibits 
stem cell self-renewal (Yi et al., 2008). These data suggest that miR-203 is 
critical for anoikis and the loss of miR-203 potentially contributes to anoikis 
resistance in invasive cancers, therefore we focused our experiments on the role 
of miR-203 in anoikis. In order to identify the mechanism by which miR-203 is 
induced, we tested transcriptional activation of the precursor-miR-203 (pre-miR-
203). Increased transcription of the primary miR-203 (pri-miR-203) transcript 
would result in an increased expression of pre-miR-203 however, the results of 
Figure 4.4 show that only the mature miR-203 is significantly induced upon 
detachment whereas the expression of pre-miR-203 is not significantly changed. 
These results suggest that the induction of miR-203 is due to the increased 
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processing of mature miR-203 instead of increased transcription of the primary 
miR-203 transcript. 
 
miR-203 is critical for anoikis and is induced by the loss of integrin 
signaling 
 
 To determine if the induction of miR-203 promotes cell death after 
detachment from the ECM we ectopically expressed miR-203 in attached cells by 
transducing MCF10A cells with a retrovirus containing pre-miR-203 (Figure 4.5), 
which leads to high levels of mature miR-203 as a result of endogenous 
processing machinery (Isobe et al., 2014) or an empty vector control. The cells 
were treated with puromycin for 4 days after which survival was monitored by 
crystal violet staining and cell death was monitored by annexin-V.. The cells that 
contain the ectopically expressed pre-miR-203 show a significant decrease in 
survival (Figure 4.6) and a significant increase in cell death (Figure 4.7) as 
compared to an empty vector control in attached MCF10A cells.  This data 
demonstrates that the increased level of miR-203 causes cell death in MCF10A 
cells.  
 
 In order to prove that miR-203 is critical for detachment-induced apoptosis 
we performed inhibition experiments in MCF10A cells. Briefly, we transduced 
MCF10A cells with a lentiviral miR-203 inhibitor or a lentiviral scrambled control 
and cultured the cells in attached conditions or detached conditions for 96 hours 
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and analyzed cell death by annexin-V staining. We observed significantly 
decreased cell death in MCF10A cells expressing the miR-203 inhibitor upon 
detachment from the ECM as compared to the scrambled control expressing 
detached MCF10A cells (Figure 4.8). We confirmed the activity of the miR-203 
inhibitor in 293T cells with a GFP miR-203 sensor. The miR-203 sensor is 
manufactured to contain 2 miR-203 seed sequence sites in the 3’UTR of GFP so 
that increased GFP expression would indicate lower miR-203 activity and vice 
versa (Figure 4.9). This data shows that not only is miR-203 sufficient to cause 
cell death in MCF10A cells but it is necessary for normal levels of anoikis in 
MCF10A cells upon detachment from the ECM.   
 
 Anoikis occurs after cells detach from the ECM primarily because of the 
loss of integrin signaling (Frisch and Ruoslahti, 1997). We sought to confirm that 
induction of miR-203 after detachment is also primarily due to the loss of integrin 
signaling in order to solidify miR-203 as an anoikis effector. We restored integrin 
signaling in detached cells by adding growth factor reduced matrigel to the media 
and monitored the expression of miR-203 by miRNA-qRT-PCR. The results of 
Figure 4.10 show that the addition of growth factor reduced Matrigel basement 
membrane-like matrix, which restores integrin signaling, to the media significantly 
blocks the induction of miR-203 in detached cells. Therefore, miR-203 is induced 
following detachment from the ECM due to the loss of integrin signaling.  
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Identification of miR-203 target genes in breast epithelial cells through 
RNA-seq and AGO2-IP-RNA-seq  
 
 We next sought to determine the direct target genes that are critical for the 
function of miR-203 during anoikis by utilizing a dual unbiased, deep sequencing 
approach (Furuta et al., 2013). First, we performed RNA co-immunoprecipitation 
with an anti-Ago2 antibody in MCF10A cells expressing pre-miR-203 or an empty 
vector control followed by RNA-sequencing of the mRNAs from the Ago2-IP 
(Ago2-IP-Seq). A previous study has shown that the ectopically expressed 
miRNA overloads the RISC machinery in comparison to the endogenous 
miRNAs and the majority of mRNAs that are enriched in the Ago2-IP are direct 
targets of the miRNA of interest; however false positives are still a problem 
(Furuta et al., 2013). To rule out false positives from the AGO2-IP-Seq, we 
measured the global gene expression changes caused by the induction of miR-
203 by performing genome wide expression profiling RNA-sequencing in 
MCF10A cells that were transduced with either pre-miR-203 or an empty vector 
control. We then compared the negatively correlated genes in both sets of 
experiments (with p-values of less than 0.05) that were downregulated in the 
total-RNA-seq data but enriched in the AGO2-IP-RNA-seq data (Figure 4.11). 
We then compared the negatively correlated data with the list of predicted miR-
203 target genes from TargetScan (Appendix I). The combination of these data 
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analyses produced a list of 41 direct miR-203 target genes in MCF10A cells 
(Figure 4.12).   
 
 Recent evidence suggests that the dominant mechanism by which 
miRNAs repress their target genes is through mRNA degradation (Guo et al., 
2010) therefore, we validated miR-203 candidate target genes by monitoring 
mRNA expression using qRT-PCR analysis after ectopic expression of miR-203. 
We transduced MCF10A cells with pre-miR-203 or an empty vector control and 
monitored the expression of each target gene by qRT-PCR.  The results of 
Figure 4.13 show that 30 miR-203 target genes were significantly downregulated 
after ectopic expression of miR-203. Thus, these 30 genes are likely direct 
targets of miR-203 in MCF10A cells.  
 
 We then hypothesized that upon detachment, the induction of miR-203 
causes repression of at least a subset of miR-203 candidate target genes. To 
test this hypothesis, we measured the expression levels of the 41 miR-203 
candidate target gene mRNAs in detached MCF10A cells, cultured in suspension 
for 24 hours, by qRT-PCR analysis. The expression of 24 candidate target genes 
was significantly downregulated in detached cells as compared to attached 
MCF10A cells (Figure 4.14). These results suggest that the induction of miR-203 
after detachment of MCF10A cells leads to the downregulation of direct target 
mRNAs.  
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miR-203 targets a network of pro-survival genes to induce cell death upon 
detachment 
 
In the subset of the 24 miR-203 target genes that are downregulated upon 
detachment in MCF10A cells, 18 of those target genes correlate with the 
validated miR-203 target genes (Figures 4.13, 4.14 and Table 4.3).  After 
pathway and biological process analysis, these 18 anoikis-related miR-203 target 
genes do not seem to belong to the same pathway or contribute to the same 
biological process, therefore we hypothesized that these genes might contribute 
to cell survival and the repression of these genes upon miR-203 induction 
promotes anoikis. To test this hypothesis we transduced MCF10A cells with 
shRNAs against each of the 18 miR-203 anoikis-related target genes and 
monitored cell survival by crystal violet staining. Ten days after the shRNA 
transduction we stained the surviving cells with crystal violet to visualize the 
surviving colonies of each knockdown cell line. The results of Figure 4.15 show 
that the knockdown of 10 miR-203 target genes leads to some level of decreased 
survival or decreased proliferation in attached MCF10A cells as compared to a 
non-silencing (NS) control shRNA. We further confirmed these results by using a 
second unrelated shRNA against all 10 genes (Figure 4.16). These results 
suggest that miR-203 promotes anoikis by targeting and repressing a network of 
pro-survival genes in MCF10A cells upon detachment from the ECM.  
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miR-203 down regulation in invasive breast cancer cells contributes to 
anoikis resistance 
 
 Finally, miR-203 has previously been implicated as a tumor 
suppressive miRNA (Bueno et al., 2008) and as a suppressor of migration and 
invasion (Wang et al., 2012). Additionally, miR-203 has been shown to be highly 
downgregulated in triple negative breast cancer cells lines as compared to 
normal breast epithelial cells and less-invasive breast cancer cells lines by 
miRNA-microarray analysis (Luo et al., 2013). Certain subtypes of triple negative 
(not expressing the HER2, PR, or ER receptors, also named “basal-like”) breast 
cancers have been shown to be highly invasive and result in a poor prognosis 
(Cheang et al., 2008). These findings suggest the intriguing possibility that miR-
203 is critical for anoikis and that the loss of miR-203 and subsequent increase in 
anoikis resistance can contribute to invasiveness a subset of triple negative 
breast cancer cell lines.  
 
We sought to determine the role of downregulation of miR-203 in invasive 
triple negative breast cancer cells. First, consistent with previous studies (Luo et 
al., 2013) we observed that miR-203 is highly downregulated in two triple 
negative breast cancer cell lines, MDA-MB-231 and HS578T, as compared to 
MCF10A cells and less-invasive types of breast cancer cell lines, MCF7, BT474, 
and T47D cells (Figure 4.18). We have previously shown that all of these breast 
cancer cell lines are resistant to anoikis in cell culture (Pedanou et al., 2016). 
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Therefore, we proposed that miR-203 would not be induced upon detachment in 
these breast cancer cell lines, which could contribute to anoikis resistance. To 
test this hypothesis, we measured the expression of miR-203 by miRNA-qRT-
PCR in attached and detached MDA-MB-231 cells using MCF10A as a control. 
As expected, miR-203 was not induced upon detachment in MDA-MB-231 cells 
but was significantly induced upon detachment in MCF10A suggesting that miR-
203 is not functional in MDA-MB-231 cells (Figure 4.19). Next, we tested whether 
ectopic expression of miR-203 would be sufficient to decreased cell survival in 
MDA-MB-231 cells. We transduced MDA-MB-231 cells with pre-miR-203 or an 
empty vector control and monitored cell survival by crystal violet staining. Ten 
days after transduction we stained the cells with crystal violet to visualize the 
surviving colonies and found that the ectopic expression of miR-203 results in 
increased decreased survival or decreased proliferation in MDA-MB-231 cells. 
 
Finally, we sought to determine if the loss of miR-203 in triple negative 
breast cancer cells causes the elevation of the pro-survival anoikis-related miR-
203 target genes. We utilized The Cancer Genome Atlas (TCGA) database for 
breast cancer samples (Cancer Genome Atlas, 2012) and analyzed the 
expression of all 10 pro-survival anoikis-related miR-203 target genes (Figure 
4.15) in triple negative breast cancer tumors in comparison to the other 3 
subtypes of breast cancer (Her2, Luminal A, and Luminal B). Our analysis shows 
that 4 of these genes (WDR69, PRKAB1, HBEGF, and PRPS2) are significantly 
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elevated in triple negative breast cancer (Figure 4.21).  We next tested if the 
repression of these 4 elevated genes would lead to decreased survival in MDA-
MB-231 cells by transducing the cells with shRNAs against WDR69, PRKAB1, 
HBEGF, and PRPS2. Ten days after transduction we stained the cells with 
crystal violet to monitor the surviving cells. We show that the knockdown of all 4 
genes results in the decrease survival or decreased proliferation in MDA-MB-231 
cells (Figure 4.22). These results demonstrate that the elevation of WDR69, 
PRKAB1, HBEGF, and PRPS2 likely contributes to cell survival in triple negative 
breast cancer. Our results, together with previous studies that show the ectopic 
expression of miR-203 in MDA-MB-231 cells causes decreased invasion (Wang 
et al., 2012) suggests that the loss of miR-203 in triple negative breast cancer 
cells leads to anoikis resistance and contributes to the invasiveness of those 
cells.  
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Figures 
 
   
Sample Read Count % miRNA 
ATT_1 14,488,438 85.40% 
ATT_2 10,059,871 85.90% 
ATT_3 12,154,307 85.60% 
DET24H_1 18,775,691 85.50% 
DET24H_2 13,829,444 78.90% 
   
Table 4.1. Each sample for small RNA sequencing had a miRNA content of 
greater than 75%. After mapping to the human genome, the sequencing read 
count and percent miRNA for each attached (ATT) and detached (DET24H) 
small RNA sample from MCF10A cells is shown.  
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miRNA Log2 Fold Change P-Value 
hsa-miR-186-5p -4.618775671 8.10E-24 
hsa-miR-25-3p -3.028709298 2.33E-09 
hsa-miR-221-3p -2.975523674 1.34E-09 
hsa-miR-222-3p -2.905830044 6.66E-09 
hsa-miR-769-5p -2.117528652 0.000166001 
hsa-miR-99b-3p -1.792771293 0.002713491 
hsa-miR-33a-5p -1.752293009 0.00070066 
hsa-miR-671-5p -1.563884613 0.005425343 
hsa-miR-301a-3p 1.705978293 0.006965854 
hsa-miR-15a-5p 1.765685166 0.00754879 
hsa-miR-4301 1.824008742 0.004810525 
hsa-miR-197-3p 1.903970642 0.008652361 
hsa-miR-324-5p 1.941355323 0.007021097 
hsa-miR-15b-5p 1.96426179 0.00202066 
hsa-miR-1246 2.229184889 0.000488131 
hsa-miR-17-5p 2.856327723 3.27E-05 
hsa-miR-203a 3.313176801 1.62E-06 
   
 
 
  
Table 4.2. Changes in miRNA expression after detachment. The 
miRNAs that change in expression 24 hours post detachment in 
MCF10A cells are listed. The Log2 fold change is compared to attached 
MCF10A cells. All miRNAs included had a count per million that was 
greater than 100.  
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Figure 4.1. Several miRNAs show a significant change in expression 
upon detachment in MCF10A cells. Small RNA sequencing reveals that 9 
miRNAs are significantly (P<0.01) upregulated and 8 miRNAs are 
significantly (P<0.01) downregulated 24 hours after detachment in MCF10A 
cells.  
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Figure 4.2. Three miRNAs are significantly upregulated upon detachment 
in MCF10A cells. miRNA-qRT-PCR analysis of miR-203, miR-197, and miR-
324 at 24 and 48 hours post detachment in MCF10A cells. Statistics are 
compared to the values in attached cells, which were set to 1. U6 RNA was 
used as an internal control. Error bars indicate SD. *P<0.05; **P<0.01.  
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Figure 4.3. Confirmation of miR-203 upregulation upon detachment in 
MCF10A cells. (A) Northern blot analysis of miR-203 expression 24 and 48 
hours post detachment of MCF10A cells. (B) Quantification of the northern 
blot in A, using U6 as a loading control.  
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Figure 4.4. The induction of miR-203 is due to increased processing 
of the mature miRNA. (A) miRNA-qRT-PCR analysis of miR-203 in 
attached and detached MCF10A cells. U6 was used as an internal control. 
(B) qRT-PCR analysis of pre-miR-203 in the same attached and detached 
MCF10A samples used in A. RPL41 was used as an internal control.  Error 
bars indicate SD. **P<0.01. n.s.= not significant. 
n.s. 
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Figure 4.5. Ectopic expression of miR-203 in MCF10A cells. miRNA-
qRT-PCR analysis shows successful ectopic expression of miR-203 in 
MCF10A cells as compared to an empty vector control (EV).  Error bars 
indicate SD. **P<0.01. 
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Figure 4.6. Ectopic expression of miR-203 results in decreased cell 
survival or decreased proliferation in MCF10A cells. Crystal violet 
staining of MCF10A cells expressing vector or pre-miR-203.  
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Figure 4.7. Ectopic expression of miR-203 results in cell death in 
MCF10A cells. (A) Cell death, monitored by annexin-V staining, in MCF10A 
cells expressing an empty vector control or pre-miR-203. Error bars indicate 
SD. **P<0.01. (B) Representative FACS plots corresponding to A.  
A 
B 
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Figure 4.8. Inhibition of miR-203 causes resistance to anoikis in 
MCF10A cells. Cell death, monitored by annexin-V staining, in attached or 
detached (cultured in suspension for 96 h) MCF10A cells stably expressing a 
miR-203 inhibitor or a scrambled control. Error bars indicate SD. **P<0.01.  
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Figure 4.9. Confirmation of miR-203 inhibitor activity in 293T cells. 
Immunoblot analysis monitoring GFP expression after transfection of a 
GFP miR-203 sensor in 293T cells stably expressing either the miR-203 
inhibitor (miR-203i) or a scrambled control (SC). α–tubulin was monitored 
as a loading control.  
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Figure 4.10. The induction of miR-203 after detachment from the ECM is 
due to the loss of integrin signaling. miRNA-qRT-PCR analysis of miR-203 
in attached MCF10A cells or detached MCF10A cells cultured in suspension 
for 24 h and treated in the presence or absence of Matrigel. U6 was used as 
an internal control. Error bars indicate SD. 
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Figure 4.11. Schematic of the design of the dual RNA sequencing approach to 
identify direct targets of miR-203.  
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Figure 4.12. Forty-two candidate miR-203 target genes were identified by the 
dual RNA sequencing approach. Log2 fold change of genes that were 
significantly (P<0.05) enriched in the AGO2-IP sequencing and significantly 
(P<0.05) downregulated in the miR-203 ectopic expression RNA sequencing, all of 
which are also identified as potential miR-203 target genes in the Targetscan 
database.  
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Figure 4.13. Validation of thirty direct miR-203 target genes. qRT-PCR analysis 
of miR-203 target genes in MCF10A cells ectopically expressing miR-203 or an 
empty vector control. The expression of each gene is shown relative to that obtained 
in attached cells which was set to 1.  RPL41 was used as an internal control. Error 
bars indicate SD. *P<0.05; **P<0.01.   
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Figure 4.14. Twenty-five miR-203 target genes are significantly 
downregulated upon MCF10A cell detachment from the ECM. qRT-PCR 
analysis of the expression levels of miR-203 target genes in MCF10A cells 
cultured in suspension for 24 h. The expression of each gene is shown relative 
to that obtained in attached cells which was set to 1. RPL41 was used as an 
internal control. Error bars indicate SD. *P<0.05; **P<0.01.   
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Biological Process Gene Symbol Gene name
WDR69 dynein assembly factor with WD repeats 1
PDE6D phosphodiesterase 6D
PRKAB1 protein kinase AMP-activated non-catalytic subunit beta 1
HBEGF heparin binding EGF like growth facto
IFIT3 Interferon induced protein with tetratricopeptide repeats 3
SEMA5A semaphorin 5A
RPRD2 regulation of nuclear pre-mRNA domain containing 2 
SOX13 SRY-box 13
ZNF440 zinc finger protein 440
ZXDB zinc finger, X-linked, duplicated B 
Nucleotide biosynthesis PRPS2 phosphoribosyl pyrophosphate synthetase 2
Transporter ANKH ANKH inorganic pyrophosphate transport regulator
Cell adhesion NEDD9 neural precursor cell expressed, developmentally down-regulated 9
Cell differentiation PARP11 poly(ADP-ribose) polymerase family member 11 
KIAA1430 KIAA1430
LNX2 ligand of numb-protein X 2
C4orf33 chromosome 4 open reading frame 33 
PDE4D phosphodiesterase 4D
Signal Transduction
Positive regulation of cell migration or proliferation
Transcription regulation
Unkown 
Table 4.3. The list of miR-203 direct target genes that are degraded by 
miR-203 after detachment from the ECM in MCF10A cells. The target 
genes are sorted by biological process.  
  
 
129 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.15. The knockdown of ten miR-203 target genes results in decreased 
cell survival or decreased proliferation in MCF10A cells. Crystal violet staining 
of MCF10A cells expressing shRNAs against ten direct miR-203 target genes or a 
NS control shRNA.  
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 Figure 4.16. Confirmation of the results of Figure 4.15 with a second 
unrelated shRNA. Crystal violet staining of MCF10A cells expressing shRNAs 
against ten direct miR-203 target genes or a NS control shRNA.  
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Figure 4.17. Analysis miR-203 target shRNA knockdown efficiencies. qRT-
PCR analysis monitoring knockdown efficiencies of shRNAs directed against ten 
miR-203 target genes in MCF10A cells. Error bars indicate SD. **P<0.01.  
  
 
132 
 
 
 
 
Gene shRNA sequence 
C4ORF33 GAAGCTCTTTACCCTGTACCT 
HBEGF CTTCTCATGTTTAGGTACCAT 
KIAA1430 CCTCCCAAAGTGTTGGGATTA 
NEDD9 GCAGCTCAAGACCATAGTCAT 
PDE6D GCACATCCAGAGTGAGACTTT 
PRKAB1 GCCTGGCTATGGAACTAAATA 
PRPS2 GTCACAAACACAATTCCGCAA 
SEMA5A CCACAGATTACGGAACCATTA 
SOX13 CCTAAGACTATGTTGGTACTT 
WDR69 GCAGCAAGGATAATACCTGTA 
 
 
 
 
 
 
 
 
 
 
  
Table 4.4. List of shRNA sequences against ten miR-203 target genes.   
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Figure 4.18. miR-203 is highly downregulated in invasive breast cancer 
cell lines. miRNA-qRT-PCR analysis of miR-203 in 2 triple negative and 
invasive breast cancer cell lines (MDA-MB-231 and Hs578t) compared to 
MCF10A cells and 2 luminal type, non-invasive breast cancer cell lines (MCF7 
and T47D). U6 was used as an internal control. Error bars indicate SD. 
**P<0.01 
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Figure 4.19. miR-203 is not induced upon detachment in a triple negative 
breast cancer cell line. miRNA-qRT-PCR analysis of miR-203 in attached and 
detached MCF10A cells (left) and MDA-MB-231 cells (right). Each detached 
sample was compared to the attached sample of the same cell line, which was 
set to 1. U6 was used as an internal control.  Error bars indicate SD. **P<0.01 
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Figure 4.20. Ectopic expression of miR-203 causes decreased cell 
survival or decreased proliferation in a triple negative breast cancer cell 
line. (A) Crystal violet staining of MDA-MB-231 expressing an empty vector 
control or pre-miR-203. (B) Quantification of the crystal violet staining from A.  
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Figure 4.21. Four miR-203 target genes are elevated in triple negative 
breast cancer samples from the TCGA dataset. RNA-sequencing analysis 
of the TCGA dataset comparing the expression of miR-203 target genes in the 
four subtypes of breast cancer (Basal, Her2, Luminal A, and Luminal B). 
*P<0.05  
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NS WDR69 PRKAB1 PRPS2 HBEGF 
Figure 4.22. Knockdown of the four miR-203 target genes that are elevated 
in triple negative breast cancer results in decreased cell survival or 
decreased proliferation in a triple negative breast cancer cell line. Crystal 
violet staining of MDA-MB-231 cells expressing shRNAs directed against the 
four miR-203 target genes or a NS control.  
  
 
138 
 
Conclusions 
 
In this study, we have identified miR-203 as an anoikis effector miRNA. 
We initially discovered that miR-203 is induced upon detachment of breast 
epithelial cells through unbiased small RNA sequencing. We then found that 
miR-203 is both necessary and sufficient for detachment-induced cell death. 
Furthermore, we have identified several direct targets of miR-203 that act as pro-
survival genes in attached cells. We propose a model where, upon detachment, 
miR-203 is induced and subsequently binds to the 3’UTRs of direct target genes 
resulting in mRNA degradation of those pro-survival target genes finally resulting 
in anoikis (Figure 4.23).  
 
 These results both provide further insight into the mechanisms of 
detachment-induced cell death and further define the role of miR-203 as a growth 
and invasion suppressor miRNA. With this study we provide an intriguing link 
between miR-203 expression and function and anoikis resistance. As miR-203 
was previously identified to be a tumor-, migration-, and invasion-suppresor 
miRNA but has not been studied in the context of anoikis (Chen et al., 2015; 
Viticchie et al., 2011). 
 
 We have shown that the induction of miR-203 upon detachment is due to 
the loss of integrin signaling. Furthermore, we have demonstrated that this 
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induction is due to the increased processing of the mature miR-203 rather than 
increased transcriptional activation of the precursor miR-203. This is an intriguing 
result because the most common cause of elevated expression of specific 
miRNAs is due to the increased transcription of the precursor miRNA (Bail et al., 
2010; Calin et al., 2002). This is potentially one of the most interesting avenues 
of future research stemming from our investigation. Further research into the 
mechanism of increased processing of miR-203 upon the loss of integrin 
signaling would provide further understanding of the mechanism of miR-203 
during anoikis and potentially further our understanding of the loss of miR-203 in 
invasive breast cancer.  
 
 We have identified a network of pro-survival direct miR-203 target genes 
that are downregulated following the induction of miR-203, most likely by mRNA 
degradation. While these target genes are not known to be part of the same 
biological pathways (as shown in Table 4-4), we have identified that 10 of the 
target genes (SEC24D, PRPS2, HBEGF, WDR69, KIAA1430, PRKAB1, C4orf33, 
PDE6D, NEDD9, and SOX13) are pro-survival genes in MCF10A cells. Four of 
those pro-survival target genes (HBEGF, PRKAB1, PRPS2, and WDR69) are 
elevated in and potentially contribute to anoikis resistance in invasive breast 
cancer. Continued studies should concentrate on further defining the mechanism 
of how these genes contribute to cell survival.   
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 To date there has been no genome wide study of miRNAs involved in 
anoikis. There are only a few dozen directed studies of the role of specific 
miRNAs in anoikis, which leaves the field wide open for advances in miRNA 
research (Howe et al., 2012; Yu et al., 2013; Zhang et al., 2013). On the other 
hand, miRNAs have been very well studied in cancer, especially breast cancer 
(Hesse et al., 2013; Luo et al., 2013). This creates the possibility of correlating 
specific miRNA expression changes in anoikis with the corresponding expression 
level in the cancer of interest. We have done this with miR-203 by finding that 
miR-203 is induced upon detachment and subsequently found that miR-203 is 
highly downregulated invasive breast cancer cell lines. Since miR-203 was 
already implicated as a tumor- and invasion-suppressor, our data further defines 
the role of miR-203 and provides a link between miR-203 and anoikis resistance 
in cancer.  
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Figure 4.23.  Model of miR-203 during detachment. In attached cells miR-203 
is expressed at low levels, which leaves its pro-survival target genes expressed at 
normal levels leading to cell survival. Following detachment and the loss of 
integrin signaling, miR-203 is induced. The increased levels of miR-203 then bind 
to the 3’UTR of target genes and cause mRNA degradation of those target genes.  
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CHAPTER V: DISCUSSION AND CONCLUDING REMARKS 
 
Collectively, the results I present here in my dissertation reveal two novel 
anoikis pathways that provide further insight into the process of detachment-
induced apoptosis. My studies have revealed that (I) the histone demethylase, 
KDM3A is induced upon detachment from the ECM, which leads to cell death 
through the pro-apoptotic BNIP3 and BNIP3L BH3-only proteins and (II) miR-203 
is also induced following detachment from the ECM subsequently targeting and 
degrading a panel of pro-survival genes. Both of these pathways are 
dysfunctional in at least some types of breast cancer, which contributes to 
anoikis resistance in breast cancer cells.  
 
In my first investigation I used an unbiased genome wide shRNA screen to 
identify the H3K9me1/2 demethylase KDM3A as an anoikis effector. I show that 
the knockdown of KDM3A leads to anoikis resistance in a breast epithelial cell 
line. Furthermore, I found that KDM3A is transcriptionally induced upon 
detachment from the ECM due to the loss of integrin signaling and subsequent 
loss of FAK, EGFR and RAF/MEK/ERK signaling. I showed that KDM3A then 
demethylates H3K9me1/2 on the promoters of the pro-apoptotic proteins BNIP3 
and BNIP3L to promote anoikis. Finally, I revealed that KDM3A expression is low 
in human breast cancer samples and that the knockdown of Kdm3a causes a 
non-metastatic mouse breast carcinoma cell line to metastasize to the lungs. 
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Together, these results reveal a novel role for KDM3A in anoikis and provide 
insight into a potential mechanism of anoikis resistance.  
 
My results, combined with other published investigations discussed in 
Chapter I, suggest that there are multiple non-redundant pathways that promote 
anoikis, including the pathway that promotes Bim mediated cell death and the 
pathway identified in my study where KDM3A promotes BNIP3 and BNIP3L 
mediated cell death. Inhibition of each individual pathway results in 
approximately a 2-fold reduction in anoikis (Pedanou et al., 2016; Reginato et al., 
2003) suggesting that multiple factors are responsible for detachment induced 
cell death. To directly test this hypothesis, further experiments such as using 
shRNAs to knockdown both Bim and BNIP3 to determine if the double 
knockdown would result in a synergistic resistance to anoikis in detached 
MCF10A cells. These results could help to confirm that these pathways work 
separately from each other to result in anoikis.  
 
Although BNIP3 and BNIP3L, like Bim, are pro-apoptotic proteins they 
function differently than Bim, which could account for the results that BNIP3 and 
BNIP3L promote anoikis in a pathway that is separate from Bim. Bim is a classic 
BH3-only pro-apoptotic protein that functions primarily through BAX or BAK 
induced apoptosis (Willis et al., 2007). Alternatively, BNIP3 and BNIP3L are also 
BH3-only pro-apoptotic proteins that function through BAX or BAK induced 
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apoptosis but also function through Beclin-1 induced authophagy and possibly 
necrosis (Dhingra et al., 2014; Sowter et al., 2001). While Bim, BNIP3 and 
BNIP3L all function as general pro-apoptotic proteins, the specific mechanism of 
Bim differs from that of BNIP3 and BNIP3L leading to the possibility that these 
pro-apoptotic factors promote anoikis through separate mechanisms.  
 
In addition to the conclusions of my first investigation, I have also 
developed a novel assay to study anoikis in vivo. Classically, anoikis has been 
difficult to study in vivo. In cell culture experiments the cells can be forcibly 
detached from the ECM and grown in suspension whereas the same cannot be 
done in a mouse. This leaves many studies to only test tumor growth and 
metastasis in vivo to make inferences about anoikis instead of directly studying 
anoikis. The in vivo anoikis assay I present in my investigation takes advantage 
of the fact that normal epithelial cells require their native ECM signals to survive 
and when those cells encounter a foreign ECM the normal survival signaling 
would not be initiated leading to anoikis. I used a mouse breast epithelial cell line 
and injected this cell line into the lungs of syngeneic mice (via tail vein injection) 
with the premise that the cells should not survive in the foreign environment of 
the lung. As we expected, the vast majority of the control cells did not survive 
whereas a significantly higher number of the Kdm3a knockdown cells did survive. 
As this was consistent with my in vitro cell culture results, it shows that this assay 
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is sufficient to test anoikis in vivo and will now allow cell culture results to be 
confirmed in a mouse model. 
  
The basis of anoikis is that when cells detach from the ECM, integrin 
signaling is lost leading to cell death as discussed in depth in Chapter I, this was 
also the principle that both of my investigations were based on. However, I must 
add that while this is true in normal and non-malignant epithelial cells, such as 
MCF10A and MDCK cells (Frisch et al., 1996; Reginato et al., 2003), in most 
transformed cell lines integrin signaling is not lost upon detachment because 
some components of the pathway are constitutively activated (Shaw et al., 1997). 
This helps to explain why most cancer cell lines are not sensitive to anoikis in cell 
culture assays, as I showed for breast cancer cell lines in Figure 3.21.  
 
As stated in the Discussion of Chapter III, there have been differing 
conclusions about the function of KDM3A in cancer. I hypothesize that there are 
factors upstream of KDM3A, such as transcription factors or miRNAs that control 
the transcriptional activation of KDM3A and these factors may differ between 
tissue types and may even differ between subtypes of the same cancer type. We 
know that the inactivation of the FAK, EGFR, and RAF/MEK/ERK pathways 
leads to induction of KDM3A but we have not defined the exact mechanism of 
this induction. I hypothesize that either integrin, FAK, EGFR, and RAF/MEK/ERK 
signaling activate a transcriptional or translational repressor of KDM3A under 
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normal attached conditions or that the loss of these signaling pathways activates 
a transcriptional activator of KDM3A under detached conditions. There are 
examples in the literature of transcription and translation factors that are 
controlled by these signaling pathways (Decarlo et al., 2015; Gilley et al., 2003). 
A scientist following up on my KDM3A data could perform directed experiments 
with these known factors by using shRNA or CRISPR knockout to determine if 
the depletion of any of these transcription or translation factors affects the 
expression of KDM3A. Another method of testing this hypothesis would be to 
analyze the promoter of KDM3A for transcription factor binding sites and 
analyzing the interaction of those transcription factors in attached versus 
detached conditions. This hypothesis warrants further research to identify such 
factors and gain further insight into the role of KDM3A in cancer. Once these 
upstream factors are identified, their potential role in cancer might be able to 
explain the differences in KDM3A being both pro- and anti-oncogenic.  
 
In addition to transcription and translation factors that potentially control 
the expression of KDM3A, there is also the possibility that a miRNA could 
regulate KDM3A expression. Analyzing the 3’ UTR of KDM3A for miRNA seed 
sequences should reveal potential miRNA candidates. It would be especially 
interesting if one of the miRNAs identified as being significantly downregulated in 
Chapter IV of this dissertation were to control KDM3A expression so that in 
attached conditions the miRNA represses expression of KDM3A and upon 
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detachment and the loss of integrin signaling that miRNA is downregulated 
leading to increased expression of KDM3A.  After identification of a miRNA that 
controls KDM3A expression, it would be interesting to test if levels of that miRNA 
are controlled by FAK, EGFR, and/or RAK/MEK/ERK signaling which has been 
demonstrated in the past and would correlate well with all of my KDM3A data 
(Mito et al., 2013).  
 
While my results oppose most of the results in the other recently published 
study on KDM3A in breast cancer (Ramadoss et al., 2016), there is one 
unpublished observation that I made while performing my KDM3A knockdown 
experiments that could be consistent with the other published study. When I 
deplete KDM3A using shRNA in MCF10A cells I have observed that the cells 
seem to senesce, the cells proliferate slower than the non-silencing controls and 
the cells seem to flatten out on the plates. I have not measured this in any way 
so it is an unconfirmed opinion but it does warrant further investigation, as this 
would be consistent with the recent study from the Wang group. I hypothesize 
that the depletion of KDM3A causes MCF10A cells to senesce, which provides 
protection from anoikis upon detachment. The phenomenon of senescence being 
anti-apoptotic has been demonstrated in previous studies (Seluanov et al., 2001) 
and warrants further investigation in the case of KDM3A during anoikis. To test 
this hypothesis initially, one could assess the level of senescence following 
KDM3A knockdown through SA-beta-galactosidase staining (Dimri et al., 1995).  
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 In my KDM3A investigation, in collaboration with Dr. Peter Siegel’s lab at 
McGill University, we found that the knockdown of Kdm3a increased metastasis 
to the lungs, whereas the Wang group found that knockdown of KDM3A 
decreased metastasis to the lungs. These results stick out as the most glaring 
opposition between our investigations. While we used different model systems, 
ours was the 4T1 series of cell lines using syngeneic mice and the Wang group 
used a human breast cancer cell line with nude mice, both models were breast 
cancer so I would not anticipate such opposing results. While there is the 
unfortunate possibility that one of these studies could be due to some unknown 
experimental artifact, it should also be noted that the Wang group never 
performed a full metastatic assay where the cells are injected into the mammary 
fat pad and allowed to metastasize from there as we performed for my 
investigation. This could lead to some of the differences in results between the 
two studies. 
 
My data also seems to conflict with the previously published observation 
that hypoxia protects against anoikis in mammary epithelial cells (Whelan and 
Reginato, 2014). The conflict is that HIF1alpha transcriptionally activates KDM3A 
under hypoxic conditions (Beyer et al., 2008) and we observe that the induction 
of KDM3A is critical for normal levels of anoikis. There is another piece to this 
puzzle however, that the induction of BNIP3 by HIF1alpha leads to autophagic 
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cell death under hypoxic conditions (Azad et al., 2008). Both published results 
give conflicting views on the influence of hypoxia on cell death.  
 
Other aspects of the role of KDM3A that should be further studied are the 
global downstream transcriptional targets that are activated by KDM3A after 
detachment from the ECM. A genome wide ChIP-sequencing experiment in 
detached cells with both the KDM3A antibody and H3K9me1/2 antibodies would 
be a functional way of discovering all of the downstream targets of KDM3A. This 
avenue of study would offer even further insight into the function of KDM3A and 
would further define this novel anoikis pathway.  
 
Further animal studies could also be performed in order to delineate the 
role of KDM3A in breast cancer progression and anoikis resistance and could 
maybe resolve the discrepancies between my data and the Wang group’s 
KDM3A data. One could make a transgenic mouse with a conditional knock-in of 
KDM3A using a mammary specific promoter, such as WAP (Andres et al., 1988) 
in a mouse model of metastatic breast cancer (Fantozzi and Christofori, 2006). 
After the primary tumor has developed in the animals, we could add Cre, which 
would lead to expression of Kdm3a to determine if the ectopic expression of 
KDM3A would lead to decreased metastasis in this model. This experiment 
would constitute a “rescue” experiment that is missing from my study, as I used 
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RNAi experiments for the majority of the mechanistic studies in my investigation 
and used RNAi for all of the in vivo experiments.  
 
One of the classic controls for RNAi experiments is the rescue experiment, 
where the gene of interest is manipulated to be resistant to the shRNA or siRNA 
being used, and then the gene is ectopically expressed in the knockdown cell line 
(Jackson et al., 2003a). This is done to “rescue” the phenotype that is observed 
with the knockdown of the gene of interest and confirms that the RNAi results are 
most likely specific to the gene of interest. This control experiment is missing in 
both my KDM3A investigation and miR-203 investigation. Adding rescue 
experiments to all of the RNAi results in each study would strengthen the overall 
results and conclusions of each, especially in the in vivo studies of the KDM3A 
investigation. 
 
In Chapter III of this dissertation, many of the experiments I performed to 
support the hypothesis that KDM3A is novel anoikis effector genes involve 
depletion of KDM3A and other factors using shRNAs. While these experiments 
are standard in the field, they are not perfect because of the potential off target 
effects of shRNAs (Franceschini et al., 2014; Jackson et al., 2003b). In most 
experiments in both Chapter III and Chapter IV I tried to minimize the effect of 
off-target effects by using two shRNAs. Inconsistent results using two separate 
shRNAs for the same gene suggests that one of those shRNAs could be 
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targeting another gene that then affects the results of the assay. Our lab is 
especially careful with using two or more shRNAs when validating candidates 
from genome wide shRNA screens, where we rule out candidates if they only 
validate by one shRNA.  
  
There are two in vivo experiments in Chapter III in which I only used one 
shRNA (Figures 3-27 and 3-29). The results and conclusions from these 
experiments would have been stronger had I used two shRNAs to rule out off 
target effects. In the future, it should be a requirement for publication to use at 
least two shRNAs in each experiment. There is also one experiment in Chapter 
IV where I only used one shRNA (Figure 4.22) from which the conclusions would 
be strengthened by using at least one more shRNA against each of the four 
genes I tested. I would suggest that this should be done before the results of 
Chapter IV are published.  
 
Another limitation to my data is the lack of an integrin blocking experiment 
in the matrigel rescue experiments in Figure 3.7 and 4.10. For both experiments I 
used a growth factor reduced version of matrigel to limit the effect of growth 
factors in my results because I wanted to analyze the effect of integrin signaling 
alone and not growth factor signaling. However, there are likely residual growth 
factors in the matrigel (as it is labeled “reduced growth factors”, not “without 
growth factors”) so I should have included a control to demonstrate that the 
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results I observed were an effect of integrin signaling and not influenced by 
growth factor signaling. The addition of an integrin beta-1 blocking antibody to  
 
In my second investigation I used another unbiased genome wide 
approach, small RNA sequencing, to identify miR-203 as an anoikis effector 
miRNA in breast epithelial cells. My results show that miR-203 is significantly 
induced upon detachment from the ECM and the induction of miR-203 leads to 
degradation of a network of pro-survival target genes leading to anoikis. 
Furthermore, the loss of miR-203 expression in triple negative breast cancer and 
corresponding elevation of a subset of the pro-survival target genes likely 
contributes to the invasiveness of the triple negative subtype of breast cancer. 
Collectively, these results present a additional evidence toward the tumor and 
invasiveness-suppresive role of miR-203 and reveal a novel miRNA pathway 
involved in anoikis.  
 
Further studies should focus on the increased processing of miR-203 
upon detachment from the ECM. The majority of miRNA expression changes 
stem from the transcriptional control of the pri-miRNA however, I found that 
following detachment the levels of the precursor of miR-203 (pre-miR-203) 
remains constant whereas only the mature form is induced leading to the 
hypothesis that the loss of integrin signaling leads to the increased DICER 
processing of miR-203. Factors that regulate DICER processing and specifically 
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factors that control specific miRNA processing differences have been studied 
only in recent years. This leaves the opportunity of identifying a novel miRNA 
processing control mechanism, specifically for miR-203 processing after 
detachment.  
 
A limitation to the data in Chapter IV is that I only used crystal violet 
staining of colony forming assays to test our hypotheses about the effects of the 
knockdown of miR-203 target genes on cell survival (Figures 4.15, 4.16, 4.20, 
and 4.22).  While this assay does provide information about the effect of these 
knockdowns on cell survival, I am not able to specifically assess the effects. 
Colony forming assays can demonstrate differences in, but not distinguish 
between, cell survival, cell death, changes in proliferation, and cell senescence, 
all of which would alter the number of colonies in these assays. In order to 
definitively say that the knockdown of these pro-survival genes results in cell 
death, future experiments should monitor annexin-V levels by FACS analysis. 
Additionally, the crystal violet assays I have included are not quantitative as I 
performed them with the plan to only present the photo of the crystal violet 
stained cells. However, these assays can be done in a quantitative way by 
seeding very few cells and making sure that the assay is stained at a time point 
where the colonies in the control plates are easy to count. In the assays in my 
data the colonies in the control NS plates merged making it very difficult to count 
individual colonies.  
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Another aspect of miR-203 that deserves a great deal more research is 
the loss of miR-203 in triple negative breast cancers. This result was known from 
previous studies and I expanded on it by showing that 4 anoikis-related miR-203 
target genes are elevated in triple negative breast cancer, providing a link 
between anoikis resistance and an invasive form of breast cancer. The pro-
invasive and pro-oncogenic role of these target genes could each warrant 
additional study, which would give further insight into the miR-203 pathway in 
anoikis and invasive cancer. Secondly, miRNAs are being tested in pre-clinical 
studies and even some clinical trials as gene therapy (Reid et al., 2016). In vivo 
mouse model studies that use miR-203 expression to treat triple negative breast 
cancer would provide an answer as to whether miR-203 could be considered as 
a viable treatment for patients with triple negative breast cancer.  
 
Arguably the aspect of my second investigation that requires the most 
follow-up study is defining the role of the panel of 10 anoikis-related pro-survival 
target genes in normal attached cells (Figure 4.15). While a few of these genes 
have been implicated as pro-survival genes in previous studies (HBEGF and 
PRPS2), most of the genes have not been. My results suggest that these 10 
genes all play a role in cell survival and upon detachment these genes are 
repressed by miR-203, which contributes to anoikis. Investigating the specific 
pro-survival role of these 10 genes could each be its own investigation.  
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Research into the mechanism of anoikis resistance is important to fully 
understand metastasis, as there are two steps in the metastatic cascade where 
anoikis resistance in necessary. Metastatic cells resist anoikis first when tumor 
cells detach from the primary tumor and from their primary ECM and again when 
the tumor cell enters a secondary microenvironment and encounters an ECM 
with different composition and therefore different signaling molecules.  I have 
identified two novel pathways through which we have gained insight into anoikis 
resistance in breast cancer.  
 
In addition to KDM3A and miR-203, both of the genome wide screens I 
completed have lists of multiple potential anoikis effectors genes and miRNAS 
(Tables 3.1 and 4.2). Genome wide screens create huge datasets that leave you 
with a massive amount of leads to follow up on, these lists can act as a blueprint 
for further studies on anoikis and anoikis resistance in breast epithelial cells and 
could most likely continue to be studied for years to come. One thing that my 
studies have taught me is that the initial genome wide screen is the “easy” part of 
the experimental plan whereas deciding how to follow up on massive data sets 
can prove to be difficult. In both of my investigations I decided to follow and 
delineate the mechanism of one factor identified in each screen. On the other 
hand, other studies from the Green lab have taken a more network centered 
follow-up approach (Bhatnagar et al., 2014; Lin et al., 2014; Ma et al., 2014). 
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Either way, each genome wide study leaves a large amount of data that could 
potentially initiate a multitude of future investigations in the lab.   
 
Additionally, a systems biology approach that could incorporate the 
datasets from both of my investigations would likely give a clearer picture of the 
process of anoikis on a genome wide level. There do exist methods to integrate 
biological datasets that could be used to integrate the datasets I produced for my 
studies to define a biological network that is critical for anoikis in MCF10A cells 
(Gligorijević and Pržulj, 2015).  Another data integration approach is to input all of 
the genes and miRNAs from datasets in my dissertation into a Gene Ontology 
(GO, (Consortium, 2000)) or Ingenuity analysis (Raponi et al., 2004) to determine 
and common pathways or biological processes.  
 
Taken together, these two investigations have allowed me to gain an 
appreciation for the complexity of studying biological processes. In both of my 
research projects I studied the general process of anoikis and sought to identify 
novel anoikis pathways, in the first study I identified a novel anoikis effector gene, 
KDM3A, and in my second study I identified a novel anoikis effector miRNA, miR-
203. I have also shown that both KDM3A and miR-203 likely contribute to anoikis 
resistance in at least some breast cancers. In looking at the lists of genes and 
miRNAs that were generated from both of my projects, I conclude with the finding 
that anoikis, along with all other biological processes, is an extremely complex 
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process that cannot be defined from the mechanism of just one factor or 
pathway, however I propose that my investigations have moved the field one 
step forward towards the understanding of this complex process.  
  
  
 
158 
 
APPENDIX I 
 
List of predicted miR-203 target genes from Targetscan (www.targetscan.org) 
 
Target 
gene 
Representative 
transcript Gene name 
3-Sep NM_019106 septin 3 
AAK1 NM_014911 AP2 associated kinase 1 
ABCE1 NM_001040876 ATP-binding cassette, sub-family E (OABP), member 1 
ABL1 NM_005157 c-abl oncogene 1, non-receptor tyrosine kinase 
ABLIM3 NM_014945 actin binding LIM protein family, member 3 
ACADSB NM_001609 acyl-CoA dehydrogenase, short/branched chain 
ACO2 NM_001098 aconitase 2, mitochondrial 
ACSL1 NM_001995 acyl-CoA synthetase long-chain family member 1 
ACSL3 NM_004457 acyl-CoA synthetase long-chain family member 3 
ACSL6 NM_001009185 acyl-CoA synthetase long-chain family member 6 
ACTR10 NM_018477 actin-related protein 10 homolog (S. cerevisiae) 
ACVR2A NM_001616 activin A receptor, type IIA 
ACVR2B NM_001106 activin A receptor, type IIB 
ADAMTS15 NM_139055 ADAM metallopeptidase with thrombospondin type 1 motif, 15 
ADAMTS17 NM_139057 ADAM metallopeptidase with thrombospondin type 1 motif, 17 
ADAMTS5 NM_007038 ADAM metallopeptidase with thrombospondin type 1 motif, 5 
ADAMTS6 NM_197941 ADAM metallopeptidase with thrombospondin type 1 motif, 6 
ADAMTS8 NM_007037 ADAM metallopeptidase with thrombospondin type 1 motif, 8 
ADARB2 NM_018702 adenosine deaminase, RNA-specific, B2 
ADCY9 NM_001116 adenylate cyclase 9 
ADK NM_001123 adenosine kinase 
ADPGK NM_031284 ADP-dependent glucokinase 
ADRBK2 NM_005160 adrenergic, beta, receptor kinase 2 
AFAP1L2 NM_001001936 actin filament associated protein 1-like 2 
AFF2 NM_001169122 AF4/FMR2 family, member 2 
AFF4 NM_014423 AF4/FMR2 family, member 4 
AGPAT6 NM_178819 1-acylglycerol-3-phosphate O-acyltransferase 6  
AGPS NM_003659 alkylglycerone phosphate synthase 
AHR NM_001621 aryl hydrocarbon receptor 
AK4 NM_001005353 adenylate kinase 4 
AKAP13 NM_006738 A kinase (PRKA) anchor protein 13 
AKAP6 NM_004274 A kinase (PRKA) anchor protein 6 
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AKIRIN1 NM_001136275 akirin 1 
AKIRIN2 NM_018064 akirin 2 
AKT2 NM_001626 v-akt murine thymoma viral oncogene homolog 2 
ALG10B NM_001013620 
asparagine-linked glycosylation 10, alpha-1,2-
glucosyltransferase 
AMFR NM_001144 autocrine motility factor receptor 
AMOT NM_001113490 angiomotin 
AMOTL1 NM_130847 angiomotin like 1 
AMPD3 NM_000480 adenosine monophosphate deaminase 3 
ANGPTL1 NM_004673 angiopoietin-like 1 
ANKH NM_054027 ankylosis, progressive homolog (mouse) 
ANKRD13B NM_152345 ankyrin repeat domain 13B 
ANKRD13C NM_030816 ankyrin repeat domain 13C 
ANKRD17 NM_032217 ankyrin repeat domain 17 
ANKRD44 NM_001195144 ankyrin repeat domain 44 
ANKRD52 NM_173595 ankyrin repeat domain 52 
ANKRD7 NM_019644 ankyrin repeat domain 7 
ANO8 NM_020959 anoctamin 8 
ANP32A NM_006305 acidic (leucine-rich) nuclear phosphoprotein 32 family, member A 
ANP32E NM_001136478 acidic (leucine-rich) nuclear phosphoprotein 32 family, member E 
ANTXR2 NM_058172 anthrax toxin receptor 2 
ANXA4 NM_001153 annexin A4 
AP1S2 NM_003916 adaptor-related protein complex 1, sigma 2 subunit 
AP2B1 NM_001030006 adaptor-related protein complex 2, beta 1 subunit 
APBB2 NM_001166050 amyloid beta (A4) precursor protein-binding, family B, member 2 
APC NM_000038 adenomatous polyposis coli 
APLP1 NM_001024807 amyloid beta (A4) precursor-like protein 1 
APOOL NM_198450 apolipoprotein O-like 
APPL1 NM_012096 
adaptor protein, phosphotyrosine interaction, PH domain leucine 
zipper 1 
ARHGAP1 NM_004308 Rho GTPase activating protein 1 
ARHGAP32 NM_001142685 Rho GTPase activating protein 32 
ARHGAP42 NM_152432 Rho GTPase activating protein 42 
ARHGEF3 NM_001128615 Rho guanine nucleotide exchange factor (GEF) 3 
ARID1B NM_017519 AT rich interactive domain 1B (SWI1-like) 
ARID2 NM_152641 AT rich interactive domain 2 (ARID, RFX-like) 
ARID3B NM_006465 AT rich interactive domain 3B (BRIGHT-like) 
ARNTL NM_001030272 aryl hydrocarbon receptor nuclear translocator-like 
ARSB NM_000046 arylsulfatase B 
ASB4 NM_016116 ankyrin repeat and SOCS box containing 4 
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ASPH NM_001164750 aspartate beta-hydroxylase 
ASXL1 NM_015338 additional sex combs like 1 (Drosophila) 
ATG14 NM_014924 ATG14 autophagy related 14 homolog (S. cerevisiae) 
ATM NM_000051 ataxia telangiectasia mutated 
ATP10D NM_020453 ATPase, class V, type 10D 
ATP11B NM_014616 ATPase, class VI, type 11B 
ATP1B4 NM_001142447 ATPase, Na+/K+ transporting, beta 4 polypeptide 
ATP2B1 NM_001001323 ATPase, Ca++ transporting, plasma membrane 1 
ATP2C1 NM_001199179 ATPase, Ca++ transporting, type 2C, member 1 
ATP5G3 NM_001190329 
ATP synthase, H+ transporting, mitochondrial Fo complex, 
subunit C3 
B3GALNT2 NM_152490 beta-1,3-N-acetylgalactosaminyltransferase 2 
B3GNT5 NM_032047 
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 
5 
BAGE2 NM_182482 B melanoma antigen family, member 2 
BAGE3 NM_182481 B melanoma antigen family, member 3 
BAHD1 NM_014952 bromo adjacent homology domain containing 1 
BANF1 NM_001143985 barrier to autointegration factor 1 
BCL11B NM_022898 B-cell CLL/lymphoma 11B (zinc finger protein) 
BCL2L2 NM_001199839 BCL2-like 2 
BCL7A NM_001024808 B-cell CLL/lymphoma 7A 
BEND4 NM_001159547 BEN domain containing 4 
BIRC5 NM_001012270 baculoviral IAP repeat containing 5 
BMI1 NM_005180 BMI1 polycomb ring finger oncogene 
BPTF NM_004459 bromodomain PHD finger transcription factor 
BSN NM_003458 bassoon (presynaptic cytomatrix protein) 
BTBD7 NM_001002860 BTB (POZ) domain containing 7 
C10orf46 NM_153810 chromosome 10 open reading frame 46 
C11orf68 NM_001135635 chromosome 11 open reading frame 68 
C11orf91 NM_001166692 chromosome 11 open reading frame 91 
C12orf4 NM_020374 chromosome 12 open reading frame 4 
C12orf75 NM_001145199 chromosome 12 open reading frame 75 
C13orf23 NM_025138 chromosome 13 open reading frame 23 
C14orf129 NM_016472 chromosome 14 open reading frame 129 
C14orf147 NM_138288 chromosome 14 open reading frame 147 
C14orf28 NM_001017923 chromosome 14 open reading frame 28 
C16orf45 NM_001142469 chromosome 16 open reading frame 45 
C18orf1 NM_001003674 chromosome 18 open reading frame 1 
C18orf34 NM_001105528 chromosome 18 open reading frame 34 
C1orf122 NM_001142726 chromosome 1 open reading frame 122 
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C1orf144 NM_001114600 chromosome 1 open reading frame 144 
C1orf172 NM_152365 chromosome 1 open reading frame 172 
C1orf173 NM_001002912 chromosome 1 open reading frame 173 
C1orf210 NM_001164829 chromosome 1 open reading frame 210 
C20orf11 NM_017896 chromosome 20 open reading frame 11 
C20orf24 NM_001199534 chromosome 20 open reading frame 24 
C2orf80 NM_001099334 chromosome 2 open reading frame 80 
C3orf15 NM_033364 chromosome 3 open reading frame 15 
C3orf17 NM_015412 chromosome 3 open reading frame 17 
C3orf63 NM_001112736 chromosome 3 open reading frame 63 
C4orf33 NM_001099783 chromosome 4 open reading frame 33 
C5orf41 NM_153607 chromosome 5 open reading frame 41 
C6orf35 NM_018452 chromosome 6 open reading frame 35 
C7orf42 NM_017994 chromosome 7 open reading frame 42 
C8orf4 NM_020130 chromosome 8 open reading frame 4 
C8orf44-
SGK3 NM_001204173 C8orf44-SGK3 readthrough 
CAB39 NM_001130849 calcium binding protein 39 
CABP7 NM_182527 calcium binding protein 7 
CACNA1E NM_000721 calcium channel, voltage-dependent, R type, alpha 1E subunit 
CACNG7 NM_031896 calcium channel, voltage-dependent, gamma subunit 7 
CALML4 NM_001031733 calmodulin-like 4 
CAMTA1 NM_001195563 calmodulin binding transcription activator 1 
CAPN14 NM_001145122 calpain 14 
CAPRIN1 NM_005898 cell cycle associated protein 1 
CAPS NM_004058 calcyphosine 
CASC4 NM_138423 cancer susceptibility candidate 4 
CASK NM_001126054 
calcium/calmodulin-dependent serine protein kinase (MAGUK 
family) 
CAV1 NM_001172895 caveolin 1, caveolae protein, 22kDa 
CBL NM_005188 Cas-Br-M (murine) ecotropic retroviral transforming sequence 
CBX5 NM_001127321 chromobox homolog 5 
CCDC141 NM_173648 coiled-coil domain containing 141 
CCDC148 NM_138803 coiled-coil domain containing 148 
CCDC50 NM_174908 coiled-coil domain containing 50 
CCNG1 NM_004060 cyclin G1 
CCNG2 NM_004354 cyclin G2 
CCNY NM_145012 cyclin Y 
CDH10 NM_006727 cadherin 10, type 2 (T2-cadherin) 
CDH6 NM_004932 cadherin 6, type 2, K-cadherin (fetal kidney) 
  
 
162 
CDHR3 NM_152750 cadherin-related family member 3 
CDK13 NM_003718 cyclin-dependent kinase 13 
CDKL2 NM_003948 cyclin-dependent kinase-like 2 (CDC2-related kinase) 
CDV3 NM_001134422 CDV3 homolog (mouse) 
CEP68 NM_015147 centrosomal protein 68kDa 
CHD2 NM_001271 chromodomain helicase DNA binding protein 2 
CHD9 NM_025134 chromodomain helicase DNA binding protein 9 
CHORDC1 NM_001144073 cysteine and histidine-rich domain (CHORD) containing 1 
CHST7 NM_019886 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 
CIT NM_001206999 citron (rho-interacting, serine/threonine kinase 21) 
CITED2 NM_001168388 Cbp/p300-interacting transactivator 2 
CKAP2 NM_001098525 cytoskeleton associated protein 2 
CLASP2 NM_001207044 cytoplasmic linker associated protein 2 
CLDN1 NM_021101 claudin 1 
CLEC12B NM_001129998 C-type lectin domain family 12, member B 
CLLU1 NM_001025233 chronic lymphocytic leukemia up-regulated 1 
CLOCK NM_004898 clock homolog (mouse) 
CLSTN3 NM_014718 calsyntenin 3 
CLTC NM_004859 clathrin, heavy chain (Hc) 
CNNM3 NM_017623 cyclin M3 
CNTFR NM_001207011 ciliary neurotrophic factor receptor 
COL17A1 NM_000494 collagen, type XVII, alpha 1 
COL4A4 NM_000092 collagen, type IV, alpha 4 
COMMD3-
BMI1 NM_001204062 COMMD3-BMI1 readthrough 
COPS7B NM_022730 
COP9 constitutive photomorphogenic homolog subunit 7B 
(Arabidopsis) 
CORO1C NM_014325 coronin, actin binding protein, 1C 
COX10 NM_001303 COX10 homolog, cytochrome c oxidase assembly protein 
COX15 NM_004376 COX15 homolog, cytochrome c oxidase assembly protein (yeast) 
CPEB4 NM_030627 cytoplasmic polyadenylation element binding protein 4 
CPNE8 NM_153634 copine VIII 
CREB1 NM_004379 cAMP responsive element binding protein 1 
CREB3 NM_006368 cAMP responsive element binding protein 3 
CREBZF NM_001039618 CREB/ATF bZIP transcription factor 
CRK NM_005206 v-crk sarcoma virus CT10 oncogene homolog (avian) 
CSN2 NM_001891 casein beta 
CSRNP2 NM_030809 cysteine-serine-rich nuclear protein 2 
CTDSPL2 NM_016396 CTD small phosphatase like 2 
CTSS NM_001199739 cathepsin S 
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CUL1 NM_003592 cullin 1 
CUL2 NM_001198777 cullin 2 
CXorf1 NM_004709 chromosome X open reading frame 1 
CXorf21 NM_025159 chromosome X open reading frame 21 
CXorf23 NM_198279 chromosome X open reading frame 23 
CXorf38 NM_144970 chromosome X open reading frame 38 
CYP8B1 NM_004391 cytochrome P450, family 8, subfamily B, polypeptide 1 
D4S234E NM_001040101 
DNA segment on chromosome 4 (unique) 234 expressed 
sequence 
DAB2 NM_001343 
disabled homolog 2, mitogen-responsive phosphoprotein 
(Drosophila) 
DAZAP2 NM_001136264 DAZ associated protein 2 
DCC NM_005215 deleted in colorectal carcinoma 
DCP1A NM_018403 DCP1 decapping enzyme homolog A (S. cerevisiae) 
DCP2 NM_001242377 DCP2 decapping enzyme homolog (S. cerevisiae) 
DCUN1D3 NM_173475 DCN1, defective in cullin neddylation 1, domain containing 3 
DCUN1D4 NM_001040402 DCN1, defective in cullin neddylation 1, domain containing 4 
DCUN1D5 NM_032299 DCN1, defective in cullin neddylation 1, domain containing 5  
DCX NM_000555 doublecortin 
DDX6 NM_004397 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 
DGCR2 NM_001173533 DiGeorge syndrome critical region gene 2 
DGKB NM_004080 diacylglycerol kinase, beta 90kDa 
DGKE NM_003647 diacylglycerol kinase, epsilon 64kDa 
DGKZ NM_001105540 diacylglycerol kinase, zeta 
DICER1 NM_001195573 dicer 1, ribonuclease type III 
DIO2 NM_000793 deiodinase, iodothyronine, type II 
DIXDC1 NM_001037954 DIX domain containing 1 
DLG5 NM_004747 discs, large homolog 5 (Drosophila) 
DLX5 NM_005221 distal-less homeobox 5 
DMRT2 NM_001130865 doublesex and mab-3 related transcription factor 2 
DNAJC14 NM_032364 DnaJ (Hsp40) homolog, subfamily C, member 14 
DNAJC21 NM_001012339 DnaJ (Hsp40) homolog, subfamily C, member 21 
DNAJC24 NM_181706 DnaJ (Hsp40) homolog, subfamily C, member 24 
DNAJC27 NM_001198559 DnaJ (Hsp40) homolog, subfamily C, member 27 
DNAL1 NM_001201366 dynein, axonemal, light chain 1 
DNM1L NM_005690 dynamin 1-like 
DNMT3B NM_001207055 DNA (cytosine-5-)-methyltransferase 3 beta 
DOCK10 NM_014689 dedicator of cytokinesis 10 
DPH3 NM_001047434 DPH3, KTI11 homolog (S. cerevisiae) 
DPY19L4 NM_181787 dpy-19-like 4 (C. elegans) 
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DR1 NM_001938 
down-regulator of transcription 1, TBP-binding (negative cofactor 
2) 
DUSP5 NM_004419 dual specificity phosphatase 5 
DUT NM_001025248 deoxyuridine triphosphatase 
DYRK1A NM_001396 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A 
E2F3 NM_001949 E2F transcription factor 3 
EBF1 NM_024007 early B-cell factor 1 
EBF3 NM_001005463 early B-cell factor 3 
ECHDC2 NM_001198961 enoyl CoA hydratase domain containing 2 
EDA NM_001005609 ectodysplasin A 
EDNRA NM_001166055 endothelin receptor type A 
EGR3 NM_001199880 early growth response 3 
EHF NM_001206615 ets homologous factor 
EID2 NM_153232 EP300 interacting inhibitor of differentiation 2 
EIF4E NM_001130678 eukaryotic translation initiation factor 4E 
EIF5A2 NM_020390 eukaryotic translation initiation factor 5A2 
ELK4 NM_001973 ELK4, ETS-domain protein (SRF accessory protein 1) 
ELL2 NM_012081 elongation factor, RNA polymerase II, 2 
ELMOD1 NM_001130037 ELMO/CED-12 domain containing 1 
ELMOD2 NM_153702 ELMO/CED-12 domain containing 2 
ELOVL6 NM_001130721 ELOVL fatty acid elongase 6 
EN2 NM_001427 engrailed homeobox 2 
ENAH NM_001008493 enabled homolog (Drosophila) 
EPC2 NM_015630 enhancer of polycomb homolog 2 (Drosophila) 
EPHA3 NM_005233 EPH receptor A3 
ERLIN2 NM_001003790 ER lipid raft associated 2 
ESR1 NM_000125 estrogen receptor 1 
ETS2 NM_005239 v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 
ETV1 NM_001163147 ets variant 1 
EVI2B NM_006495 ecotropic viral integration site 2B 
EYA4 NM_004100 eyes absent homolog 4 (Drosophila) 
FAM104A NM_001098832 family with sequence similarity 104, member A 
FAM114A1 NM_138389 family with sequence similarity 114, member A1 
FAM116A NM_152678 family with sequence similarity 116, member A 
FAM117B NM_173511 family with sequence similarity 117, member B 
FAM120C NM_017848 family with sequence similarity 120C 
FAM126A NM_032581 family with sequence similarity 126, member A 
FAM126B NM_173822 family with sequence similarity 126, member B 
FAM135B NM_015912 family with sequence similarity 135, member B 
FAM13A NM_001015045 family with sequence similarity 13, member A 
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FAM155A NM_001080396 family with sequence similarity 155, member A 
FAM170B NM_001164484 family with sequence similarity 170, member B 
FAM198B NM_001031700 family with sequence similarity 198, member B 
FAM55C NM_001134456 family with sequence similarity 55, member C 
FAM84A NM_145175 family with sequence similarity 84, member A 
FAM8A1 NM_016255 family with sequence similarity 8, member A1 
FASTKD2 NM_001136193 FAST kinase domains 2 
FAT3 NM_001008781 FAT tumor suppressor homolog 3 (Drosophila) 
FBXL19 NM_001099784 F-box and leucine-rich repeat protein 19 
FBXL20 NM_001184906 F-box and leucine-rich repeat protein 20 
FBXO11 NM_001190274 F-box protein 11 
FBXO28 NM_001136115 F-box protein 28 
FBXO44 NM_001014765 F-box protein 44 
FBXO45 NM_001105573 F-box protein 45 
FGD4 NM_139241 FYVE, RhoGEF and PH domain containing 4 
FGF2 NM_002006 fibroblast growth factor 2 (basic) 
FGF5 NM_004464 fibroblast growth factor 5 
FGL2 NM_006682 fibrinogen-like 2 
FJX1 NM_014344 four jointed box 1 (Drosophila) 
FKBP5 NM_001145775 FK506 binding protein 5 
FKBP7 NM_001135212 FK506 binding protein 7 
FLRT2 NM_013231 fibronectin leucine rich transmembrane protein 2 
FMOD NM_002023 fibromodulin 
FOSL2 NM_005253 FOS-like antigen 2 
FOXJ3 NM_001198850 forkhead box J3 
FOXK1 NM_001037165 forkhead box K1 
FOXK2 NM_004514 forkhead box K2 
FOXP1 NM_032682 forkhead box P1 
FOXP2 NM_001172766 forkhead box P2 
FUBP3 NM_003934 far upstream element (FUSE) binding protein 3 
G6PC2 NM_001081686 glucose-6-phosphatase, catalytic, 2 
GABARAPL
1 NM_031412 GABA(A) receptor-associated protein like 1 
GABBR2 NM_005458 gamma-aminobutyric acid (GABA) B receptor, 2 
GABRA1 NM_000806 gamma-aminobutyric acid (GABA) A receptor, alpha 1 
GABRA5 NM_000810 gamma-aminobutyric acid (GABA) A receptor, alpha 5 
GABRB2 NM_000813 gamma-aminobutyric acid (GABA) A receptor, beta 2 
GALNT10 NM_198321 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 10  
GALNT7 NM_017423 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 7 
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GATC NM_176818 
glutamyl-tRNA(Gln) amidotransferase, subunit C homolog 
(bacterial) 
GDA NM_001242506 guanine deaminase 
GDAP1 NM_001040875 ganglioside-induced differentiation-associated protein 1 
GEMIN8 NM_001042479 gem (nuclear organelle) associated protein 8 
GINS4 NM_032336 GINS complex subunit 4 (Sld5 homolog) 
GJB6 NM_001110219 gap junction protein, beta 6, 30kDa 
GLCCI1 NM_138426 glucocorticoid induced transcript 1 
GLI3 NM_000168 GLI family zinc finger 3 
GLS NM_014905 glutaminase 
GLTP NM_016433 glycolipid transfer protein 
GMFB NM_004124 glia maturation factor, beta 
GNG2 NM_053064 guanine nucleotide binding protein (G protein), gamma 2 
GNG4 NM_001098721 guanine nucleotide binding protein (G protein), gamma 4 
GOSR1 NM_001007024 golgi SNAP receptor complex member 1 
GP5 NM_004488 glycoprotein V (platelet) 
GPATCH1 NM_018025 G patch domain containing 1 
GPBP1L1 NM_021639 GC-rich promoter binding protein 1-like 1 
GPHN NM_001024218 gephyrin 
GPKOW NM_015698 G patch domain and KOW motifs 
GPR155 NM_001033045 G protein-coupled receptor 155 
GPR180 NM_180989 G protein-coupled receptor 180 
GPR26 NM_153442 G protein-coupled receptor 26 
GPR85 NM_001146265 G protein-coupled receptor 85 
GRHL3 NM_001195010 grainyhead-like 3 (Drosophila) 
GRPR NM_005314 gastrin-releasing peptide receptor 
GRSF1 NM_001098477 G-rich RNA sequence binding factor 1 
GTF3C3 NM_012086 general transcription factor IIIC, polypeptide 3, 102kDa 
GXYLT1 NM_001099650 glucoside xylosyltransferase 1 
GYS1 NM_001161587 glycogen synthase 1 (muscle) 
HADHB NM_000183 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase beta 
subunit 
HBEGF NM_001945 heparin-binding EGF-like growth factor 
HBP1 NM_012257 HMG-box transcription factor 1 
HCAR2 NM_177551 hydroxycarboxylic acid receptor 2 
HCAR3 NM_006018 hydroxycarboxylic acid receptor 3 
HCCS NM_001122608 holocytochrome c synthase 
HDX NM_001177478 highly divergent homeobox 
HERC2 NM_004667 hect domain and RLD 2 
HERPUD2 NM_022373 HERPUD family member 2 
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HLA-DOA NM_002119 major histocompatibility complex, class II, DO alpha 
HMGN2 NM_005517 high mobility group nucleosomal binding domain 2 
HNRNPA2
B1 NM_002137 heterogeneous nuclear ribonucleoprotein A2/B1 
HNRNPL NM_001005335 heterogeneous nuclear ribonucleoprotein L 
HNRNPR NM_001102397 heterogeneous nuclear ribonucleoprotein R 
HNRNPUL2 NM_001079559 heterogeneous nuclear ribonucleoprotein U-like 2 
HOMER1 NM_004272 homer homolog 1 (Drosophila) 
HOOK3 NM_032410 hook homolog 3 (Drosophila) 
HPS3 NM_032383 Hermansky-Pudlak syndrome 3 
HRASLS5 NM_001146728 HRAS-like suppressor family, member 5 
HS6ST3 NM_153456 heparan sulfate 6-O-sulfotransferase 3 
HSPB8 NM_014365 heat shock 22kDa protein 8 
HSPC159 NM_014181 galectin-related protein 
HTR2A NM_000621 5-hydroxytryptamine (serotonin) receptor 2A 
HTR2C NM_000868 5-hydroxytryptamine (serotonin) receptor 2C 
ID4 NM_001546 
inhibitor of DNA binding 4, dominant negative helix-loop-helix 
protein 
IFNA2 NM_000605 interferon, alpha 2 
IGF2R NM_000876 insulin-like growth factor 2 receptor 
IGFBP5 NM_000599 insulin-like growth factor binding protein 5 
IL15 NM_000585 interleukin 15 
IL24 NM_001185156 interleukin 24 
ILDR2 NM_199351 immunoglobulin-like domain containing receptor 2 
IMPA1 NM_001144878 inositol(myo)-1(or 4)-monophosphatase 1 
IMPACT NM_018439 Impact homolog (mouse) 
INA NM_032727 internexin neuronal intermediate filament protein, alpha 
INO80D NM_017759 INO80 complex subunit D 
INSIG1 NM_005542 insulin induced gene 1 
INTS6 NM_001039938 integrator complex subunit 6 
IPO7 NM_006391 importin 7 
IRS2 NM_003749 insulin receptor substrate 2 
ITGA2 NM_002203 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 
ITGAV NM_001144999 integrin, alpha V 
ITPR2 NM_002223 inositol 1,4,5-trisphosphate receptor, type 2 
IVNS1ABP NM_006469 influenza virus NS1A binding protein 
JMY NM_152405 junction mediating and regulatory protein, p53 cofactor 
JOSD1 NM_014876 Josephin domain containing 1 
KAT6A NM_001099412 K(lysine) acetyltransferase 6A 
KAZN NM_001017999 kazrin, periplakin interacting protein 
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KCMF1 NM_020122 potassium channel modulatory factor 1 
KCNC1 NM_004976 
potassium voltage-gated channel, Shaw-related subfamily, 
member 1 
KCNE2 NM_172201 potassium voltage-gated channel, Isk-related family, member 2 
KCNJ15 NM_002243 potassium inwardly-rectifying channel, subfamily J, member 15 
KCNK10 NM_021161 potassium channel, subfamily K, member 10 
KCNN3 NM_001204087 potassium calcium-activated channel, subfamily N, member 3 
KCNQ5 NM_001160130 potassium voltage-gated channel, KQT-like subfamily, member 5 
KCTD16 NM_020768 potassium channel tetramerisation domain containing 16 
KCTD9 NM_017634 potassium channel tetramerisation domain containing 9 
KHDRBS1 NM_006559 
KH domain containing, RNA binding, signal transduction 
associated 1 
KIAA0240 NM_015349 KIAA0240 
KIAA0247 NM_014734 KIAA0247 
KIAA0664 NM_015229 KIAA0664 
KIAA0930 NM_001009880 KIAA0930 
KIAA1009 NM_014895 KIAA1009 
KIAA1147 NM_001080392 KIAA1147 
KIAA1211 NM_020722 KIAA1211 
KIAA1244 NM_020340 KIAA1244 
KIAA1429 NM_015496 KIAA1429 
KIAA1804 NM_032435 mixed lineage kinase 4 
KIAA1919 NM_153369 KIAA1919 
KIF2A NM_001098511 kinesin heavy chain member 2A 
KIRREL2 NM_032123 kin of IRRE like 2 (Drosophila) 
KLHL15 NM_030624 kelch-like 15 (Drosophila) 
KPNB1 NM_002265 karyopherin (importin) beta 1 
KRT1 NM_006121 keratin 1 
KRT35 NM_002280 keratin 35 
KRT85 NM_002283 keratin 85 
KYNU NM_001032998 kynureninase 
LAMC1 NM_002293 laminin, gamma 1 (formerly LAMB2) 
LAMP2 NM_013995 lysosomal-associated membrane protein 2 
LARP1B NM_018078 La ribonucleoprotein domain family, member 1B 
LASP1 NM_006148 LIM and SH3 protein 1 
LCOR NM_001170765 ligand dependent nuclear receptor corepressor 
LCORL NM_001166139 ligand dependent nuclear receptor corepressor-like 
LIFR NM_001127671 leukemia inhibitory factor receptor alpha 
LIMCH1 NM_001112717 LIM and calponin homology domains 1 
LIN28B NM_001004317 lin-28 homolog B (C. elegans) 
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LIN7C NM_018362 lin-7 homolog C (C. elegans) 
LMO4 NM_006769 LIM domain only 4 
LNX2 NM_153371 ligand of numb-protein X 2 
LOC100507
421 NM_001195278 transmembrane protein 178-like 
LOX NM_001178102 lysyl oxidase 
LPHN1 NM_001008701 latrophilin 1 
LPIN1 NM_145693 lipin 1 
LPO NM_001160102 lactoperoxidase 
LPP NM_001167671 LIM domain containing preferred translocation partner in lipoma 
LRAT NM_004744 
lecithin retinol acyltransferase(phosphatidylcholine-retinol O-
acyltransferase) 
LRRTM2 NM_015564 leucine rich repeat transmembrane neuronal 2 
LUZP2 NM_001009909 leucine zipper protein 2 
MAFB NM_005461 v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
MAGI1 NM_004742 membrane associated guanylate kinase, 1 
MAN1A2 NM_006699 mannosidase, alpha, class 1A, member 2 
MAP3K1 NM_005921 mitogen-activated protein kinase kinase kinase 1 
MAP3K13 NM_001242314 mitogen-activated protein kinase kinase kinase 13 
MAP3K2 NM_006609 mitogen-activated protein kinase kinase kinase 2 
MAPK10 NM_002753 mitogen-activated protein kinase 10 
MAPK1IP1
L NM_144578 mitogen-activated protein kinase 1 interacting protein 1-like 
MAPK9 NM_002752 mitogen-activated protein kinase 9 
MAPRE1 NM_012325 microtubule-associated protein, RP/EB family, member 1 
MAST4 NM_001164664 microtubule associated serine/threonine kinase family member 4 
MATR3 NM_001194954 matrin 3 
MBD6 NM_052897 methyl-CpG binding domain protein 6 
MBNL1 NM_021038 muscleblind-like (Drosophila) 
MBNL3 NM_001170701 muscleblind-like 3 (Drosophila) 
MCCC2 NM_022132 methylcrotonoyl-CoA carboxylase 2 (beta) 
MCTP2 NM_001159643 multiple C2 domains, transmembrane 2 
MED14 NM_004229 mediator complex subunit 14 
MEF2C NM_001131005 myocyte enhancer factor 2C 
MEGF11 NM_032445 multiple EGF-like-domains 11 
METTL8 NM_024770 methyltransferase like 8 
MEX3C NM_016626 mex-3 homolog C (C. elegans) 
MGAT3 NM_001098270 
mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase 
MIDN NM_177401 midnolin 
MINA NM_001042533 MYC induced nuclear antigen 
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MKL2 NM_014048 MKL/myocardin-like 2 
MKLN1 NM_001145354 muskelin 1, intracellular mediator containing kelch motifs 
MLANA NM_005511 melan-A 
MLLT4 NM_001040000 myeloid/lymphoid or mixed-lineage leukemia ); translocated to, 4 
MMAB NM_052845 methylmalonic aciduria (cobalamin deficiency) cblB type 
MMP24 NM_006690 matrix metallopeptidase 24 (membrane-inserted) 
MON2 NM_015026 MON2 homolog (S. cerevisiae) 
MORF4L1 NM_006791 mortality factor 4 like 1 
MORF4L2 NM_001142418 mortality factor 4 like 2 
MPP3 NM_001932 
membrane protein, palmitoylated 3 (MAGUK p55 subfamily 
member 3) 
MRVI1 NM_001098579 murine retrovirus integration site 1 homolog 
MSL1 NM_001012241 male-specific lethal 1 homolog (Drosophila) 
MSR1 NM_002445 macrophage scavenger receptor 1 
MYEF2 NM_016132 myelin expression factor 2 
MYLK4 NM_001012418 myosin light chain kinase family, member 4 
MYO5A NM_000259 myosin VA (heavy chain 12, myoxin) 
MYOZ2 NM_016599 myozenin 2 
N4BP3 NM_015111 NEDD4 binding protein 3 
NAA30 NM_001011713 N(alpha)-acetyltransferase 30, NatC catalytic subunit 
NAA50 NM_025146 N(alpha)-acetyltransferase 50, NatE catalytic subunit 
NAP1L4 NM_005969 nucleosome assembly protein 1-like 4 
NBEA NM_001204197 neurobeachin 
NCALD NM_001040624 neurocalcin delta 
NCL NM_005381 nucleolin 
NDRG3 NM_022477 NDRG family member 3 
NDST3 NM_004784 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 3 
NEDD4L NM_001144964 
neural precursor cell expressed, developmentally down-
regulated 4-like 
NEDD9 NM_001142393 
neural precursor cell expressed, developmentally down-
regulated 9 
NEGR1 NM_173808 neuronal growth regulator 1 
NEMF NM_004713 nuclear export mediator factor 
NFIB NM_001190737 nuclear factor I/B 
NFIL3 NM_005384 nuclear factor, interleukin 3 regulated 
NFYA NM_002505 nuclear transcription factor Y, alpha 
NIPSNAP3
B NM_018376 nipsnap homolog 3B (C. elegans) 
NKD1 NM_033119 naked cuticle homolog 1 (Drosophila) 
NLK NM_016231 nemo-like kinase 
NMNAT2 NM_015039 nicotinamide nucleotide adenylyltransferase 2 
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NOVA1 NM_002515 neuro-oncological ventral antigen 1 
NPAS4 NM_178864 neuronal PAS domain protein 4 
NPR3 NM_000908 natriuretic peptide receptor C/guanylate cyclase C 
NPRL2 NM_006545 nitrogen permease regulator-like 2 (S. cerevisiae) 
NR1D2 NM_001145425 nuclear receptor subfamily 1, group D, member 2 
NR2C2 NM_003298 nuclear receptor subfamily 2, group C, member 2 
NR5A2 NM_003822 nuclear receptor subfamily 5, group A, member 2 
NRBP2 NM_178564 nuclear receptor binding protein 2 
NRG1 NM_001159995 neuregulin 1 
NRG2 NM_001184935 neuregulin 2 
NSL1 NM_001042549 NSL1, MIND kinetochore complex component, homolog 
NSUN7 NM_024677 NOP2/Sun domain family, member 7 
NUAK1 NM_014840 NUAK family, SNF1-like kinase, 1 
NUDT21 NM_007006 nudix (nucleoside diphosphate linked moiety X)-type motif 21 
NUFIP2 NM_020772 nuclear fragile X mental retardation protein interacting protein 2 
NUMBL NM_004756 numb homolog (Drosophila)-like 
NXPH3 NM_007225 neurexophilin 3 
OBFC1 NM_024928 oligonucleotide/oligosaccharide-binding fold containing 1 
OCLN NM_001205254 occludin 
OLFM1 NM_006334 olfactomedin 1 
OLIG3 NM_175747 oligodendrocyte transcription factor 3 
OPA1 NM_015560 optic atrophy 1 (autosomal dominant) 
OR2L13 NM_175911 olfactory receptor, family 2, subfamily L, member 13 
OR9Q1 NM_001005212 olfactory receptor, family 9, subfamily Q, member 1 
ORC2 NM_006190 origin recognition complex, subunit 2 
OSBPL1A NM_001242508 oxysterol binding protein-like 1A 
OSBPL8 NM_001003712 oxysterol binding protein-like 8 
OVOL1 NM_004561 ovo-like 1(Drosophila) 
PACS2 NM_001100913 phosphofurin acidic cluster sorting protein 2 
PADI2 NM_007365 peptidyl arginine deiminase, type II 
PAFAH1B2 NM_002572 platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 
PAIP2B NM_020459 poly(A) binding protein interacting protein 2B 
PALM2 NM_001037293 paralemmin 2 
PAPD5 NM_001040284 PAP associated domain containing 5 
PAPSS2 NM_001015880 3'-phosphoadenosine 5'-phosphosulfate synthase 2 
PAQR3 NM_001040202 progestin and adipoQ receptor family member III 
PARM1 NM_015393 prostate androgen-regulated mucin-like protein 1 
PARP11 NM_020367 poly (ADP-ribose) polymerase family, member 11 
PARP16 NM_017851 poly (ADP-ribose) polymerase family, member 16 
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PARP8 NM_001178055 poly (ADP-ribose) polymerase family, member 8 
PBRM1 NM_018165 polybromo 1 
PCBP2 NM_001098620 poly(rC) binding protein 2 
PCDH10 NM_032961 protocadherin 10 
PCDH19 NM_001105243 protocadherin 19 
PCLO NM_014510 piccolo (presynaptic cytomatrix protein) 
PCSK1 NM_000439 proprotein convertase subtilisin/kexin type 1 
PCSK2 NM_001201528 proprotein convertase subtilisin/kexin type 2 
PDAP1 NM_014891 PDGFA associated protein 1 
PDE3B NM_000922 phosphodiesterase 3B, cGMP-inhibited 
PDE4D NM_001104631 phosphodiesterase 4D, cAMP-specific 
PDE6D NM_002601 phosphodiesterase 6D, cGMP-specific, rod, delta 
PDE6H NM_006205 phosphodiesterase 6H, cGMP-specific, cone, gamma 
PDGFD NM_025208 platelet derived growth factor D 
PDGFRA NM_006206 platelet-derived growth factor receptor, alpha polypeptide 
PDHA1 NM_000284 pyruvate dehydrogenase (lipoamide) alpha 1 
PDK3 NM_001142386 pyruvate dehydrogenase kinase, isozyme 3 
PDPN NM_001006624 podoplanin 
PDSS2 NM_020381 prenyl (decaprenyl) diphosphate synthase, subunit 2 
PEX3 NM_003630 peroxisomal biogenesis factor 3 
PHACTR4 NM_001048183 phosphatase and actin regulator 4 
PHC3 NM_024947 polyhomeotic homolog 3 (Drosophila) 
PHF12 NM_001033561 PHD finger protein 12 
PHF19 NM_015651 PHD finger protein 19 
PHKA1 NM_001122670 phosphorylase kinase, alpha 1 (muscle) 
PHLDA1 NM_007350 pleckstrin homology-like domain, family A, member 1 
PHLDA3 NM_012396 pleckstrin homology-like domain, family A, member 3 
PHLDB1 NM_001144758 pleckstrin homology-like domain, family B, member 1 
PIK3CA NM_006218 phosphoinositide-3-kinase, catalytic, alpha polypeptide 
PIK3CD NM_005026 phosphoinositide-3-kinase, catalytic, delta polypeptide 
PIM3 NM_001001852 pim-3 oncogene 
PITPNB NM_012399 phosphatidylinositol transfer protein, beta 
PKD2 NM_000297 polycystic kidney disease 2 (autosomal dominant) 
PLAA NM_001031689 phospholipase A2-activating protein 
PLAGL2 NM_002657 pleiomorphic adenoma gene-like 2 
PLD1 NM_001130081 phospholipase D1, phosphatidylcholine-specific 
PLD2 NM_002663 phospholipase D2 
PLEKHG3 NM_015549 pleckstrin homology domain containing, family G  member 3 
PNMA1 NM_006029 paraneoplastic antigen MA1 
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PPAP2B NM_003713 phosphatidic acid phosphatase type 2B 
PPM1A NM_021003 protein phosphatase, Mg2+/Mn2+ dependent, 1A 
PPM1D NM_003620 protein phosphatase, Mg2+/Mn2+ dependent, 1D 
PPM1E NM_014906 protein phosphatase, Mg2+/Mn2+ dependent, 1E 
PPP1CB NM_002709 protein phosphatase 1, catalytic subunit, beta isozyme 
PPP1R12A NM_001143885 protein phosphatase 1, regulatory (inhibitor) subunit 12A 
PPTC7 NM_139283 PTC7 protein phosphatase homolog (S. cerevisiae) 
PRELP NM_002725 proline/arginine-rich end leucine-rich repeat protein 
PRICKLE2 NM_198859 prickle homolog 2 (Drosophila) 
PRKAB1 NM_006253 protein kinase, AMP-activated, beta 1 non-catalytic subunit 
PRKAB2 NM_005399 protein kinase, AMP-activated, beta 2 non-catalytic subunit 
PRKAG2 NM_001040633 protein kinase, AMP-activated, gamma 2 non-catalytic subunit 
PRKCA NM_002737 protein kinase C, alpha 
PRKCB NM_002738 protein kinase C, beta 
PRKCI NM_002740 protein kinase C, iota 
PRKX NM_005044 protein kinase, X-linked 
PRPF19 NM_014502 PRP19/PSO4 pre-mRNA processing factor 19 homolog  
PRPS2 NM_001039091 phosphoribosyl pyrophosphate synthetase 2 
PRUNE2 NM_015225 prune homolog 2 (Drosophila) 
PSMA4 NM_001102667 proteasome (prosome, macropain) subunit, alpha type, 4 
PTCH1 NM_000264 patched 1 
PTGS1 NM_000962 prostaglandin-endoperoxide synthase 1  
PTP4A1 NM_003463 protein tyrosine phosphatase type IVA, member 1 
PTPN1 NM_002827 protein tyrosine phosphatase, non-receptor type 1 
PTPN3 NM_001145368 protein tyrosine phosphatase, non-receptor type 3 
PTPRB NM_001109754 protein tyrosine phosphatase, receptor type, B 
PURB NM_033224 purine-rich element binding protein B 
PXDN NM_012293 peroxidasin homolog (Drosophila) 
PXN NM_001080855 paxillin 
RAB10 NM_016131 RAB10, member RAS oncogene family 
RAB15 NM_198686 RAB15, member RAS onocogene family 
RAB22A NM_020673 RAB22A, member RAS oncogene family 
RAB27B NM_004163 RAB27B, member RAS oncogene family 
RAB31 NM_006868 RAB31, member RAS oncogene family 
RAB3B NM_002867 RAB3B, member RAS oncogene family 
RALB NM_002881 v-ral simian leukemia viral oncogene homolog B 
RAP1A NM_001010935 RAP1A, member of RAS oncogene family 
RAP2A NM_021033 RAP2A, member of RAS oncogene family 
RAPGEF1 NM_005312 Rap guanine nucleotide exchange factor (GEF) 1 
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RAPH1 NM_213589 
Ras association (RalGDS/AF-6) and pleckstrin homology 
domains 1 
RASAL2 NM_004841 RAS protein activator like 2 
RASGRF1 NM_001145648 Ras protein-specific guanine nucleotide-releasing factor 1 
RAVER2 NM_018211 ribonucleoprotein, PTB-binding 2 
RBBP5 NM_001193272 retinoblastoma binding protein 5 
RBM20 NM_001134363 RNA binding motif protein 20 
RBM25 NM_021239 RNA binding motif protein 25 
RBM44 NM_001080504 RNA binding motif protein 44 
RBM47 NM_001098634 RNA binding motif protein 47 
RBMS1 NM_002897 RNA binding motif, single stranded interacting protein 1 
RCN2 NM_002902 reticulocalbin 2, EF-hand calcium binding domain 
RERG NM_001190726 RAS-like, estrogen-regulated, growth inhibitor 
RFX7 NM_022841 regulatory factor X, 7 
RGS5 NM_001195303 regulator of G-protein signaling 5 
RGS7 NM_002924 regulator of G-protein signaling 7 
RHOQ NM_012249 ras homolog gene family, member Q 
RIOK3 NM_003831 RIO kinase 3 (yeast) 
RLIM NM_016120 ring finger protein, LIM domain interacting 
RMND5A NM_022780 required for meiotic nuclear division 5 homolog A (S. cerevisiae) 
RNASE4 NM_002937 ribonuclease, RNase A family, 4 
RNF144A NM_014746 ring finger protein 144A 
RNF38 NM_022781 ring finger protein 38 
ROBO2 NM_001128929 roundabout, axon guidance receptor, homolog 2 (Drosophila) 
RPGRIP1L NM_001127897 RPGRIP1-like 
RPL23A NM_000984 ribosomal protein L23a 
RPRD2 NM_015203 regulation of nuclear pre-mRNA domain containing 2 
RS1 NM_000330 retinoschisin 1 
RSBN1 NM_018364 round spermatid basic protein 1 
RSPO1 NM_001038633 R-spondin 1 
RTCD1 NM_001130841 RNA terminal phosphate cyclase domain 1 
RTKN2 NM_145307 rhotekin 2 
RUNX1T1 NM_001198625 runt-related transcription factor 1; translocated to, 1  
RUNX2 NM_001015051 runt-related transcription factor 2 
RWDD4 NM_152682 RWD domain containing 4 
SAMD5 NM_001030060 sterile alpha motif domain containing 5 
SAV1 NM_021818 salvador homolog 1 (Drosophila) 
SBF2 NM_030962 SET binding factor 2 
SCAF11 NM_004719 SR-related CTD-associated factor 11 
SCARA5 NM_173833 scavenger receptor class A, member 5 (putative) 
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SCARB2 NM_001204255 scavenger receptor class B, member 2 
SCCPDH NM_016002 saccharopine dehydrogenase (putative) 
SCEL NM_001160706 sciellin 
SCFD1 NM_016106 sec1 family domain containing 1 
SCGB2A1 NM_002407 secretoglobin, family 2A, member 1 
SCN1A NM_001165963 sodium channel, voltage-gated, type I, alpha subunit 
SCN9A NM_002977 sodium channel, voltage-gated, type IX, alpha subunit 
SDK1 NM_152744 sidekick homolog 1, cell adhesion molecule (chicken) 
SEC62 NM_003262 SEC62 homolog (S. cerevisiae) 
SEL1L NM_005065 sel-1 suppressor of lin-12-like (C. elegans) 
SELT NM_016275 selenoprotein T 
SEMA3A NM_006080 sema domain,  secreted, (semaphorin) 3A 
SEMA5A NM_003966 sema domain, (semaphorin) 5A 
SEMA6A NM_020796 sema domain,  (semaphorin) 6A 
SENP5 NM_152699 SUMO1/sentrin specific peptidase 5 
SEPN1 NM_020451 selenoprotein N, 1 
SESTD1 NM_178123 SEC14 and spectrin domains 1 
SETBP1 NM_015559 SET binding protein 1 
SETD7 NM_030648 SET domain containing (lysine methyltransferase) 7 
SFI1 NM_001007467 Sfi1 homolog, spindle assembly associated (yeast) 
SFRP1 NM_003012 secreted frizzled-related protein 1 
SGK3 NM_001033578 serum/glucocorticoid regulated kinase family, member 3 
SGK494 NM_001174103 uncharacterized serine/threonine-protein kinase SgK494 
SGMS2 NM_001136257 sphingomyelin synthase 2 
SGTB NM_019072 
small glutamine-rich tetratricopeptide repeat (TPR)-containing, 
beta 
SH3BGR NM_001001713 SH3 domain binding glutamic acid-rich protein 
SH3BGRL2 NM_031469 SH3 domain binding glutamic acid-rich protein like 2 
SHMT1 NM_004169 serine hydroxymethyltransferase 1 (soluble) 
SIK1 NM_173354 salt-inducible kinase 1 
SIK2 NM_015191 salt-inducible kinase 2 
SIX3 NM_005413 SIX homeobox 3 
SLC10A2 NM_000452 solute carrier family 10  member 2 
SLC12A2 NM_001046 solute carrier family 12 member 2 
SLC12A5 NM_001134771 solute carrier family 12 member 5 
SLC16A2 NM_006517 solute carrier family 16, member 2 
SLC22A23 NM_015482 solute carrier family 22, member 23 
SLC24A1 NM_004727 solute carrier family 24, member 1 
SLC24A2 NM_001193288 solute carrier family 24, member 2 
SLC25A23 NM_024103 solute carrier family25, member 23 
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SLC25A36 NM_001104647 solute carrier family 25, member 36 
SLC26A9 NM_052934 solute carrier family 26, member 9 
SLC28A3 NM_001199633 solute carrier family 28 (sodium-coupled nucleoside transporter) 
SLC2A13 NM_052885 
solute carrier family 2 (facilitated glucose transporter), member 
13 
SLC2A3 NM_006931 solute carrier family 2 (facilitated glucose transporter), member 3 
SLC30A6 NM_001193513 solute carrier family 30 (zinc transporter), member 6 
SLC30A7 NM_001144884 solute carrier family 30 (zinc transporter), member 7 
SLC39A1 NM_014437 solute carrier family 39 (zinc transporter), member 1 
SLC39A9 NM_018375 solute carrier family 39 (zinc transporter), member 9 
SLC4A4 NM_001098484 
solute carrier family 4, sodium bicarbonate cotransporter, 
member 4 
SLC5A12 NM_178498 
solute carrier family 5 (sodium/glucose cotransporter), member 
12 
SLC7A14 NM_020949 solute carrier family 7 (orphan transporter), member 14 
SLCO3A1 NM_013272 solute carrier organic anion transporter family, member 3A1 
SLMAP NM_007159 sarcolemma associated protein 
SLMO2 NM_016045 slowmo homolog 2 (Drosophila) 
SMAD3 NM_001145102 SMAD family member 3 
SMAD9 NM_001127217 SMAD family member 9 
SMU1 NM_018225 smu-1 suppressor of mec-8 and unc-52 homolog (C. elegans) 
SMURF1 NM_001199847 SMAD specific E3 ubiquitin protein ligase 1 
SNAI2 NM_003068 snail homolog 2 (Drosophila) 
SNAP91 NM_001242792 synaptosomal-associated protein, 91kDa homolog (mouse) 
SNN NM_003498 stannin 
SNRPD1 NM_006938 small nuclear ribonucleoprotein D1 polypeptide 16kDa 
SNX13 NM_015132 sorting nexin 13 
SNX24 NM_014035 sorting nexin 24 
SOCS3 NM_003955 suppressor of cytokine signaling 3 
SOCS6 NM_004232 suppressor of cytokine signaling 6 
SOCS7 NM_014598 suppressor of cytokine signaling 7 
SON NM_138927 SON DNA binding protein 
SOX13 NM_005686 SRY (sex determining region Y)-box 13 
SP1 NM_003109 Sp1 transcription factor 
SP4 NM_003112 Sp4 transcription factor 
SPARC NM_003118 secreted protein, acidic, cysteine-rich (osteonectin) 
SPATA13 NM_001166271 spermatogenesis associated 13 
SPATA5 NM_145207 spermatogenesis associated 5 
SPEN NM_015001 spen homolog, transcriptional regulator (Drosophila) 
SPOPL NM_001001664 speckle-type POZ protein-like 
SPTBN1 NM_003128 spectrin, beta, non-erythrocytic 1 
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SPTY2D1 NM_194285 SPT2, Suppressor of Ty, domain containing 1 (S. cerevisiae) 
SRA1 NM_001035235 steroid receptor RNA activator 1 
SRC NM_005417 v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
SRD5A2 NM_000348 steroid-5-alpha-reductase, alpha polypeptide 2  
SRSF1 NM_001078166 serine/arginine-rich splicing factor 1 
SRSF10 NM_001191005 serine/arginine-rich splicing factor 10 
SRSF12 NM_080743 serine/arginine-rich splicing factor 12 
SRSF3 NM_003017 serine/arginine-rich splicing factor 3 
SS18L1 NM_198935 synovial sarcoma translocation gene on chromosome 18-like 1 
SSBP3 NM_001009955 single stranded DNA binding protein 3 
ST8SIA4 NM_005668 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 
STAC2 NM_198993 SH3 and cysteine rich domain 2 
STAG3L4 NM_022906 stromal antigen 3-like 4 
STEAP1 NM_012449 six transmembrane epithelial antigen of the prostate 1 
STON1 NM_001198595 stonin 1 
STRBP NM_001171137 spermatid perinuclear RNA binding protein 
STRN NM_003162 striatin, calmodulin binding protein 
STX16 NM_001001433 syntaxin 16 
STXBP5L NM_014980 syntaxin binding protein 5-like 
SUDS3 NM_022491 suppressor of defective silencing 3 homolog (S. cerevisiae) 
SV2B NM_001167580 synaptic vesicle glycoprotein 2B 
SYNC NM_001161708 syncoilin, intermediate filament protein 
SYNCRIP NM_001159673 synaptotagmin binding, cytoplasmic RNA interacting protein 
SYNJ1 NM_001160302 synaptojanin 1 
TADA1 NM_053053 transcriptional adaptor 1 
TADA2B NM_152293 transcriptional adaptor 2B 
TAF9B NM_015975 
TAF9B RNA polymerase II, TATA box binding protein (TBP)-
associated factor 
TARDBP NM_007375 TAR DNA binding protein 
TBC1D15 NM_001146213 TBC1 domain family, member 15 
TBC1D9B NM_015043 TBC1 domain family, member 9B (with GRAM domain) 
TBK1 NM_013254 TANK-binding kinase 1 
TBX3 NM_005996 T-box 3 
TCF12 NM_003205 transcription factor 12 
TCF24 NM_001193502 transcription factor 24 
TCF4 NM_001083962 transcription factor 4 
TDRD6 NM_001010870 tudor domain containing 6 
TEDDM1 NM_172000 transmembrane epididymal protein 1 
TESK1 NM_006285 testis-specific kinase 1 
TFAP2B NM_003221 transcription factor AP-2 beta (activating enhancer binding 
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protein 2 beta) 
TFDP2 NM_001178138 transcription factor Dp-2 (E2F dimerization partner 2) 
TGFB2 NM_001135599 transforming growth factor, beta 2 
TGIF2-
C20ORF24 NM_001199535 TGIF2-C20orf24 readthrough 
THRB NM_000461 thyroid hormone receptor, beta  
THSD7A NM_015204 thrombospondin, type I, domain containing 7A 
TLK2 NM_001112707 tousled-like kinase 2 
TLL2 NM_012465 tolloid-like 2 
TMED10 NM_006827 transmembrane emp24-like trafficking protein 10 (yeast) 
TMEM132A NM_017870 transmembrane protein 132A 
TMEM136 NM_001198670 transmembrane protein 136 
TMEM182 NM_144632 transmembrane protein 182 
TMEM237 NM_001044385 transmembrane protein 237 
TMEM33 NM_018126 transmembrane protein 33 
TMOD2 NM_001142885 tropomodulin 2 (neuronal) 
TNFRSF8 NM_001243 tumor necrosis factor receptor superfamily, member 8 
TNFSF15 NM_001204344 tumor necrosis factor (ligand) superfamily, member 15 
TNN NM_022093 tenascin N 
TNPO1 NM_002270 transportin 1 
TNRC6B NM_001024843 trinucleotide repeat containing 6B 
TNRC6C NM_001142640 trinucleotide repeat containing 6C 
TOR1AIP2 NM_001199260 torsin A interacting protein 2 
TOX3 NM_001080430 TOX high mobility group box family member 3 
TP63 NM_001114978 tumor protein p63 
TRA2B NM_004593 transformer 2 beta homolog (Drosophila) 
TRAM2 NM_012288 translocation associated membrane protein 2 
TRAPPC6B NM_001079537 trafficking protein particle complex 6B 
TRERF1 NM_033502 transcriptional regulating factor 1 
TRIM2 NM_001130067 tripartite motif containing 2 
TRIM71 NM_001039111 tripartite motif containing 71 
TRMT1L NM_001202423 TRM1 tRNA methyltransferase 1-like 
TRPS1 NM_014112 trichorhinophalangeal syndrome I 
TRPV3 NM_145068 
transient receptor potential cation channel, subfamily V, member 
3 
TRPV4 NM_001177428 
transient receptor potential cation channel, subfamily V, member 
4 
TSHZ2 NM_001193421 teashirt zinc finger homeobox 2 
TTC39A NM_001080494 tetratricopeptide repeat domain 39A 
TUSC2 NM_007275 tumor suppressor candidate 2 
TWF1 NM_001242397 twinfilin, actin-binding protein, homolog 1 (Drosophila) 
  
 
179 
TXLNG NM_001168683 taxilin gamma 
TXNDC16 NM_001160047 thioredoxin domain containing 16 
U2SURP NM_001080415 U2 snRNP-associated SURP domain containing 
UBASH3B NM_032873 ubiquitin associated and SH3 domain containing B 
UBE2I NM_003345 ubiquitin-conjugating enzyme E2I 
UBE2K NM_001111112 ubiquitin-conjugating enzyme E2K 
UBP1 NM_001128160 upstream binding protein 1 (LBP-1a) 
UBR1 NM_174916 ubiquitin protein ligase E3 component n-recognin 1 
UCHL5 NM_001199261 ubiquitin carboxyl-terminal hydrolase L5 
UHRF1BP1 NM_017754 UHRF1 binding protein 1 
UPF2 NM_015542 UPF2 regulator of nonsense transcripts homolog (yeast) 
USP15 NM_006313 ubiquitin specific peptidase 15 
VAMP1 NM_014231 vesicle-associated membrane protein 1 (synaptobrevin 1) 
VAPA NM_003574 
VAMP (vesicle-associated membrane protein)-associated protein 
A 
VASH2 NM_001136474 vasohibin 2 
VAV3 NM_001079874 vav 3 guanine nucleotide exchange factor 
VCPIP1 NM_025054 
valosin containing protein (p97)/p47 complex interacting protein 
1 
VEGFA NM_001025366 vascular endothelial growth factor A 
VGLL4 NM_001128219 vestigial like 4 (Drosophila) 
VPS37A NM_001145152 vacuolar protein sorting 37 homolog A (S. cerevisiae) 
VSNL1 NM_003385 visinin-like 1 
VTI1A NM_145206 vesicle transport through interaction with t-SNAREs homolog 1A 
VWA3B NM_144992 von Willebrand factor A domain containing 3B 
WAC NM_016628 WW domain containing adaptor with coiled-coil 
WDFY3 NM_014991 WD repeat and FYVE domain containing 3 
WDR3 NM_006784 WD repeat domain 3 
WDR37 NM_014023 WD repeat domain 37 
WDR52 NM_001164496 WD repeat domain 52 
WRNIP1 NM_020135 Werner helicase interacting protein 1 
WTAP NM_152857 Wilms tumor 1 associated protein 
WWC3 NM_015691 WWC family member 3 
XKR6 NM_173683 XK, Kell blood group complex subunit-related family, member 6 
XPO4 NM_022459 exportin 4 
XYLT1 NM_022166 xylosyltransferase I 
YPEL4 NM_145008 yippee-like 4 (Drosophila) 
YWHAQ NM_006826 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
protein 
ZAK NM_133646 sterile alpha motif and leucine zipper containing kinase AZK 
ZBTB44 NM_014155 zinc finger and BTB domain containing 44 
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ZBTB46 NM_025224 zinc finger and BTB domain containing 46 
ZBTB7B NM_015872 zinc finger and BTB domain containing 7B 
ZC3H12D NM_207360 zinc finger CCCH-type containing 12D 
ZC3H13 NM_015070 zinc finger CCCH-type containing 13 
ZC4H2 NM_001178032 zinc finger, C4H2 domain containing 
ZCCHC14 NM_015144 zinc finger, CCHC domain containing 14 
ZDHHC15 NM_001146257 zinc finger, DHHC-type containing 15 
ZDHHC20 NM_153251 zinc finger, DHHC-type containing 20 
ZEB1 NM_001128128 zinc finger E-box binding homeobox 1 
ZFHX3 NM_001164766 zinc finger homeobox 3 
ZFHX4 NM_024721 zinc finger homeobox 4 
ZFP1 NM_153688 zinc finger protein 1 homolog (mouse) 
ZFP106 NM_022473 zinc finger protein 106 homolog (mouse) 
ZMIZ1 NM_020338 zinc finger, MIZ-type containing 1 
ZMYM2 NM_001190964 zinc finger, MYM-type 2 
ZMYM4 NM_005095 zinc finger, MYM-type 4 
ZMYND11 NM_001202464 zinc finger, MYND-type containing 11 
ZNF148 NM_021964 zinc finger protein 148 
ZNF236 NM_007345 zinc finger protein 236 
ZNF275 NM_001080485 zinc finger protein 275 
ZNF281 NM_012482 zinc finger protein 281 
ZNF292 NM_015021 zinc finger protein 292 
ZNF532 NM_018181 zinc finger protein 532 
ZNF592 NM_014630 zinc finger protein 592 
ZNF608 NM_020747 zinc finger protein 608 
ZNF652 NM_001145365 zinc finger protein 652 
ZNF654 NM_018293 zinc finger protein 654 
ZNF704 NM_001033723 zinc finger protein 704 
ZNF831 NM_178457 zinc finger protein 831 
ZNHIT6 NM_001170670 zinc finger, HIT-type containing 6 
ZNRF3 NM_001206998 zinc and ring finger 3 
ZRANB2 NM_005455 zinc finger, RAN-binding domain containing 2 
ZSWIM4 NM_023072 zinc finger, SWIM-type containing 4 
ZXDB NM_007157 zinc finger, X-linked, duplicated B 
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